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Witness seminars: 
MEETINGS AND PUBLICATIONS 1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affiliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome 
Trust continues to fund the Witness Seminar programme via its support for 
the Centre.
The Witness Seminar is a particularly specialized form of oral history, where 
several people associated with a particular set of circumstances or events are 
invited to come together to discuss, debate, and agree or disagree about their 
memories. To date, the History of Twentieth Century Medicine Group has held 
more than 50 such meetings, most of which have been published, as listed on 
pages xi–xix. 
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been 
agreed, suitable participants are identified and invited. This inevitably leads to 
further contacts, and more suggestions of people to invite. As the organization 
of the meeting progresses, a flexible outline plan for the meeting is devised, 
usually with assistance from the meeting’s chairman, and some participants are 
invited to ‘set the ball rolling’ on particular themes, by speaking for a short 
period to initiate and stimulate further discussion.
1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.
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Each meeting is fully recorded, the tapes are transcribed and the unedited transcript 
is sent to every participant. Each is asked to check his or her own contributions and 
to provide brief biographical details. The editors turn the transcript into readable 
text, and participants’ minor corrections and comments are incorporated into that 
text, while biographical and bibliographical details are added as footnotes, as are 
more substantial comments and additional material provided by participants. The 
final scripts are then sent to every contributor, accompanied by forms assigning 
copyright to the Wellcome Trust.3 Copies of all additional correspondence received 
during the editorial process are deposited with the records of each meeting in 
archives and manuscripts, Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
2 Sir Iain Chalmers authorizes the Wellcome Trust to publish his work and to report or reproduce it in any 
form or media, including offprints, provided that it is understood that the Wellcome Trust’s right to do so 
is nonexclusive.
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introdUCtion
This Witness Seminar comes at a timely moment for clinical pharmacology, which, 
as a clinical subspecialty, finds itself in intensive care. The best use of medicines in 
clinical practice, new drug development and proper regulation of drugs each require 
medical practitioners with skills in clinical pharmacology. But in contrast, there is 
little demand for clinical pharmacologists in every day clinical practice – and it is 
the demand and opportunities for clinical practitioners that are the main drivers of 
specialty choice amongst young doctors. Clinical pharmacology must evolve and I 
will return to this at the end of this introduction.
My first contact with clinical pharmacology was at the interview for senior house 
officers at Hammersmith Hospital in 1978. Dr John Nabarro, my consultant 
at the Middlesex Hospital, knowing of my passion for research, advised me to 
apply for senior house officer (SHO) jobs at the Royal Postgraduate Medical 
School, Hammersmith Hospital and my senior registrar, Dr David Morris, 
suggested that rheumatology would be a good career choice within medicine for 
a young doctor interested in immunology. So I duly turned up to the interview, 
hoping to be appointed SHO to the rheumatology firm. The interviews were a 
formidable and curious affair, approximately 25 candidates milling around, with 
rapid fire interviews of about four or five minutes. The successful candidates 
were duly marched into the boardroom, lined up against the portraits of retired 
deans on the wall facing the interview panel and told which job they were being 
offered, with little doubt that each would accept. I found myself appointed 
SHO in clinical pharmacology and, without second thought, or any thought 
at all under the pressure of circumstances, accepted immediately. Indeed after 
many years on the other side of the interviewing table, I can only recall one 
candidate who ever did decline the offered post. 
After my appointment as a senior lecturer in rheumatology in 1985, I discovered 
that the SHO interviews were almost as stressful for the interviewers as the 
interviewees, since the members of the interview panel had no idea in advance 
whether they would be asked to ask questions of any given candidate and Keith 
Peters, then the professor of medicine, would deliberately pick as an interviewer 
anyone who gave the appearance of dozing off or of complacency. This led to 
some quite curious and challenging questions – one professor would regularly 
jerk to life and ask some hapless candidate: ‘What price a life?’ I confess to 
using the same technique as Keith Peters when eventually I became professor of 
medicine and chaired the panel myself. 
xxii
Back in 1978, as a newly appointed SHO, I had very little idea what to expect 
from clinical pharmacology. In particular, what patients would be referred to a 
clinical pharmacologist? And therein lies the paradox of clinical pharmacology. 
The skills of clinical pharmacology are essential for the practice of the best 
medicine – but the specialty ‘owns’ no diseases per se – it is the purest form of 
general medicine. In the late 1970s the department of clinical pharmacology 
at Hammersmith was the hub of the specialty in the UK. The department was 
led by Colin Dollery, supported by John Reid, Peter Lewis and Donald Davies; 
recently graduated senior academics from the department included Alasdair 
Breckenridge and Charles George, the junior staff included an array of ‘later 
to be’ professors and leaders including Morris Brown, John MacDermot, Mike 
Rawlins and Garret Fitzgerald. The clinical pharmacology firm in those days 
looked after patients with diseases requiring drugs that were difficult to manage. 
These included hypertension, Parkinson’s disease and epilepsy – but then as 
now the majority of the clinical practice was general medicine. 
The combination of working for John Nabarro, a meticulous and rigorous 
diabetologist, followed by an equally meticulous and rigorous clinical 
pharmacologist, Colin Dollery, taught me things that medical school had not. 
The first was that taking a history and clinical examination were not activities that 
were ‘plucked from memory’ on each and every occasion – the model instilled 
in medical school. Assessing a hypertensive at Hammersmith involved filling in 
a form – no question of forgetting some aspect of the history or examination 
– the results were collected rigorously and ultimately entered in to a computer 
database. The second was the quantitative aspects of drug treatment, whether in 
the prescription of insulin or the titration of the blood pressure of a patient with 
hypertension. I will never forget the patience of Colin Dollery, who personally 
titrated the blood pressure of a patient undergoing the dangerous procedure of 
surgical removal of a phaeochromocytoma, a catecholamine-secreting tumour 
of the adrenal gland. This was not a matter that he would delegate to either one 
of his juniors or to the anaesthetic team. These lessons remain important today 
in an era when properly implemented electronic records, recording clinical 
information in a systematic fashion and supported by expert systems could 
transform the practice of medicine. 
Clinical pharmacology is a very small specialty – but one that is disproportionately 
important in relation to its size. One of the notable features of the specialty has been 
the success of its practitioners in the national structures of medicine. Although the 
ranks of district hospital physicians include few clinical pharmacologists, this could 
xxiii
not be said of the ranks of medical Knights. This reflects the crucial importance 
of clinical pharmacology in the regulation and assessment of drug effects and side 
effects. Bodies such as the Medicines and Healthcare products Regulatory Agency 
(MHRA), the Medicines Commission and the National Institute for Health and 
Clinical Excellence (NICE) have each had prominent leadership by members of 
the small community of clinical pharmacologists. The pharmaceutical industry is 
similarly critically dependent on the skills of pharmacologists in the laboratory and 
the clinic for the development of new medicines. 
Six months of SHO experience is a somewhat debatable qualification for writing 
the introduction to this Witness Seminar. Directorship of the Wellcome Trust 
is a more plausible explanation for the invitation to contribute, but could be 
seen also as an equally doubtful qualification! However, I have had the pleasure 
of long-standing professional association and friendship of many of those who 
participated in this Witness Seminar, edited and presented as ably as ever, by 
Tilli Tansey and her colleagues. I have also participated in the debate about the 
future of the specialty.3 And that future probably depends on changing clinical 
pharmacology from a subspecialty of medicine in its own right to a skill set that 
is key to the future of all of the major subspecialties of medicine. For example, 
gastroenterology can only proceed if there are some gastroenterologists who can 
use the tools of clinical pharmacology to advance the specialty. This is the model 
that has worked for a discipline such as immunology, in which immunologists 
are embedded in every subspecialty of medicine. Clinical pharmacology is in 
need of rebranding and Garret Fitzgerald has suggested ‘clinical therapeutics 
and translational medicine’ as the banner for the next generation of clinical 
pharmacologists.4 Is this simply spin? I think not. The new title recognizes that 
the skill set needed to advance medicines research in the twenty-first century is 
broad and, in addition to pharmacological skills, requires skills in imaging, the 
physiology and pathology of health and disease, trial design and bioethics. This 
should be an attractive area for budding clinical scientists. But the brand alone 
will not be sufficient, first class marketing will be required as well. 
Moreover, writing this introduction provides me with the opportunity to signal 
my admiration for the Witness Seminar series as a whole. One of the important 
issues for those that are responsible for the funding of scientific research is 
how to evaluate the outcomes of the research. Witness Seminars provide an 
invaluable tool, because they illustrate the complexity of scientific discovery 
3 Breckenridge et al. (2006). 
4 Fitzgerald (2005).
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and the human side of the research endeavour. It is over-simplistic to think that 
the pathways of scientific discovery can be unravelled by simple bibliographic 
analysis of the research literature. As an example, no amount of citation analysis 
could capture the development of medical ultrasound, described in Volume 5 
of the Wellcome Witnesses to Twentieth Century Medicine, a journey from Second 
World War sonar research, through the Glasgow shipyards to the obstetric clinic. 
The present volume is not an account of specific scientific discovery. Instead it 
documents the development of an important small specialty which has been key 
to the practice of modern medicine. 
mark Walport  
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dr tilli tansey: Good afternoon ladies and gentlemen. My name is Tilli Tansey 
and I am the convenor of the Wellcome Trust’s History of Twentieth Century 
Medicine Group. This was established some years ago by the Wellcome Trust, to 
bring together historians, scientists and clinicians interested in recent medical 
history, and also to provide material resources for present and future historians. 
One of the ways we have been most successful in doing this is this idea of a 
Witness Seminar, where we gather together people who have been involved in 
particular debates or discoveries, and ask them to talk among themselves about 
their own personal reminiscences, about what happened, when, why and who 
were the main drivers of various discoveries, or non-discoveries in some cases.1 
An important part of any meeting is of course the selection of the chairman, 
and we are delighted that when Jeff Aronson suggested that we had a meeting 
on clinical pharmacology, Rod Flower – who has been to some of our meetings 
before – was not only available but willing to take on this onerous duty, so we 
are very grateful that Rod is here to do so, and without further ado I will hand 
over to him.
Professor rod flower:2 Thanks very much, Tilli, and I would like to add my 
welcome to all of you to what we hope will be a great session. It’s appropriate 
that I start by thanking Tilli, Daphne, Wendy and Lois and the team here for 
hosting this meeting, and also Jeff for putting in a lot of groundwork in setting 
out agendas and ideas for what I hope will be a really stunning afternoon. I think 
that when we first sat down to consider this entire area, we quickly realized that 
there was far too much to cover in an afternoon meeting and so we made a 
decision to cut the subject matter in half. We are going to have a second meeting 
later in the year, which will deal specifically with clinical pharmacologists and 
the regulatory bodies. That will be on 25 September 2007 and you will all get an 
invitation to that event. We do hope that you will be able to come and complete 
the circle.3 It is just impossible to get everything covered in one afternoon. 
Quite why I was selected as chairman for this meeting, I don’t know, except 
that I am quite probably the only person in the room without a clinical 
qualification. With that in mind, I would just like to say that whether scientists 
or clinicians, we all have this subject very close to our hearts. When I first 
1 For the background to the Witness Seminar as an historical tool, see pages vii–viii.
2 Biographical notes appear on pages 101–20.
3 The Witness Seminar, ‘Clinical pharmacology in the UK, c.1950–2000: Industry and regulation’, was held 
on Tuesday, 25 September 2007, and is published as volume 34 in the series Wellcome Witnesses to Twentieth 
Century Medicine (Reynolds and Tansey (2008)).
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began in pharmacology, the very title ‘clinical pharmacology’ always struck me 
as a little counter-intuitive, because, after all, all physicians give their patients 
drugs, so why shouldn’t pharmacology be clinical? Why do you have to make 
a special case for it? It was only later I came to appreciate the rather turbulent 
history of the subject which, in conversation with a student once, I likened 
to that of a young person growing up in the 1940s and 1950s, full of self-
confidence and new ideas, becoming increasingly embarrassed by their elderly 
father ‘therapeutics’. I don’t know whether that is a close approximation to what 
actually happened, but I guess we are going to find out. We also, hopefully, are 
going to discover why it wasn’t called ‘human pharmacology’; the relationship 
between clinical pharmacology and pharmaceutical medicine; and the answer 
to lots of other important questions as well. 
I will just say a few words about how we are going to operate. This is very much 
a forum for you to speak, and to share your recollections. I only have two jobs 
to do today: one is to finish at four o’clock for tea, and the other is to ensure we 
finish at 6 o’clock in time for drinks, so in between I will just attempt to guide 
the discussion, if I think it is flagging, or if I want to move into a different area. 
But other than that, it is up to you to talk, and we will endeavour to capture 
everything faithfully and transcribe it for your later attention. So in order to set 
the ball rolling, I am going to ask Jeff Aronson from the Radcliffe Infirmary in 
Oxford to kick off with a few remarks. 
dr Jeffrey aronson: Thank you. First of all I would like to add my thanks to 
Tilli and her colleagues for all the hard work they have done in organizing this, 
and to Rod for being so willing to chair it. We did pick him because we wanted 
somebody who wasn’t a clinical pharmacologist, but who knew his way around, 
and I think we have found the perfect man. Tilli and Rod have asked me if I 
would give a kind of brief historical introduction and I tried to tackle that by 
producing a sheet of paper that’s in your pack on which I have included some 
key publications and events.4 I have started with the British National Formulary 
in 1946, which replaced the National War Formulary,5 and I have gone on 
right up to the 75th anniversary of the British Pharmacological Society (BPS) 
last year.6 
4 For some key publications and events in clinical pharmacology, see Appendix 1 on pages 77–79, provided 
by Dr Jeffrey Aronson.
5 For further details, see the Glossary, page 121. See also Wade (1993).
6 Cuthbert (2006); Aronson (2006); Dollery (2006). 
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I am conscious that I will have picked publications and events that some of you 
might think ought not to be there, or there may be some that I have missed that 
you think ought to be there. So, I encourage you to annotate this sheet of paper 
with any additional information you think might be valuable – publications 
I don’t know about, events I have forgotten – and at some time in the future 
let us have it back, so that we can increase the amount of information in this 
chronology. On the other side of the paper you will find something I have 
called ‘Towards a map of the history of academic departments’. If at some time 
– perhaps today, but it doesn’t have to be – you could try, particularly those of 
you who were professors of clinical pharmacology or lecturers or whatever, in 
different institutions, to answer those questions, it would be very helpful in 
building up a map of the history of the subject, to see where people came from, 
where they were at particular times, and so on. I hope that you will be able to 
add your bits of information to those two sheets of paper.7 
7 The returned forms (although insufficient for the proposed analysis) will be deposited, along with 
the other records of this meeting, in GC/253 in archives and manuscripts, Wellcome Library, London. 
See also Aronson (2004).
figure 1: a woodcut of ge hong, c. 15th century.
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I guess we think about clinical pharmacology as being largely a twentieth-century 
subject, but actually for hundreds of years, as we all know, physicians have been 
developing drugs in one way or another, using tools that we would now recognize 
as being those of a clinical pharmacologist. A good example that I know of, and 
one that we illustrated on one of the issues of the British Journal of Clinical 
Pharmacology last year – well known for its green cover – is Ge Hong.8 
He was a fourth-century Chinese physician, who took some qinghaosu – what 
we nowadays call Artemisia annua – dunked it in water and squeezed it out. And 
that was the first demonstration that you could make an extract from a plant to 
treat malaria, intermittent fevers actually. He described all this in a text called 
Emergency Prescriptions Kept up One’s Sleeve.9 Because the substances that are 
in this plant are so unstable, it is now believed that this squeezing-out process 
somehow creates an emulsion that allows you to extract the active ingredient. 
You wouldn’t be able to do it other than by traditional methods. Whether that’s 
true or not, I have no idea, though it makes a good story. But I think that Ge 
Hong was a clinical pharmacologist, at least a pharmacognosist. Then there 
were the Peruvians who used cinchona bark to treat ague (malaria).10 There was 
also William Withering, a favourite of mine, and his meticulous description 
of the use of foxglove in dropsy.11 And the Reverend Edward Stone, observing 
the efficacy of willow bark as a febrifuge.12 All of these people, I think, could be 
called clinical pharmacologists in one way or another. And we are just taking 
it up to date with modern techniques, and that’s often what I think defines 
a subject. 
Being interested in words,13 I thought I would look at the words that describe 
our discipline, and so I have done a little bit of very, very sketchy research 
on the terms: ‘therapeutics’, ‘materia medica’ and ‘clinical pharmacology’. 
8 The image of Ge Hong was featured on the cover of the issue of the British Journal of Clinical Pharmacology 
[(2006) 61: 647–790] to celebrate the 75th anniversary of the British Pharmacological Society and the 15th 
International Union of Pharmacology [IUPHAR] congress in Beijing. 
9 Hsu (2006).
10 Containing quinine. See Collier (1984); Bruce-Chwatt (1988).
11 Digitalis was first prescribed by the English physician and botanist William Withering (1741–99), who 
used it to treat oedema (dropsy). See Withering (1785); Aronson (1985); Sheldon (2004).
12 Stone (1763); see also Hedner and Everts (1998).
13 See, for example, Dr Jeffrey Aronson’s series of articles on medical linguistics, published under the general 
heading ‘When I use a word…’, which has appeared in the British Medical Journal since 1994. 
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‘Therapeutics’, in its original singular form, ‘therapeutic’, as a noun, first appears 
in the Oxford English Dictionary in a citation from the sixteenth century. But its 
modern form, the plural form ‘therapeutics’, first occurs in 1671, as long ago as 
that, in a book by William Salmon called Synopsis Medicinae, or a Compendium 
of Physick. He wrote that ‘the Therapeuticks, or active part of Physick, is either 
Material, or Relative’.14 And that’s a very old term, to which Rod alluded. 
I have traced the term ‘materia medica’ back to the beginning of the nineteenth 
century. It was originally used specifically to describe medicines, rather than the 
art of using them, which, I think, is how we would now think of it. And in the 
early days the definition given was ‘the remedial substances used in the practice 
of medicine’. But William Cullen in 1789 used it in this latter sense in his 
Treatise of the Materia Medica, and the Materia Medica Americana [Potissimum 
regni vegetabilis], of 1787, which I translate as ‘the materia medica of America, 
especially plants’, where ‘plants’ implies members of the vegetable kingdom (‘regni 
vegetabilis’).15 So the term materia medica is very old. But the first textbook to 
my knowledge to use the term was Elements of Materia Medica and American 
Therapeutics by Edward Ballard and Alfred Baring Garrod, which was published 
in 1845.16 The Bodleian Library’s catalogue lists a rather impressive 790 titles 
containing the words materia medica, and I haven’t surveyed all of them. 
When I grew up in Glasgow the subject that I studied was materia medica, not 
clinical pharmacology. Materia medica was what was on the syllabus, although 
the textbook that we used was Dilling’s Clinical Pharmacology. It’s an interesting 
textbook, because it was first published in 1884 by a man called John Mitchell 
Bruce, who wrote it, and he called it Materia Medica and Therapeutics. When 
Dilling came on board it was called Bruce and Dilling’s Materia Medica and 
Therapeutics, but when the twentieth edition appeared in 1960, it was called 
Dilling’s Clinical Pharmacology.17 That’s the first time that the term clinical 
pharmacology appears in a textbook to my knowledge, and in the same year 
of course Desmond Laurence published the first edition of his now famous 
textbook Clinical Pharmacology.18 So, 1960 is the first time that we see this term 
in the title of a textbook. 
14 Salmon (1671).
15 Cullen (1789); Schoepf (1787). 
16 Ballard and Garrod (1845). 
17 Bruce (1884); Dilling (1960). 
18 Laurence (1960).
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I found a translation of a German book in the Bodleian Library, Oxford, by 
two pharmacologists, Hans Horst Meier and Rudolph Gottlieb. The original 
German title translates into something like Experimental Pharmacology and the 
Basis of Therapeutics. It was translated from the German by John Taylor Halsey 
– I don’t know who he was – with the English title, Pharmacology, Clinical and 
Experimental, in 1914.19 It’s not quite there, but already by 1914 it sounds as if 
people are thinking about clinical pharmacology. 
The first use of the precise term ‘clinical pharmacology’ and by whom is not 
clear. It has been attributed to Harry Gold, a US physician of Russian ancestry, 
who did some fantastic work on cardiac glycosides in the late 1920s and early 
1930s, delineating the pharmacokinetics of digoxin, purely by measuring the 
stuff in the urine.20 Incredible, and, I think, amazing clinical pharmacology, 
given the limitations of the technique. He certainly used the term ‘clinical 
pharmacology’. We have evidence of this in John Gaddum’s Dixon Memorial 
Lecture of 1954, entitled ‘Clinical pharmacology’, who said he used the term 
because Gold had.21 And again, at a symposium that Desmond Laurence edited 
in 1958 (he kindly sent me a copy), in which Gold again, in a lecture entitled 
‘Human pharmacology’, used the term ‘clinical pharmacology’. In that lecture, 
Gold says that he thinks that human pharmacology is a much better term for 
the subject than clinical pharmacology, and he argues the case.22 Some of you 
may have views about that and may be able to throw some light on it. 
Finally, I want to contribute a personal reminiscence, since this is a Witness 
Seminar. On the list of publications that I have given you, I particularly included 
some from around the late 1960s–early 1970s, because these were the publications 
that actually influenced me to come into clinical pharmacology.23 There was 
a 1967 British Medical Journal editorial, ‘Future of clinical pharmacology’; a 
1969 British Medical Journal editorial, ‘Clinical pharmacology as a specialty’; 
the Royal College of Physicians’ Report of 1969; and a Lancet editorial in 1970, 
‘The image of clinical pharmacology’.24 
19 Meyer and Gottlieb (1914).
20 See Hutcheon (1972); Miller (1981); see also Aronson (2007).
21 Gaddum (1954).
22 See Gold (1959): 47; see also Gold (1968).
23 See list of publications and key events in Appendix 1, page 77.
24 Ware (1969); Royal College of Physicians of London (1969); Anon. (1970). 
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In July 1970, I had just passed the final exams, MB ChB, in Glasgow and a 
neighbour of ours, Jake Davidson, a radiologist at the Western Infirmary in 
Glasgow, came across the road – he lived across from us – to congratulate me on 
passing. He asked, ‘What are you going to specialize in?’ Well, I hadn’t a clue, 
I hadn’t thought about it; you didn’t have to in those days, not the way they do 
nowadays. He said, ‘Well, what was your best subject in medical school?’ I said, 
materia medica, because I had got a distinction; it was the only thing I had a 
distinction in at all. I was absolutely fascinated by it. He said, ‘Well, you have 
got to be a clinical pharmacologist.’ I said, ‘What’s that?’ He said, ‘Go and read 
about it’. And I did, and these are the papers that I read: the BMJ editorial, the 
Report of the Royal College, the WHO Report of 1970, the Lancet editorial; 
and I thought, ‘That’s for me’.25 I was hooked. So that’s why I became a clinical 
pharmacologist. I wonder if anybody else was influenced by those publications 
at that time, either to continue their studies or to take them up, and I would be 
interested to hear that. But that’s all I have to say.
flower: Thanks very much, Jeff. Does anyone want to comment on the question 
of the nomenclature and how clinical pharmacology got its name? Concerning 
early influences on career choice, I should say that you are not the only person 
who got into pharmacology by accident, without knowing what it was. I am 
sure there is a long list of us who had to go and look it up in the dictionary 
before we applied for posts. Would anyone like to come in on this point?
dr andrew herxheimer: I got interested because I was almost the only person 
in my year at medical school at St Thomas’ Hospital Medical School, London 
who enjoyed the therapeutics lectures, and when I had done my house job I 
asked Dr R S (Sam) Stacey, who was the reader, whether there was a job in his 
department. I started to do some experiments of conventional pharmacology, 
animal work, and I got really stuck and didn’t like working with animals and 
made a mess of it. But I also started doing human experiments, which worked, 
and I thought for that reason what interested me was human pharmacology. 
I was as interested in healthy human beings as in patients at that point, and I 
thought that ‘human’ pharmacology included healthy and unhealthy people. 
So, I preferred the expression human pharmacology.
Professor michael orme: Just to say, Jeff, that I predate you by only a few years, 
I think. But my particular seminal influence was Colin Dollery’s article in 1966.26 
25 WHO (1970). See Figure 5, page 41. 
26 Dollery (1966).
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At that stage I was doing a house job at the Hammersmith, and I think that, 
combined with the presence of many august bodies, persons that are here at this 
meeting as well, influenced me to specialize in clinical pharmacology. It was a 
combination of the clinical work with the pharmacology and therapeutics that 
was my stimulation.
Professor denis mcdevitt: I got in by serendipity and I suspect that I am 
not the only one.27 I hadn’t read anybody’s article. When I had qualified and 
was starting training in medicine, the department from which it was known 
that people were most likely to pass the Membership of the Royal College of 
Physicians was the one that Owen Wade ran at the department of therapeutics 
and pharmacology at Queen’s University, Belfast. I went to work there, not 
because I was attracted to clinical pharmacology; it was more because I wanted 
to pass the Membership and then make a decision about my career. Once 
I got there I got hooked, particularly because of working with Robin Shanks, 
who had come from ICI, where he had worked with Sir James Black.28 We 
started to do work with propranolol in thyroid disease, some of the early work.29 
It turned out to be a really fascinating thing to do, and I never wanted to do 
anything else.
Professor owen Wade: I used the words ‘clinical pharmacology’ because when 
I was appointed at Belfast, most of the other pharmacologists were ‘preclinical 
pharmacologists’. British pharmacology was very much dominated in the 1930s 
by an influx of Germans: Wilhelm Feldberg, Hugh Blaschko and others.30 
27 This is a recurring theme in other Witness Seminars. See, for example, Zallen et al. (eds) (2004): 30. 
See also the special issue, ‘Creativity and discovery in biomedical sciences’ of Creativity Research Journal 
 (1994) 7. For a further perspective see Booth (1990) and Pepys (2007). 
28 Propranolol [Inderal (ICI 45520)] was launched in 1964 by ICI. See Black et al. (1964). See also Reynolds 
and Tansey (eds) (2008). 
29 McDevitt et al. (1968); McDevitt (1976).
30 Professor Owen Wade wrote: ‘The best description of Feldberg, Blaschko and Chain is in Medawar and 
Pyke (2000). Feldberg and Blaschko were much older than me. Indeed, Feldberg taught me in my first year 
as a student in Cambridge University Medical School, department of physiology, in 1939. Many years later 
when Feldberg was in retirement and still working in the NIMR, his department was infiltrated by an anti-
vivisectionist who criticized Feldberg’s anaesthesia of the animals he was working on. This got enormous 
publicity in the press that was quite unjustified and I was upset that no senior member of the Physiological 
Society came forward to defend this great scientist, who had found out so much about the transmission of 
nerve signals by acetylcholine, which is immediately destroyed by anticholinesterase.’ Part of a note on draft 
transcript, 11 July 2008. See also, for example, Bisset and Bliss (1997).
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They were using drugs, not to treat patients, but in order to explore human 
physiology. I was amazed how little they knew about the use of drugs like 
penicillin, streptomycin and cortisone, which had come on the scene by the 
time I went to Belfast in 1957.31
Professor desmond laurence: I fell into the subject completely by accident 
when I was an ex-service registrar at St Thomas’ Hospital, London, in 1948 
and I associated myself with the department of medicine, because there were 
two very attractive people there, Peter Sharpey-Schafer, professor of medicine, 
and Tony Dornhorst, a reader and consultant.32 They showed me what clinical 
science was, which I had never even heard of. One day I was summoned by 
the dean and the professor of medicine and they said, ‘What are you going to 
do with yourself?’ I said, ‘I suppose I am going to be one of the 50 people now 
applying for each hospital registrar post.’ They said, ‘Would you like to be a 
lecturer in therapeutics? We are going to provide the reader in therapeutics with 
a lecturer; he wants a non-medical lecturer, but we are not going to let him have 
one. And, if you will accept the job, we will force you on him.’ And not long 
after that Andrew Herxheimer and I shared a room in the same department. So, 
that’s how it started for me, no intentions at all; it just grew on me.
flower: A bit like taking the ‘King’s shilling’.33
Professor Jim ritter: I was first exposed to pharmacology within Bill Paton’s 
department and several of the pharmacologists there: Hugh Blaschko (in whose 
house in Park Town, Oxford, I rented a flat), Edith Bülbring and a number 
of other distinguished pharmacologists.34 But a lot of pharmacologists were 
actually clinicians: Blaschko was a clinician – having done clinical medicine 
before he did pharmacology – and Bill Paton had done clinical medicine, but 
I don’t think Edith Bülbring had.35 But Bill Paton, in particular, even though 
he was a scientist par excellence, was very proud of his background in clinical 
medicine and not only proud of it, but felt that it contributed very substantially 
31 See Tansey and Reynolds (eds) (1997).
32 See also Reynolds and Tansey (eds) (2000): 59, 63.
33 Accepting the ‘King’s shilling’ from a recruiting sergeant was formal acceptance of the conditions of Her/
His Majesty’s Army as an enlisted man.
34 Medawar and Pyke (2000). See also note 30. For details of the department of pharmacology in Oxford 
during Paton’s tenure, see Rang and Perry (1996): 299–301.
35 See Born and Banks (1996).
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to the way that he thought about scientific problems.36 I can remember him 
arguing the toss with Humphrey Rang, who was another great influence in my 
life, and who also had done clinical medicine at the time.37 Humphrey and Bill 
Paton used to debate the relative merits of having done clinical medicine before 
one did one’s basic pharmacology.
Professor david grahame-smith: The great influence on me was the man who 
is sitting next to me on my left, Sir Stanley Peart. At some point in about 1960, 
I went to see him and said I wanted to do some research, not knowing at all 
what research was all about. At the time I was a registrar in medicine at St 
Mary’s Hospital, London, where he was professor of medicine. He said, ‘What 
do you want to do?’ I said, ‘I don’t know, I want to do research, and you are 
the professor of medicine.’ So he said, ‘Well, there’s a patient on the ward with 
something called the carcinoid syndrome’, which had only fairly recently been 
described. He said, ‘This tumour makes something called serotonin (5HT) and 
it seems nobody knows really how it is made. Why don’t you find out?’ So I 
did, although my approach was a bit messy.38 I was placed in Albert Neuberger’s 
department of chemical pathology, and he was very kind to me, as were the 
people in that department. I knew no biochemistry at all, but learned it as I 
went along, kitchen sink stuff then. And having done that, and Hugh Blaschko 
having examined my PhD, I went to the US to become an endocrinologist, and 
did some work on ACTH, and cyclic AMP, and steroidogenesis.39 
So, I was very thoroughly a clinical biochemical pharmacologist, not a 
pharmacologist. And while I was in the US, Stan Peart wrote to me and said 
that there was a senior lectureship in clinical pharmacology coming up at St 
Mary’s: ‘What about it?’ Well, as a young married man with two young children, 
what was I going to do? So, I came back to be a senior lecturer in clinical 
pharmacology. But my career progress was not structured and one of the things 
36 See, for example, Paton (1982); Paton and Rang (1965). See also Colquhoun (2006). Professor Edith 
Bülbring’s papers (PP/BUL) are held in archives and manuscripts, Wellcome Library, London, as are those 
of the British Pharmacological Society (SA/BPS). See Bolton and Brading (1992).
37 See Rang and Dale (1987). 
38 Page (1954); Grahame-Smith (1964); Twarog (1988). The Serotonin Club, an international association 
for scientists interested in serotonin (5-hydroxytryptamine), was founded in 1987 and sponsors a satellite 
meeting at the International Congress of Pharmacology (IUPHAR) every four years and hosts annual 
lectures and dinners, including one meeting annually of the British Pharmacological Society. See also 
Green (2008). 
39 See, for example, Grahame-Smith et al. (1967).
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that worries me now is the terribly rigid structure of medical academic careers. 
It worries me that people can’t move from one thing to another in the way that 
they used to be able to do. It takes the fun out of career development.
Professor sir Charles george: Like Denis McDevitt, I went in by serendipity. I 
was doing cardiology in Birmingham and Brian Pentecost said, ‘You must go and 
work for John Goodwin and Celia Oakley’. But, that job came up two or three 
months later, and I had just done a trial of ICI 50172 or practolol in angina, and 
so I applied for Colin Dollery’s registrar post in 1969 and got that, and the rest 
is history.40
Professor duncan Vere: I think I got into clinical pharmacology and therapeutics 
for entirely negative reasons. I was on the house, and very interested in medicines 
and drugs, but my recollection is of the extraordinary primitivity of the work that 
was going on. I remember a patient with malignant hypertension who did not 
have long to live and there were no real treatments then, apart from Kempner’s 
rice diet or a total sympathectomy, or whatever.41 And Clifford Wilson turned up 
one day, having just been to Oxford, and fished in his waistcoat pocket and said, 
‘I have got something here which Bill Paton gave me, called hexamethonium. 
Would you like to try it on Mr So and So?’ I said, ‘What is the dose?’ And he 
said, ‘Well, we have no idea.’ [Flower:  He gave you a form of consent then, 
obviously.] I gave the patient a very small amount and he went out like a light. 
He did recover and lived for about three more days, but that’s another story.42 
I was supposed to be becoming a nephrologist, but I was doing research on the 
then fairly new metabolic ward and discovered that all the experiments went 
wrong and produced results that I would not have expected. So I tried to find 
out why and discovered that the patients were getting the wrong drugs and the 
wrong electrolytes. And the atmosphere was unbelievable. If I could just say that 
in those days the nurses had to add up the amounts of dietary constituents to six 
places of decimals, from wartime tables by McCance and Widdowson, which 
40 Briant et al. (1973). Practolol was withdrawn in 1975 following yellow card reports to the Committee on 
Safety of Medicines of unforeseen side effects concerning serious skin, eye and abdominal problems. See, 
for example, the debate in the House of Commons on ‘Drugs (Adverse Effects)’, 16 March 1977, Hansard 
928: cols 583–94. For further details of the practolol problem, see Reynolds and Tansey (2008): 4–5, 30; 
Abraham and Davis (2006). 
41 See Glossary, page 123.
42 Paton (1982).
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were totally irrelevant.43 I remember remonstrating with an assistant matron 
about this, and she said: ‘But it does them good, Dr Vere.’ That sort of thing. 
We investigated. There were errors of complex prescribing (some 22 per cent of 
drug administrations), which we wrote up. One day Jim Crooks came into the 
lab and said, ‘Look, we have published something about complex prescribing. 
We have found exactly the same things in Ireland and so on, and in Dundee.’44 
And so my interest was kindled. 
We also worked on the reaction of patients to subcutaneous drainage and to 
the thromboembolic effects of acid intravenous fluids and found, of course, 
thrombosis and so on.45 So the final straw was that Clifford Wilson came and 
saw me one day and said, ‘Look here, don’t you think you ought to be a clinical 
pharmacologist?’ Then he gave me the very references that Jeff Aronson has 
referred to.46 So, that was how I came into it.
Professor david Barnett: It’s interesting that the influences that people have 
described on the way that they have chosen a career vary. My choice was also 
somewhat serendipitous in that I had just finished my Membership of the RCP 
and Robert Kilpatrick said there was some money for a research fellowship, 
funded, I think, by Roche at the time, and then I became involved in the 
possibility of a Merck fellowship. That, I think, was the transition zone for 
me, because I spent two years in San Francisco with Ken Melmon and the 
Cardiovascular Research Institute and it did two things.47 One is that it helped 
me to fall in love with biology and to understand the science ethic. But also 
the alternative pathway of clinical pharmacology, that is of understanding how 
drugs affect physiology, and that kick-started my interest. So I didn’t read the 
background material, it just happened by accident, but it was a joyous experience 
and I never really looked back.
Professor laurie Prescott: I am interested to hear how everybody fell into 
clinical pharmacology almost by accident. In my case it was quite different. I 
had always been interested in chemistry and pharmacology and from an early 
43 See, for example, McCance and Widdowson (1946).
44 Crooks (1975); Wier et al. (1976).
45 Vere (1965).
46 The list of articles circulated at the meeting can be found in Appendix 1, page 77. See also notes 24 
and 25.
47 See, for example, Barnett et al. (1978).
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stage after qualifying in medicine I seriously intended to become involved in 
some way with the clinical use of drugs. I happened to see an editorial entitled 
‘Clinical pharmacology’ by Louis Lasagna at the Johns Hopkins Hospital, 
Baltimore, Maryland.48 I wrote to him saying that I was interested in becoming 
a clinical pharmacologist and did he have any suggestions? He invited me to 
apply for a research fellowship, and a very pleasant pub lunch with him in 
London turned out to be my interview for the position. This was 1963 and 
I was probably one of the first to hold a formal research fellowship in clinical 
pharmacology. I was at the Johns Hopkins Hospital for two years, during which 
time I gained much experience, and I learnt to start work early and to really 
work hard.49 I came back to a lectureship in therapeutics in the department of 
materia medica and therapeutics in Aberdeen with Professor Alastair Macgregor. 
At that time, Jim Crooks was a senior lecturer in the department. So, I started 
with a very purposeful intention of specializing in clinical pharmacology.
aronson: I ought to say that Laurie’s mention of Lou Lasagna reminds me 
that all but one of the papers I listed here are UK papers. I concentrated on 
the UK story because that’s what we are here for. There’s one US report and 
one interesting Anglo–American report, when British and US pharmacologists 
got together and had a meeting. It was published in the journal Clinical 
Pharmacology and Therapeutics and is absolutely fascinating.50 But Laurie is 
right – Lou Lasagna was writing about clinical pharmacology in the 1960s and 
publishing editorials. 
Perhaps I may add a reminiscence. Hearing David Grahame-Smith saying 
how much Stan Peart had influenced him, I ought to say how much David 
influenced me. Although I had decided to become a clinical pharmacologist 
before I met him, he was a huge influence on me throughout the time he was 
Rhodes professor of clinical pharmacology in Oxford. I had been working in 
Abe Goldberg’s department in the Stobhill Hospital, Glasgow – John Reid’s 
stamping ground – and Abe had been Stanley Alstead’s successor as Regius 
professor, and I worked there for a few years before I decided to leave Glasgow 
and look for clinical pharmacology jobs elsewhere.51 There was a man called 
Brian Whiting there who was measuring plasma digoxin concentrations, and I 
48 Lasagna (1959, 1966).
49 See, for example, Prescott (1964).
50 Melmon and Turner (1986). See also Appendix 1.
51 See, for example, Goldberg (1983).
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thought, ‘What a waste of time’. Bloody fool – me, I mean, not Brian. ‘Why is 
he measuring plasma concentrations? This stuff is distributed all over the place. 
How does he know that the plasma concentration has got anything to do with 
cardiac concentrations? It’s a drop in the ocean, surely. It can’t tell you anything.’ 
I wanted to find a way, or to think of a way, of measuring the effects of the 
material, but I hadn’t a clue, I really didn’t know anything about it. And when 
I came down to Oxford, looking for a job, David told me about the sodium–
potassium pump.52 I had never heard of it. I didn’t know what it was. But my 
eyes just lit up when I heard him talk about it, because here was a method for 
measuring the effect of a drug.53 The fact that it was in a red cell miles from the 
heart actually didn’t strike me, and that I should have been thinking exactly the 
same thing as plasma concentrations and cardiac concentrations when it came 
to ATPase in red cells and the heart. But that’s what really turned me on to 
working with David, and, as I say, I was hugely influenced by everything he did 
scientifically while he was professor.
Professor Patrick Vallance: I guess I just drifted into clinical pharmacology. What 
I was thinking about as people have been talking was how I ended up having 
the substrate to even think about drifting into it. The answer is undergraduate 
teaching, and there were three people who taught me and who influenced a large 
number of individuals and they were Humphrey Rang,54 Joe Collier55 and Brian 
Robinson.56 There were two things about undergraduate pharmacology that led 
me into clinical pharmacology. The first was that it was an integrating science, it 
wasn’t just about looking at the biochemistry or physiology, something actually 
changed when you intervened, you could see biology in action. The second 
point was that this was clearly demonstrated. In those days (c. 1978–80) at St 
George’s Hospital Medical School, London (St George’s, University of London 
since 2005), there was an integrated pharmacology and clinical pharmacology 
52 See Eisner and Smith (1991).
53 See, for example, Aronson et al. (1977); Boon et al. (1984).
54 Professor Humphrey Rang worked on the binding of radiolabelled atropine to smooth muscle of the gut 
for his PhD in Oxford. See Paton and Rang (1965).
55 Professor Joe Collier wrote: ‘Brian (Fyfe) Robinson retired from his chair in cardiovascular medicine at 
St George’s Hospital Medical School around 1985 (as I recall). He had been a student at St George’s and 
after his obligatory stint in the armed services (call-up) he came back to St George’s where, barring a research 
stint in the US, he gradually rose through the ranks both as a clinician and as an academic to get his personal 
chair.’ E-mail to Mrs Lois Reynolds, 3 August 2008. See Collier et al. (1970).
56 See, for example, Benjamin et al. (1995).
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course and there were a couple of practicals where β-blockers or atropine were 
given to what was called a volunteer – somebody encouraged out of the audience 
by Joe Collier and injected with a β-blocker.57 We saw physiological parameters 
changing, and I think that was incredibly important for a large number of 
students. It inspired them to go on to try to understand what they had seen. I 
think rather few of them ended up as clinical pharmacologists, but many took 
away a basic understanding and some inspiration.
Professor Brian Prichard: I suppose the reason I went into clinical pharmacology 
is possibly almost unique. I started at King’s College, London, aged 17, and I 
thought, ‘Well, I don’t want to complete preclinical studies too quickly and start 
clinical studies’. (I should also add in parentheses that my favourite pastime was 
spending the long vacation cycling across Europe to the Alps and back with a 
couple of friends.) So, I did a BSc in physiology, which meant two extra-long 
vacations, besides just one for the ordinary preclinical course. The part of the 
BSc that I enjoyed particularly was pharmacology with George Brownlee and 
Peter Quilliam. Having done the BSc and wanting another long vacation, I 
thought I would spend one more year and do a Master’s degree by examination 
in pharmacology. After qualifying in medicine at St George’s, I spent four 
years doing various clinical posts there when Desmond Laurence advertised 
his research assistantship in clinical pharmacology. It was due to the MSc that 
I was appointed on 1 December 1961, at University College Hospital Medical 
School (UCHMS). My entry into clinical pharmacology could be put down to 
a passion for transcontinental cycling.
flower: What about industrial clinical pharmacology? We have several people 
from industry here: Arthur Fowle, Tony Peck and Trevor Jones. OK, Arthur is 
going to say a few words about how he became a clinical pharmacologist.
dr arthur fowle: I am afraid it is entirely unglamorous. I had a long suit in 
cardiovascular research, which seemed to be the best-funded way of studying 
clinical science, which I always thought I was in. I went to the Wellcome 
Foundation by accident and thought that I was there to solve problems for them, 
such as finding out why British drivers weren’t welcome in Europe because of 
the number of accidents they had, which I thought was probably due to very 
cheap alcohol on the boat, but French authorities thought was due to Marzine, 
57 For a description of Paton’s UCH preclinical practical classes and students’ self-administration of drugs to 
observe their effects, see Rang and Perry (1996): 297.
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which most travellers used to take at that time.58 And, I solved those kind of 
problems from 1965 and thought of myself as a clinical scientist, until I read 
Colin Dollery’s article.59 Colin and I had been housemen together and good 
friends, and I suddenly realized that perhaps I was a clinical pharmacologist and 
so it really had nothing to do with training, but just copying.
dr tony Peck: Yes, I had a fellow feeling with David Grahame-Smith that I 
needed a living, and Eric Neil, professor of physiology, and Franz Hobbiger, 
reader in pharmacology at the Middlesex, had a job going and I went into 
clinical pharmacology for that reason.60 Of course, the Middlesex Hospital, 
which will come out later I am sure, was the one medical school in London 
that never had a department of clinical pharmacology. It had a pharmacology 
department, which C A Keele headed for a long time, with Desirée Armstrong, 
and their work on substances causing pain and itch was quite seminal.61 But 
the Middlesex was not a place to do clinical pharmacology, because, as I said, 
it never had a department. Its medicine was regarded as an extension of Harley 
Street, London. Anyway, it provided me with a living and a lot of fun teaching, 
but it was only when I joined the dear old Wellcome Foundation down at 
Beckenham in 1969 that I really had the opportunity to start doing human 
research and had a great deal of fun for 25 years.62
flower: But when you joined the Wellcome Foundation in those days there was 
no department of clinical pharmacology, was there? I mean, did they call it that 
in those days?
Peck: May I pass that to Arthur?
fowle: Yes, we did. We changed the name from medical department to clinical 
pharmacology in 1966, and Tony came to join us when he said he did.
Professor donald davies: First of all to correct you, chairman. I am a 
biochemical pharmacologist who went into a clinical pharmacology 
department, so there are at least two of us here.63 I had studied for my PhD 
58 Cyclizine hydrochloride, a H1-receptor antagonist.
59 Dollery (1966).
60 See, for example, Anon. (1957, 1959).
61 See, for example, Armstrong et al. (1957).
62 See, for example, Peck (2004).
63 Professors Donald Davies and Geoff Tucker.
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with Professor Tecwyn (Tec) Williams at St Mary’s Medical School, London, 
on drug metabolism. I then joined Bernard Brodie’s laboratory at the National 
Institutes of Health (NIH, Bethesda, Maryland) in the US, where the research 
was directed to relationships between kinetics and metabolism and drug action 
in man.64 While I was at Brodie’s laboratory, Colin Dollery applied to the 
MRC for a grant to set up the MRC Clinical Pharmacology Research Group 
at the Hammersmith Hospital.65 Fortunately for me, Tecwyn Williams was 
one of the reviewers and it is alleged that he suggested that Dollery appoint 
a biochemical pharmacologist and put my name forward. I came back to the 
Royal Postgraduate Medical School (RPMS) at the Hammersmith Hospital, 
London, in 1967 and brought with me analytical techniques and knowledge of 
kinetics and metabolism, reactive metabolites and drug interactions, and that’s 
how I got started in clinical pharmacology.
flower: We have talked about how we got into the subject, but maybe now is 
a good time to start talking about the way in which the subject developed in 
different centres around the country, and Don [Davies], I don’t know whether 
you would like to say a few words about the Hammersmith, when you first 
began there and so on?
davies: There are others here who might correct me, but we began applying a 
knowledge of kinetics, drug metabolism, analytical techniques to solving drug 
problems in patients at the Hammersmith, particularly work on drug interactions 
with Alasdair Breckenridge and Michael Orme, and on cardiovascular drugs, 
differences in dose–response, with Charles George and John Reid.66 That led to 
a great output of research, and perhaps those were the low-hanging fruits that 
were easily gathered. Where it became more difficult – we will see what others 
think – is when clinical pharmacologists moved into mechanisms of drug action, 
but possibly more importantly, mechanisms of disease processes, without the 
firm foundation of drug metabolism and kinetics to back up the research. That 
was more complex and it became more difficult to obtain research funds.
flower: What we are trying to get now is a sense of what was happening at the 
beginning when academic departments began to call themselves ‘departments 
of clinical pharmacology’ and how the subject gathered momentum.
64 See, for example, Neff et al. (1965); Vesell (ed.) (1971).
65 MRC grants for ‘research groups’ were introduced in 1961. See Thomson (1973): 153. 
66 See, for example, Breckenridge et al. (1971).
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laurence: It really happened for me when Tony Dornhorst at St Thomas’ asked, 
‘Are you going to apply for the readership at UCH/UCL made vacant by Bill 
Paton [in 1956]?’ I said, ‘No, because I am not yet qualified to be a reader.’ 
He said, ‘Go and see Max Rosenheim, professor of medicine (that’s Sir Max 
Rosenheim after 1967), and tell him I told you to.’67 So I did and, briefly, 
the job was demoted for me, and it was, interestingly, a joint appointment 
between University College London and UCH Medical School, which were 
then separate, later to come together. At the interview I was supported by Max 
Rosenheim and for many years after; he was a great man for supporting people. I 
attended the interview committee and this was in the days when the title ‘senior 
physician’ was bandied about and meant something, and the ‘senior physician’ 
at UCH said to me, ‘Tell me, Dr Laurence, what is this chemical pathology 
that you are so interested in?’68 I got the post and it was titled Pharmacology 
and Therapeutics, joint with UCL, and I believe it originated when Harry 
Himsworth, later secretary of the Medical Research Council (MRC), was 
professor of medicine (1939–49). He and the then professor of pharmacology 
at UCL got together – I am afraid I don’t know who it was at UCL at that 
time.69 They perceptively saw this was a coming scientific and clinical subject, 
and that there should be clinicians integrated with basic sciences. Anyway, I got 
the job. My background was clinical, so my work in UCL was limited; I simply 
did clinical pharmacology at the medical school, and we developed from there. 
flower: How many people were there when you first began?
67 Professor Desmond Laurence wrote: ‘When Max Rosenheim was president of the Royal College of 
Physicians (PRCP), the College ran Advanced Medicine Conferences. I was told I must contribute, so 
I put my best foot forward and showed Max my text. He said it was too complex. I replied: “This is an 
Advanced Medicine Conference”. He said, “Exactly, so keep it simple.” He was a marvellous man, also what 
is known as a “doctor’s doctor”, ie sick doctors sought him out.’ Note on draft transcript, 21 June 2008. 
Professor Desmond Laurence wrote: ‘Rosenheim, although not a clinical pharmacologist, was the first editor 
of the Department of Health’s Prescribers’ Journal. It was then entirely more appropriate that a physician 
should have edited this.’ Note on draft transcript, 4 July 2008. See also note 117. See Biographical note 
on page 114.
68 Professor Desmond Laurence wrote: ‘Many senior doctors thought clinical pharmacology was a rash term 
for mindless prescribing. The senior physician once chased me round the medical school as he thought I 
had criticized his treatment of a patient. Max Rosenheim told me not to let it bother me.’ Note on draft 
transcript, 21 June 2008.
69 Frank Winton was professor of pharmacology at UCL from 1938 to 1961. For the history of the 
department, see www.ucl.ac.uk/Pharmacology/history.html (visited 7 May 2008). See also Black (1994).
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laurence: One in UCH Medical School: there was just me and it gradually 
developed. It was always a fairly modest enterprise. I went to the joint post in 
1954 from St Thomas’ Hospital Medical School.
mcdevitt: I think there are a number of different models that operated in 
the 1960s, during that transition phase. For example, there were places like 
Belfast, where they had had a department of pharmacology, and it certainly 
wasn’t a research department as far as I was able to find out historically, and 
they really moved right over to appoint a professor of clinical pharmacology 
– Owen [Wade] will correct me – and effectively abandoned pharmacology as 
a subject. So, that was one model, I think, but what they did critically was to 
make it a clinical department and they gave the department its own beds. Now, 
another model, I think, was the one that existed in Scotland, where they always 
had chairs of materia medica in most of the medical schools, and there were 
clinical departments, but, I think, they also had departments of pharmacology, 
or certainly pharmacologists present. Then there were other places where a 
clinical pharmacologist was added on to a department of pharmacology, and 
that was often extremely difficult, because they often didn’t have very much in 
the way of clinical access. So, I don’t think there is a model that applies to all, 
and sometimes I think it critically influenced what happened beyond that, as to 
how the thing was set up.
Prichard: When I joined Desmond as his research assistant at the end of 
1961, we had very little clinical base, though we were located in the clinical 
faculty. Our clinical activity at that time was a matter of performing a couple 
of outpatient sessions, mainly in the care of hypertension patients. This was in 
Max Rosenheim’s hypertension clinic and attending his ward rounds. However, 
over a number of years the clinical commitment developed, and in 1966 I was 
given charge of beds and in due time ran a full clinical service. Of course, such 
commitment is very heavy in terms of time, the total number of sessions one has 
to perform, and I guess until Patrick Vallance came to UCH we were understaffed. 
A seven-tenths clinical commitment and teaching obligation didn’t leave so 
much time for research. In spite of the commitment and pressure on research, 
I think it is very important that one has a clinical base, though the roots of the 
subject of course, scientifically, are in pharmacology. In the late 1960s and early 
1970, Robin Shanks, the late Paul Turner and myself with others, including 
Colin Dollery, Duncan Vere and Desmond Laurence, set about establishing the 
Clinical Section of the British Pharmacological Society (BPS).70 As our scientific 
70 See, for example, Aronson (2006).
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roots were in pharmacology, the British Pharmacological Society was where we 
felt the forum for clinical pharmacology in the UK should be. I guess it also had 
a fair amount to do with the fact that most of us were members of the BPS in 
any case. I think that’s a very important point that deserves emphasis – if you 
are going to practise clinical pharmacology you do need your feet in the clinical 
area, but not forgetting one’s scientific roots. 
[Professor Sir James Black commented that Brian Prichard was being 
too modest. They first met in 1960, when Prichard was working with 
surrogate markers and in 1962 Black took him pronethalol, which 
Prichard gave to patients, gradually adjusting the dose until all the 
patients had pulse rates at rest at 60/minute before the trial monitoring 
their blood pressure. This was a trial of equal effects, not equal doses and 
their blood pressure slowly came down.71 When propranolol came along 
in 1964, Prichard again tried to achieve a 60/minute heart rate, which 
was the first study of β-blockers in hypertension. The range from the 
smallest to the highest dose of propranolol was about ten-fold, which 
got Prichard into bad odour with his colleagues.72]
flower: Brian, you have been severely censured for being too modest, but do 
you want to deny or confirm the fact that you got into bad odour with your 
colleagues?
Prichard: I thank Sir James Black, the pioneer of β-blockers, for his comments. I 
had a little trouble with ICI, who I had to cajole into making stronger tablets. At 
first they only produced 10mg tablets of propranolol. Some of my patients were 
taking 40 tablets a day, at least they told me they were.73 I persuaded ICI to make 
40mg and 80mg, and then 100mg for patients with angina and hypertension, and 
250mg tablets of propranolol for hypertension patients. I think the important 
71 Prichard et al. (1963). Professor Brian Prichard wrote: ‘We started patients suffering from angina pectoris 
on a small dose of pronethalol and gradually increased the dose up to the maximum tolerated. Patients 
entered the double blind phase of the trail at the highest dose that was free of side effects. Pronethalol 
was found to produce tumours in mice and was withdrawn for that reason and was not well tolerated. 
Propanolol became available in January 1964 and was devoid of sympathomimetic activity. The reduction 
of blood pressure seen in normotensive angina patients with pronethalol was reported and described in 
hypertensive patients, as was the use of propranolol in 1964. Several papers followed with a series of 109 
patients described in 1969. ’ Note on draft transcript, 20 September 2008. 
72 Prichard (1964). 
73 Prichard and Gillam (1969).
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principle of what Sir James has just referred to is that I always felt you should 
apply dose–response principles evaluating new drugs in patients, having been 
trained by performing dose–response curves to various agonists in the guinea-pig 
ileum for about three solid months.74 This means once you have the principle of 
dose–response hammered into your brain, it never leaves you. We applied this 
to attacks of angina, and we did a 4-log incremental dose–response curve of 
propranolol plus placebo in angina pectoris, and obtained a beautiful straight-
line dose–response relationship over the doses used: as shown in Figure 2.75 
laurence: I think I heard Brian Prichard say that he was my assistant. Well, it 
didn’t seem like that to me. He always did exactly what he wanted.
Professor John reid: Can we go back to the origins of clinical pharmacology 
and some of its most successful groups? I am struck, having been chairman of 
a large academic division of medicine for the last 10–15 years, by the relatively 
74 The relationship between the dose of a drug administered during a trial to measure direct drug effects and 
the response of the organism to the drug over time (mg/minute) as illustrated in a graph. See, for example, 
Aellig (1981).
75 Prichard and Gillam (1971); Gillam and Prichard (1971). 
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figure 2: dose–response curve to propranolol on the number of attacks of anginal pain.
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small scale of some of these influential early groups. I went from Oxford to 
the Hammersmith Hospital in 1969. When Donald Davies joined him, Colin 
Dollery was the only clinical academic. Alasdair Breckenridge was a senior 
registrar and Jim Paterson and Michael Orme were registrars. Alasdair later 
joined the staff, but when he went to Liverpool I was recruited back from 
NIH on a Wellcome Trust senior clinical fellowship. What was an enormously 
influential group in drug metabolism and cardiovascular pharmacology was a 
very small team. I am sure the same is true at UCH and Bart’s. 
flower: Brian, you mentioned Paul Turner a minute ago, so I am going to ask 
Mark Caulfield, who was present in Paul’s department for many years and a very 
close colleague, to say a few words about him, and then I would like maybe to 
ask Duncan Vere to talk about things at the Royal London and how they got 
going, if that is appropriate, Duncan.
Professor mark Caulfield: Thanks very much. It’s a pleasure to talk about 
Paul. I wasn’t there, obviously, when the department was formulated, because 
I was still at primary school, but I think that Paul was an incredibly kind and 
influential man in clinical pharmacology.76 He was passionate about the subject, 
and believed that he really should put his entire endeavour into making sure 
that as many people got as enthusiastic as he was about the subject. And his 
influence was Sir Thomas Lauder Brunton, who is probably an early example 
of the medical transfer market that we now enjoy in medical schools, because 
we poached him from his lectureship in materia medica at the Middlesex 
in about 1897 to be the first lecturer in materia medica at Bart’s.77 And his 
principles were observation, measurements and experiment. There’s a picture of 
him in the north wing of the medical school, and on his arm there is a Marey 
sphygmograph used to record changes in arterial tension, similar to one that 
you used to use, Patrick, and others, in measuring hand vein changes in vessel 
dilatation. He was very much an inspiration to Paul Turner.
Paul was influenced by him, but also by some of the people he came across 
earlier in his career. For example, Sheila Sherlock wouldn’t let him have a day 
off, and even when he wanted a day off to plan his wedding, she said, ‘Well, 
Turner, if you have finished all the ward work, off you go and draw graphs’.78 
76 See, for example, Turner (1993).
77 See Brunton (1897, 1906); note vase of foxgloves (from which digitalis is derived) in Figure 3. See also 
Medvei and Thornton (1974).
78 Turner et al. (1962).
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Basically, he got this fundamental training in observation, measurements 
and experiment from his early career. Turner went to work with Professor 
Quilliam (also known as Q) at Bart’s where he and Mike Besser – whom 
some of you may have heard of vaguely – were contemporaries in Q’s lab. 
And it looked like Mike Besser – you probably don’t know this – was being 
earmarked for the first lectureship in clinical pharmacology, but he went off to 
the US for a while, and in that time Sir Eric Scowen appointed Paul Turner to 
the lectureship in clinical pharmacology. So, as a result of that, Mike became 
an endocrinologist.79 
But Paul’s enthusiasm for the subject was really manifest in his teaching. I 
trained at the London with Duncan Vere, Tony D’Mello and Ziggy Kruk, 
79 See, for example, Delitala et al. (1983).
figure 3: sir thomas lauder Brunton, 1913. oil on canvas portrait by  
sir hubert von herkomer, presented to st Bartholomew’s hospital in 1960. 
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and the foundation in basic pharmacology there was fantastic. One of the 
things that was incredible was to watch Paul Turner teaching medical students, 
because he always taught them as if they were standing at the end of a bed with 
somebody that they had to treat and save. And so, in his teaching, he always 
had a strong connection with the students. When I came in 1989 – because 
I had applied for a job with Denis McDevitt – but Paul didn’t shortlist me, 
probably very wisely, as he was ill at the time having had coronary grafts, and so 
what happened was that I got appointed in his absence. So, at my first meeting 
with him, he said: ‘Your responsibility, Mark, is to make sure that with all the 
medical students, the teaching is really well organized; we pride ourselves here 
in making everyone a rational and safe prescriber when they get to the point of 
exit from this medical school, it is really important.’80 And, as Charles George 
will attest, because he inspected my post – unfortunately one of the drawbacks 
of my post was that you spent most of your time doing clinical work or teaching 
as a result. But Paul also recognized the value of developing countries and the 
wealth of talent that was hidden there that needed to be drawn out and he had 
a long history of people coming from all over the world. 
The other thing is that he wanted to create clinical pharmacology across 
multiple specialties, and so he always had fellows, and this may be one thing 
that in the modern day we would criticize him for, and that’s perhaps the lack 
of a focused research strategy in one disease area. But he believed that one of the 
great things about clinical pharmacology was you could go where you wanted 
to, and so if you found something in one area that took you somewhere else, 
there was no physical barrier to your forming collaborations to go there. So he 
had cardiologists, oncologists, palliative care doctors, all training with him in 
the time that I was there. And although it was multiple disciplines, we all learnt 
something from each other. But the fundamental core principles that make 
an excellent clinical pharmacologist were there in every one of those people, 
and although they went on to do other things they took those with them. So 
although unfortunately, as the editorial in the 1969 BMJ says, we never quite 
managed to have a clinical pharmacologist in every district general hospital, he 
was hoping that he had put some clinical pharmacology into other specialties, 
and that’s the way he worked.81 He was a very Christian person in his outlook 
and he would always try to look after his colleagues and make sure that they 
were well served in their time with him. But I think his contribution to clinical 
80 See, for example, Gorog et al. (1993). 
81 Anon. (1969).
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pharmacology probably was in trying to spread it as broadly and widely around 
the world through the many people he trained, many of whom have gone on to 
industry as well as to academia. 
flower: We are going to come back and talk about the journals in a minute, as I 
think that is a very important topic. First, Duncan, do you want to say anything 
about the development of the subject at the Royal London?
Vere: Very briefly, it was a series of U-bends. What happened at the London 
was that I was seconded across to the department of pharmacology under Miles 
Weatherall; Andrew Herxheimer, Tony D’Mello and so on were there. And I 
spent some time there in pharmacology. But then I was elected to the staff as a 
physician, so with that went beds and outpatient sessions. It was a tremendous 
load of work, particularly as the clinic was on a Saturday morning in the East 
End of London. And then, of course, with that went registrar posts, and so John 
Dunne and Maurice Cuthbert came into those posts, in SHO and registrar 
posts, but as clinical pharmacologists in the making. And, of course, they have 
since gone on to much else in clinical pharmacology. But that was how it began, 
by a series of growths round U-bends. It was very difficult to find the time 
to teach clinical pharmacology, therapeutics and so on. We had 130 hours of 
teaching time in those days. Now this has all evaporated, gone. But that was 
what happened near the start.82 
Prichard: I would like to make two points about Paul Turner. Paul was a devout 
Christian, and, in fact, when I went to India as the BPS (British Pharmacological 
Society) visitor, he suggested to Professor Molly Thomas in Vellore that I should 
take a service in one of the churches of South India.83 While I had not preached 
in very many churches, it was as a result of Paul Turner that I had the privilege 
in India. But, another point to make about Paul is that early on in the Clinical 
Section of the BPS when I was secretary, I was doing preliminary work for 
setting up the British Journal of Clinical Pharmacology, and I was delighted when 
he agreed to be volunteered, press-ganged, into becoming our first editor of that 
journal.84 He certainly made a great success of that task, setting the journal on 
a successful course. 
82 See Vere (1987).
83 Dr Jeffrey Aronson wrote: ‘Universally known in India as “Doctor Molly”.’ Note on draft transcript, 
14 July 2008.
84 See Aronson (2004).
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dr Kenneth hunter: May I take up John Reid’s point about how clinical 
pharmacologists, even though few in number – in his case he was mentioning the 
Hammersmith – cooperated together and, in a sense, were more than the sum 
total of their individual parts. Because I think the same was true at UCH, where 
I was a student. I became aware of clinical pharmacology as a house physician in 
the medical unit there, and I think one of the things that hasn’t been emphasized 
enough by Desmond Laurence and Brian Prichard, was the tremendous influence 
of the professor of medicine, Max Rosenheim, at the time.85 He was the one that 
encouraged clinical pharmacology. I am sure Desmond would say that he was 
given a very free rein and was able to do it, but it was very much helped by 
Max Rosenheim’s stature and his tremendous influence. I remember as a house 
physician we used to have a weekly business meeting, where we went through 
all the patients that had been discharged and talked about them, and Desmond 
Laurence would come along to the meeting, and to other teaching meetings and 
so on, and gave a different input to the discussion as a clinical pharmacologist. 
I think it was the influence of clinical pharmacology that permeated through 
the medical unit certainly, and probably, in a sense, through the whole hospital, 
which was very important. And then I went back as a registrar, and registrars in 
medicine at that time could rotate through all sorts of firms, like neurology, and I 
was working in neurology and a post came up which was between neurology and 
clinical pharmacology, because levodopa was a new drug and the MRC wanted 
people to study that. That was a tremendous experience, working jointly, half 
in clinical pharmacology and half in clinical neurology, for a couple of years. I 
think it was the influence of clinical pharmacology going out into all the other 
departments that was terribly important. 
flower: Thanks very much, Ken. I don’t want to be too ‘London-centric’ here, 
because obviously things were happening in other parts of the country. Phil, do 
you have any reminiscences about the development of the subject in Wales or 
in Cardiff in particular.
Professor Philip routledge: I suppose my entrée into clinical pharmacology 
was in Newcastle, and I don’t think there’s anyone else here from Newcastle, 
so just to say a few words about that. Sorry, Robin [Ferner] is here. I think 
Mike Rawlins had an enormous impact when he came in 1974 to Newcastle. 
There was a department of pharmacology but no department of clinical 
pharmacology, and Dai Davies, the late Dai Davies, was ploughing a lone furrow 
in adverse reactions; and I think Mike’s appearance crystallized those interests 
85 See biographical note, page 114.
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around the department of pharmacology and it became a joint department 
of pharmacology and clinical pharmacology.86 I think the strength of it, as we 
have heard earlier, was the beds. There hadn’t been beds attached to clinical 
pharmacology, and as soon as there was a clinical base, clinical pharmacology 
became attractive to junior doctors like myself, because they could see the 
relevance of it. So I owe my interest in pharmacology to Desmond Laurence’s 
book as a medical student, which was a delightful book to read as one of 
those of the Hammersmith diaspora who came to clinical pharmacology in 
Newcastle. 87
Professor Walter nimmo: I came to clinical pharmacology from anaesthesia 
to work with Laurie Prescott. I had trained clinically in anaesthesia before 
moving into clinical pharmacology and then went back and forward once or 
twice. Training in clinical pharmacology was useful in anaesthesia practice and 
vice versa.
Professor robin ferner: Perhaps I can draw one or two threads together in fact, 
because I had gone back to UCL and then to UCH to study medicine, whereas 
I had started off as a chemist. And at UCL there were inspirational teachers of 
pharmacology. There was Heinz Schild, who was revered; I wouldn’t say his 
lectures perhaps were as riveting as other members of staff. There was a young 
chap called Jim Black, in an interregnum I guess. Then there was the thrill of 
going to Desmond Laurence’s lectures, which were fantastic and marked by 
newspaper clippings related to awful adverse effects, a habit which I have got into 
and, I gather, he has still got a drawer of newspaper clippings somewhere, which 
one might have access to. Brian Prichard – my memory is having rows with him 
– sorry, having an academic discussion with him – about the value of measuring 
blood pressure to 2mm of mercury, which varied from one reading to another 
by 10mm of mercury, and maybe today I will learn the answer. After house 
jobs at UCH, I then went to Newcastle, not with the clinical pharmacologists, 
but with Bob Souhami, and there were a number of dramatic and important 
teachers in Newcastle, of whom George Alberti and Mike Rawlins were two. 
As you have heard, although Mike may not have lectured a great deal, he got 
his staff to teach in small groups. So the threads I would draw together are: 
 relatively small departments, as John Reid has said; very influential teachers, as 
Patrick Vallance and Mark Caulfield have said, and an exciting time.
86 See biographical note, page 113. 
87 Laurence (1966).
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orme: One or two things to draw together. First, following, I think, Denis 
[McDevitt] and others, about the importance of the clinical input. Certainly, as 
we are now moving into the 1970s, when I moved with Alasdair Breckenridge 
to Liverpool in the mid-1970s, the clinical experience for the first time was 
allowed. In contrast, in Manchester George Mawer was working at the time, but 
he was only allowed access to outpatient facilities, and perhaps as a result clinical 
pharmacology never took on there. So I would stress again the importance of 
inpatient facilities and beds. The other striking thing in Liverpool at that time, 
and Andrew Wilson’s name has already been mentioned, but he was working 
and trying to work clinically, following Dilling, who has also been mentioned.88 
The problem was that he was really kept out of the clinical work by a variety of 
rather parochial clinicians in Liverpool, and the only clinician at that time who 
was active and helpful was David Price-Evans, whose name might have come up 
– another Welshman, Don, who was very productive. He wouldn’t call himself a 
clinical pharmacologist, but I think that’s what he was and in some ways still is, 
ploughing away in Riyadh, Saudi Arabia. I think the importance of the clinical 
input was significant. 
The only other topic I would like to cover is the combination of pharmacology 
and clinical pharmacology. When Alasdair and I moved to Liverpool the 
pharmacology department was there, and we were placed in the pharmacology 
department, which gradually changed its name to pharmacology and 
therapeutics. The strengths of anything that we have achieved in the research 
side, I think, are based heavily on having a very strong pharmacology department 
with the basic sciences always there, and that allowed us, I think, to emphasize 
teaching. I guess we could talk all afternoon about teaching and maybe one 
of the things that might come up at the future meeting is the role of deans 
in this. There’s something about clinical pharmacologists that seems to be a 
disease, that they would go on and become deans – there are several of us here 
in this room; obviously the influence there is on teaching. I don’t want to side-
track us into teaching at the moment, but maybe if you are thinking of a topic 
for the September meeting, the teaching side could be touched on. But just 
to stress, I think, the importance of working with pharmacology and clinical 
pharmacology together cannot be over-emphasized.89
88 Cohen (1972).
89 For the transcript of the second Witness Seminar held on 25 September 2007, see Reynolds and Tansey 
(eds) (2008).
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Wade: What is in my mind is to make a comment about prescribing. And, I 
want to pay a tribute to Jim Crooks. He, I and Dr William Wallace, a youngster 
in my department, looked at errors in prescribing in the hospitals where we 
were working in the early 1960s.90 It was really after that that Jim produced 
the ‘Aberdeen’ prescribing form which is now so widely used in hospitals.91 In 
the old days, doctors used to write a prescription in the patient’s notes, and the 
ward sister would make a list for nurses to administer the medicines – it was all 
very casual, and accuracy was becoming much more important with the arrival 
of antibiotics and corticosteroids, etc., in the postwar period. More precision 
was needed, and I think Jim Crooks played a very big part in this important 
development.
90 Crooks et al. (1965); Wallace (1965); Crooks (1975); Wade (1966). See also note 44 and page 79.
91 Crooks et al. (1967). See also Hamley et al. (1981); Wade (1996): 98–9.
figure 4: aberdeen Prescription sheet, 1967. source: Crooks et al. (1967): 235.
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mcdevitt: Just to give an illustration of the basis of clinical pharmacology being 
in clinical medicine, and the importance of having not just access to beds, 
but preferably a ward unit that the department actually was responsible for. 
Something like 20-odd years ago, there was a meeting, not quite like this, but it 
was in America, and it was to review the first 20 years of clinical pharmacology 
in, principally, the UK and the US.92 One of the things I was asked to do was 
to survey the senior registrars in training, and one of the questions that I asked 
them was to prioritize what their ideal career post would be. And the things that 
they put at the very bottom of the list were the things where they would not 
have direct responsibility for patient care.93 I think that the success of clinical 
pharmacology in this country for a long time was the expectation that you would 
get a job where you would have your own patients to treat, and where you could 
encompass all the excitement of clinical pharmacology in your research career. 
Barnett: Just to extend the concept of the importance of the clinical input of 
clinical pharmacologists. Because of the wide spectrum of medicine that clinical 
pharmacology covers, clinical pharmacologists became general physicians, and 
have continued to be that way, taking a holistic approach to the whole of medicine 
and therapeutics. This has continued for many years, but is now gradually 
fading. General medicine was retained in clinical pharmacologists who had 
clinical practice, simply because they didn’t have another specialty, and because 
therapeutics covered all of medicine. I echo what Mike Orme was saying, that 
the issue about teaching and expressing what clinical pharmacology is across 
the general medicine horizon is still very, very important, and unfortunately it’s 
failing so badly.94 
flower: I want to encourage anyone who wants to say anything about the 
development of clinical pharmacology in centres other than London to say their 
bit if they would like to do so, before we move on to the next topic.
grahame-smith: I would just like to say a word or two about what happened 
in Oxford, and Stan Peart can give the background of the views of the 
MRC at that time better than I can. But to cut the story short, after a fairly 
frightening interview and at least two post-interview interviews in Oxford, I 
was appointed to the chair of clinical pharmacology in Oxford and director 
of the MRC Unit of Clinical Pharmacology in 1972. Now, those of you who 
92 For a discussion of the Anglo–American meeting, see page 15. See also Melmon and Turner (1986). 
93 McDevitt (1986).
94 See page 30. 
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know about these things will know that you are not just appointed; you have 
to go through a long process of producing a full programme of research until 
you are 60, which takes quite a bit of doing. This was not easy because I 
was not in the mainstream of clinical pharmacology; I was still a clinical 
biochemical pharmacologist. And I was interested in the brain, because some 
of you may know that serotonin is in the brain, and it became a popular area 
of research for the next two decades. I really wanted to develop basic and 
clinical psychopharmacology in Oxford, and Professor Michael Gelder, who 
was professor of psychiatry, was very interested in clinical psychopharmacology 
and he too was attempting to get it going, and it was clear that there would 
be a place for collaboration between the department of psychiatry and the 
department of clinical pharmacology. So in fact, all the time that I was there, 
one of my main thrusts was basic and clinical psychopharmacology, doing 
basic experiments to elucidate mostly the effects of drugs upon the serotonin 
system and translate that into the clinical sphere and also at the same time 
training people in neuropharmacology, which they could then apply to their 
work in clinical psychopharmacology. That has been very successful, and 
Phil Cowen, professor of psychopharmacology in Oxford, Guy Goodwin, 
professor of psychiatry in Oxford, Dave Nutt, professor of psychiatry in 
Bristol and Professor Paul Grasby, professor of psychiatry at Imperial College, 
London, all went through the MRC Unit of Clinical Pharmacology, learning 
both basic neuropharmacology and clinical psychopharmacology. That was, I 
think, quite successful training for them and produced a lot of papers of one 
sort or another. 
The other area that I was very interested in, in terms of biochemical pharmacology, 
was finding surrogate biochemical pharmacological markers for drug effects, 
and Jeff Aronson has spoken about sodium–potassium ATPase in red cells, 
which is a good example.95 It never quite came to anything clinically useful in 
an everyday sense, except – and to me, this was a big surprise – we showed an 
adaptive response of red blood cells to long-term treatment with digoxin in 
humans. In other words, the red cell develops more sodium–potassium ATPase 
sites. For me, this triggered a great interest in neuroadaptive responses in the 
brain to chronic treatment with antidepressants, neuroleptics and almost every 
CNS drug that you can think of, because the brain is one of the greatest adaptive 
organs, par excellence. So those were the main themes of the unit’s work over 
the years. However, I found it very difficult to establish an accepted and strong 
95 See page 16; Eisner and Smith (1991). 
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identity for clinical pharmacology in Oxford. I remember treating a very well-
known and distinguished professor of philosophy in Oxford after a mild stroke, 
who asked me: ‘What’s your specialty?’ in the way that they do in Oxford. I 
replied, ‘I am professor of clinical pharmacology’. ‘What’s that?’ So I said, ‘Well, 
studying how medicines work, what they do to the body, how the body deals 
with them, their effects and their side effects’. ‘Oh, you are the professor of 
pills’. Straight in, ‘professor of pills.’ 
When I first went to Oxford, I went to an induction party by the Rhodes Trust. 
I was introduced all round by the secretary of the Rhodes Trust as the professor 
of criminal psychology, which, of course, is very much more interesting at a 
cocktail party than the professor of clinical pharmacology. [From the floor:  I 
shall use the line myself.] And then finally, just to give the flavour of Oxford and 
how difficult it can be, going to a private dinner and sitting opposite a very nice, 
very distinguished lady of the upper classes, who said, ‘How did you get here, 
young man?’ (because I was a young man). I went through the whole rigmarole 
and she said, ‘How did they know that you would be socially acceptable?’ So, 
these are some of the things that I came across in Oxford that are relevant to the 
teething troubles of clinical pharmacology. 
But I have to say I had a row at the interview for the professorship, not a big 
row, but subsequently at the post-interview it was quite a row, because I insisted 
that I wanted to continue to do clinical medicine and this was contrary to some 
opinions in Oxford at the time. My reason was that I very much liked doing 
clinical medicine, and I don’t think that a clinical pharmacologist could hold 
his head up unless he knows, in fact, about the prescribing of drugs to people 
who are ill. Also, the clinical students will soon find you out if you are just 
a theoretician. You have got to know what you are talking about on a ward 
round or whenever you are teaching clinical students, you really must know the 
practical implications. I think it is extremely important to maintain this contact 
with ordinary, grubby, day-to-day medicine. Our problem is – and it hasn’t been 
said yet – that we are not organ-based. That’s why the subject finds its position 
difficult, because we are not organ-based. Those who fund the National Health 
Service would rather pay the pharmacists (cheaper) to look after the drugs, 
not the clinical pharmacologists. So there is still a serious problem, I think, 
in identity of the subject of clinical pharmacology and I don’t know how you 
overcome that.
flower: I think it is best if we stick to criminal psychology.
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aronson: David didn’t tell you, but he told me that when he was accused of 
being a criminal psychologist, someone asked him what did he specialize in? 
What would you say? Drugs. 
I wanted to add something to what David said about Oxford. When we arrived 
we rapidly learned that there were two groups of individuals in the hospital, those 
who thought that we were rubbish and those who were keen to collaborate – it 
was quite a divide. And you knew which ones steered clear of us, and you knew 
which ones were keen. And we also realized that there weren’t going to be jobs 
in clinical pharmacology, so we did what Mark described Paul Turner doing, 
which was to bring other specialists into the department to train them somehow 
in the use of drugs, and send them out to their disciplines, such as Nick Boon, 
for example, who is now a cardiologist in Edinburgh, and Chris Hawkey, now 
a gastroenterologist in Nottingham. We had nephrologists, psychiatrists and, 
as David has described, a whole host of people across the spectrum of different 
medical disciplines and we hope we seeded our discipline into those specialties. 
And, in turn, we were then asked to collaborate with others outside of the 
department: I published with gastroenterologists, cardiologists, nephrologists, 
psychiatrists, and so on, which has enriched my career enormously by those kinds 
of collaborations that do come if you bring others into your department and try 
to seed as we did and, as Mark Caulfield described, as did Paul Turner.96
reid: I want to add something to David Grahame-Smith’s comment before saying 
something about the Scottish medical schools and Glasgow in particular. I can 
confirm, as a student at Oxford in the preclinical and clinical school through the 
1960s, that there was absolutely no clinical pharmacology. Most students would 
not have known what it was. There was no teaching on prescribing and no 
teaching of therapeutics. In spite of this, I managed to follow a career in clinical 
pharmacology via the Hammersmith. In Scotland it was very different. I do 
not know about Dundee, because it is the newest Scottish medical school, but 
I am certain that in Aberdeen, Edinburgh and Glasgow, clinical pharmacology 
grew out of materia medica and therapeutics as an undergraduate teaching 
responsibility. The universities funded clinical academic teaching posts: lecturers 
in materia medica and therapeutics for over 200 years in Glasgow. One of the 
early ones was professor of botany as well as professor of materia medica. The 
name changed to therapeutics in Edinburgh and Aberdeen in the 1960s because 
of local interest in drug regulation and safety, led by Alastair Macgregor and 
96 See, for example, Willoughby et al. (1982); Williams et al. (1978); Brearley et al. (1993); Antia 
et al. (1995).
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Derrick Dunlop.97 Clinical pharmacology was late in coming on the scene, as 
it was more of an experimental and research discipline in the early days. The 
merger of undergraduate teaching, drug regulation and experimental medicine 
emerged as clinical pharmacology in the 1970s. However, it was firmly based 
in clinical practice with the professor of materia medica (and later clinical 
pharmacology) always having responsibility for beds in a main teaching hospital 
through the nineteenth and twentieth centuries.
Professor morris Brown: I was going to follow on from David [Grahame-
Smith]’s account of Oxford with an account of the whipper-snapper university’s 
[Cambridge] rise of clinical pharmacology, but John [Reid] got in the way. But 
that’s appropriate in a way, I suppose, because my first subconscious introduction 
to clinical pharmacology – although I have lost the accent – was getting a school 
prize awarded by [Derrick] Dunlop in Edinburgh Academy, and, of course, John 
[Reid] was my first supervisor at the Hammersmith when I came there. But 
Cambridge was very much a sort of new boy on the block, not just in clinical 
pharmacology, but in clinical medicine, in a weird sort of way. There’s been a 
clinical school in Cambridge for a long time, and I think that one of the final 
spurs to setting up clinical pharmacology in Cambridge was that there was a final 
MB in which clinical pharmacology had long featured as quite a major part, and 
the only teaching which went on in Cambridge for that was by an undergraduate 
pharmacologist with a lovely Lancastrian accent called Bill Grundy, who made 
sure that everyone passed, by telling them the questions before they got the 
paper.98 But the university in particular – one can’t call it a preclinical school, 
because there still isn’t a preclinical school in Cambridge, they can’t get the 
departments to agree on that – but the university was rather against giving much 
money to a clinical school for clinical activities. So, clinical pharmacology came 
about after the retirement of one of the physicians at Addenbrooke’s, and it was 
one of the NHS physicians, David Rubenstein, who persuaded Addenbrooke’s 
that they should fund a chair in clinical pharmacology.99 And we have still never 
had any university funding for clinical pharmacology in Cambridge. So my 
own philosophy, having come out of the department at Hammersmith, as John 
described, I suppose, has been more in the way of using drugs to investigate 
disease and physiological processes and that as I am sure you would say yourself, 
David, is challenging. But I very much also followed the Oxford philosophy 
97 See, for example, Macgregor (1965, 1969).
98 See, for example, Grundy (1968).
99 Rubenstein and Wayne (1976).
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that if we are not going to create many pure clinical pharmacologists, we have 
to influence people going into other specialties, and many of our training posts 
have been formally in clinical pharmacology and an organ-based specialty.
Prescott: I would like to follow up on what John Reid said about the Scottish 
medical schools, where there was a long tradition of departments of materia 
medica and therapeutics. These departments were often on an equal footing 
with the departments of medicine, in terms of clinical commitments and 
teaching responsibilities. This was perhaps even more so in the time of Sir 
Derrick Dunlop in Edinburgh, where the department of therapeutics probably 
eclipsed the department of medicine.100 The strong academic tradition of materia 
medica and therapeutics was a great advantage and it certainly facilitated the 
introduction of clinical pharmacology as a specialty. I was appointed as senior 
lecturer in clinical pharmacology in the department of therapeutics in Edinburgh 
in 1969 with Professor Ronnie Girdwood, who was very supportive.101 
Professor frank Woods: Strangely enough, Sheffield is rather like the 
Scottish universities. The first professor of pharmacology and therapeutics in 
Sheffield was William T Cocking (1897–1911), who was appointed in 1890, 
and thereafter you had a succession of Sir Edward Mellanby (1920–33), Sir 
Edward Wayne (1934–53), Grahame Wilson (1954–67) and Robert Kilpatrick 
(1966–75, Baron Kilpatrick of Kincraig from 1996), all of whom had a very 
strong endocrine specialty, and, indeed, towards the end of the 1960s, the 
period we are talking about – the transition if you like – and the emergence of 
clinical pharmacology, the department of therapeutics had more beds than the 
department of medicine. Indeed, whereas I accept what colleagues say that it is 
important, as David Grahame-Smith has emphasized, for respectability, but also 
in relation to the quality and power of your teaching, to be seen to be delivering 
medicine at the bedside and in the clinic, also we found some difficulty because 
100 Professor David Webb wrote: ‘Going back to earlier records [the Edinburgh University Calendar] it seems 
that the Christison chair, which I currently hold, and which was held by Sir Derrick Dunlop, was the first 
chair of therapeutics in the UK, instituted in 1919. The descriptor “therapeutics and clinical pharmacology” 
was only introduced much later, as indicated by Professor Laurie Prescott.’ E-mail to Dr Daphne Christie, 
12 February 2007. See also Blackden (1968).
101 Professor Laurie Prescott wrote: ‘In addition to general medicine, I also had a clinical base in the Regional 
Poisoning Treatment Centre where there were wonderful opportunities for research and teaching in high-
dose human pharmacology. In the course of time, Ronnie Girdwood changed the name to the department 
of therapeutics and clinical pharmacology. I think it is important to remember that the long-established 
departments of materia medica and therapeutics in the Scottish schools laid the foundations for modern 
clinical pharmacology.’ Letter to Dr Daphne Christie, 12 July 2007.
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we had too much clinical responsibility. And once it became clear that we were 
able to recruit high-quality non-clinical scientists, if I may call them that, as 
our equal colleagues, our opportunities for research, so far as I am concerned 
anyway initially, were hampered because of the weight of clinical work. I don’t 
think it did us any harm in relation to teaching and respectability, but I think it 
did hamper some of the research development.
mcdevitt: It’s just to complete the Scottish picture, because of course Dundee 
was for a long time the clinical base of St Andrews University, and so it, like the 
other Scottish medical schools, had a chair of materia medica from the nineteenth 
century onwards. When Dundee University split away from St Andrews, in 
1967, it changed the name of the chair to therapeutics.102 But, in fact, similar to 
what’s just been said by Laurie, there was tremendous power both in the chair 
of medicine and the chair of materia medica. It was actually alleged – and I can’t 
confirm this – that Sir Robert Brockie Hunter, professor of materia medica, and 
Sir Ian Hill, professor of medicine, kept their names on every clinical bed in the 
Tayside region and made a point of going round the beds at least once a month 
and changing some of the treatments, just to make sure that their empire was 
preserved. Now, in fact, when Brockie Hunter went to be vice-chancellor of 
Birmingham in 1968, James Crooks was appointed to Dundee as professor of 
therapeutics, and he was a very influential figure, not just within Scotland, but 
also within the development of clinical pharmacology in the UK.103 
Now, the other important aspect of the teaching responsibilities, which John 
Reid and Laurie Prescott have spoken about, is that very often in the Scottish 
medical schools, departments of materia medica or therapeutics had access to 
final exams, as well as teaching. One of the other difficulties encountered by some 
of these new chairs of clinical pharmacology was in getting into the examination 
system and certainly getting into the examination system after about the third 
year; whereas in Scotland, traditionally, clinical pharmacologists examined right 
up until the final MB. And I think that gave them great influence.
routledge: You asked me earlier to comment on Wales and I think this is an 
appropriate time, because Wales is a very new player on the block. I think it was 
when Alan Richens went to Cardiff in 1981 that clinical pharmacology started. 
He negotiated the beds, which was, I think, crucial. I think he did one other 
102 See www.archiveshub.ac.uk/news/02112106.html; www.dundee.ac.uk/main/about.htm (visited 24 
October 2007).
103 For example, see note 90. 
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astute thing, which was to get an exam in therapeutics mandatory for the very 
first time, so that the students couldn’t become doctors if they failed. Prior to that, 
they could scrape through on the medicine, but Richens developed the objective-
structured clinical exam, based on the Dundee model, which seems now to be the 
model for most of the exams in Cardiff.104 But I think that he recognized that if 
you want a subject to have prominence, it has to be examined and students will 
work at it. He’s left that legacy, for which we in Wales are very grateful.
aronson: I wanted to ask Phil a question about Cardiff, because I am not sure 
if Alan Richens set it up, but when I first visited Cardiff at that time, you had a 
contract unit for doing studies for pharmaceutical companies. This is something 
we haven’t discussed, and I wondered how the presence of such a unit in your 
department, and perhaps Charterhouse [at Bart’s] – I don’t know if it was 
through Paul Turner’s involvement – how did that influence the development 
of clinical pharmacology?
routledge: I think it helped in many ways and I think people like John Posner 
and Tony Peck will have worked with Alan Richens in that unit. It did really give 
opportunities first of all for income generation for other research, but secondly, 
to develop strong links with the pharmaceutical industry. I think Dave Barnett 
mentioned earlier the importance of the Merck fellows. I was a Merck fellow 
and several others were and they did a marvellous priming job in getting those 
of us who were new to clinical pharmacology in the 1970s to broaden our 
horizons and come back with renewed interest in clinical pharmacology.105 
laurence: A word about Sir Derrick Dunlop. I am not sure whether he was 
professor of materia medica or therapeutics at Edinburgh, I think it was 
therapeutics. Anyway, I was involved in setting up, for the World Health 
Organization (WHO), the Technical Group on Clinical Pharmacology in the 
early 1970s and we produced a number of reports [see e.g. Figure 5].106 They 
got in touch with me, particularly about the choice of chairman. So I decided to 
104 Harden et al. (1975); Lowry (1993).
105 See Baber (1991); Posner (1992).
106 Professor Desmond Laurence wrote: ‘The first WHO Technical Report on clinical pharmacology, chaired 
by Sir Derrick Dunlop, is a truly seminal document. Years later, for the first World Conference of Clinical 
Pharmacology at Wembley, organized by Colin Dollery, he had it reprinted for all the delegates, so good 
was it. Over the years, there have been numerous relevant WHO Reports, and also the famous Essential 
Drugs/Medicines Programme for developing countries.’ E-mail to Mrs Lois Reynolds, 20 August 2008. See 
also note 152.
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suggest somebody who was professionally allied to, but not actively professionally 
concerned with, the development of clinical pharmacology (which might lead 
to friction). I thought hard and my thoughts turned to Scotland. Of course, 
I had met Derrick Dunlop. I had heard him lecture: a man of extraordinary 
presence, charisma is certainly the right word for him. So I suggested him and 
gave my reasons. And of course, I knew that in an international meeting it was 
pretty certain that almost nobody would ever have met a character like that 
before. And the WHO got on to Dunlop and asked: ‘Would you consider this?’ 
And so he phoned me and said, ‘What’s all this about?’ And so I told him and 
I said I thought he could be a successful figure for bringing everybody together 
on this relatively new subject, and he said, ‘Well, you’ll keep me informed won’t 
you.’ And he did it, and it worked out as expected. On the first evening, Lou 
Lasagna, who I think was the vice-chairman, escorted us to the usual WHO 
buffet at the beginning of a Technical Group, and Lou Lasagna took Dunlop 
along and he said, ‘Sir Derrick, what would you like?’ and Dunlop pointed to a 
bottle of Scotch whisky, ‘The wine of my country.’107
Vere: Very briefly on Mark Caulfield’s remarks. Paul Turner was a remarkable 
colleague and friend indeed, and we agreed very strongly about joint training 
programmes. It was very difficult in the enactment. I found quite quickly, 
when I was chairing the committee of the Joint Committee on Higher Medical 
Training (now Joint Royal Colleges of Physicians Training Board) on clinical 
pharmacology, that other specialties regarded clinical pharmacology much as 
one might think of bird flu virus nowadays. A couple of brief examples of this: 
 it seemed to me that the cardiologists were the people who really would be 
most likely to accept a joint training programme. This was obvious, but no. 
There was no response at all. The worst, though, was to come, because there 
was a dentist who was a very good clinical pharmacologist and I rang up the 
chairman of the surgical committee, and he turned out rather surprisingly to be 
a pathologist. And he said, ‘No, no, no.’ I said, ‘How about setting a precedent?’ 
And his reply was, ‘We have no precedent for setting precedents.’ And that was 
it; end of conversation. I still think that Paul was right.
flower: We have 15 minutes before tea, and Desmond mentioned the WHO 
report; and somebody, I think it was David, mentioned the MRC’s involvement, 
so I wondered whether anyone might like to say a few words about the impact 
107 Professor Desmond Laurence wrote: ‘He was a great success, and drank my “duty free” bottle of whisky 
in the evening when we planned the next day’s business (he said his wife required him to come home with 
his bottle unopened).’ Note on draft transcript, 21 June 2007. See Figure 5.
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of the MRC in clinical pharmacology or that of the WHO report or the Royal 
College of Physician’s report of 1969?108 What influence did these have on the 
subject? Does anyone feel able to speak to that for a minute or two?
laurence: I think the WHO Technical Report has exerted an immense 
influence.109 I well remember when the International Conference on Clinical 
Pharmacology came to London at Wembley. Colin Dollery was the moving 
spirit and he had, I forget the year of that conference [From the floor:  1980], 
he had the WHO Technical Report reproduced as a conference paper, which I 
think is a sufficient testimonial for it.110
orme: Just a brief comment following on from Desmond on the WHO. I don’t 
know whether we would like to go beyond 2000 in our terms of reference, but 
one of the worries that I have had about WHO is that since that report there 
108 See notes 24 and 25.
109 World Health Organization, Study Group (1970). See also Gross (1986); note 152.
110 Dollery (1978); Turner (ed.) (1980). 
figure 5: Who technical report no. 446, 1970.
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has been an almost total silence from the WHO, in spite of attempts in the late 
1980s to get it brought up to date. But if there is some good news, I gather 
that the new WHO Director [Dr Margaret Chan, from 2006] is having a new 
broom and one of the things that they seem to be more interested in is not 
neglected diseases, but clinical pharmacology. So whether anything will come of 
this – the trouble is the WHO is a rather strange organization, but maybe things 
are a little bit more positive than they were during the last 25 years. 
george: I think those were incredibly important reports and they did outline 
the training programme and the potential career contributions you could 
make following a training programme. It also meant that there would be a 
certain number of physicians who carried senior registrar status; and then the 
fly in the ointment came along, which was the Department of Health’s Joint 
Planning Advisory Committee (JPAC), which had obtained some figures from 
Paul Turner that suggested that rather than there being 24 posts in clinical 
pharmacology, there should only be 12 for the whole of the UK. I managed 
to draw on Denis McDevitt’s article, which had been printed in Clinical 
Pharmacology and Therapeutics, and then to do a rapid survey round the UK 
departments of clinical pharmacology and went to JPAC with a proposal that 
we should actually have 24 posts.111 And everybody accepted my figures, and the 
late John Swales at the tail-end of the meeting said: ‘Why don’t we be generous 
and give them 25?’ And everybody went away happy, except the man from the 
Department of Health.
mcdevitt: Just an example against Charles’s background of 25 posts in England. 
When JPAC came out, and when they were starting to approve senior registrar 
training posts, we managed to ask them to approve our department for two 
posts in clinical pharmacology, but also because general medicine was part of 
the system, we had it approved for two posts in general medicine as well, and 
we managed to persuade the powers that be in Northern Ireland that we should 
have four posts.112 So, for a period of quite some years, we actually had four 
senior registrar posts within our department, and we used them basically to 
bring people through to do MDs. Dennis Johnston, who’s now the head of 
clinical pharmacology in Belfast, trained under that system. But a lot of them 
did what other people have been doing; they did, say, two or three years with 
us, and developed a particular interest and went off to become consultants in 
111 See McDevitt (1986); Reid (1997).
112 See Glossary, page 123. 
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a different specialty. But we were particularly fortunate at that stage that we 
managed to buck the system.
herxheimer: I would like to make a slightly different comment, which concerns 
the start of clinical pharmacology. Clinical pharmacology is the offspring of 
a union between pharmacology and medicine and these have not been equal 
partners. The initiative, as we have heard, the power, has always lain with 
medicine, and so pharmacology has played a hugely important maternal role, 
but the father has really determined the career of the offspring. I think that 
if we look at all the stories that we have heard from different places, we can 
see that is how that interaction has played out in its different variations. For 
example, the JPAC posts are entirely from medicine; pharmacologists played 
no part in that.113 Pharmacology was nothing to do with it; it’s like once you 
have recognized the importance of clinical pharmacology in a medical context, 
then the child has left home and the career is determined by the male ancestry. I 
think that’s very impressive, and I think it’s self-perpetuating, because medicine 
has the power everywhere, both in education and in health services and other 
places where clinical pharmacology is needed. So, we are left with that structure 
and we have to make it work.
flower: That’s a good point; would anyone like to talk to that?
fowle: I’m ex-Wellcome Foundation. When I joined Wellcome I became a 
consultant physician at the same time, and I have listened to the conversations 
from dedicated clinical pharmacologists who ran departments, and I wonder 
what they thought they were running them for, because if you have to turn 
out clinical pharmacologists, you have got to find a place to put them; not just 
teach other clinical pharmacologists. And at the time that I became a consultant 
the burning question from the other physicians interested whether you were 
going to join them or not, was: ‘Are you going to help me with my load of 
peptic ulcers?’ Have we forgotten just what a huge lot of medical outpatient 
work was considered very dull by physicians? And, they weren’t very welcoming 
to somebody who was going to be a clinical pharmacologist, who would, they 
thought, just tell them how to use digoxin. I can remember that from when 
I was a senior registrar working for Walter Somerville.114 I could not imagine 
Walter Somerville accepting advice from a clinical pharmacologist on how to 
use digoxin on his patients, and I suspect the same thing applied to physicians 
113 See, for example, Hurst (1990).
114 See Tansey and Reynolds (eds) (1999).
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in other specialties. And when I toured Australia and saw how many universities 
had departments of clinical pharmacology, dedicated to turning out graduates 
of clinical pharmacology, I wonder where they thought they were going to get 
a job. 
flower: Any Australian graduates here?
laurence: Let us not forget the considerable role of clinical pharmacologists 
from this country in developing the Essential Medicines Programme of the 
WHO, particularly in getting it off the ground.115 And just a tip for somebody 
who wants to flatter a physician who’s doubtful about clinical pharmacology, is 
to say, ‘Well, when I am ill I want a physician to come through the door, not a 
clinical pharmacologist’, and that cheers them up.
flower: We are now going to discuss various matters, but I would like to kick off 
by asking Charles George to talk a little bit about the significance of specialized 
societies dealing with clinical pharmacology, and clinical pharmacology meetings 
which have stimulated the area, publications which have had an important 
influence, and so on. 
george: Perhaps I should declare an interest; I am a non-executive director of 
the BMJ Publishing Group, which is not only concerned with the BMJ but 
also has a stable of 19 specialist journals, and of course they are very important 
to learned societies for obvious reasons. The first is that they enable people 
who presented at the meetings of the Society to tidy up their manuscripts and 
submit them to a journal which is ethical and which actually will publish some 
of their papers, either soon afterwards or subject to modification. In the case of 
the Clinical Section of the British Pharmacological Society that came into being 
in 1970, and Paul Turner was the first secretary of the editorial board of the 
journal in 1974, and did a sterling job, with assistance from other members of 
his group, Alan Richens and Anne-Marie Hedges, who acted as sub-editor and 
did a phenomenal job over many years. The proximity of the editorial offices in 
John Street to St Bartholomew’s Hospital, of course, aided and abetted the way 
that they ran the journal for many years and even though Alan subsequently 
moved to Cardiff, in 1974, he paid at least a weekly visit to John Street to run it 
the same way. I inherited the journal in 1985 and ran it from 1985–87, and if 
I made any contributions at all, it was to make it demonstrably possible to run 
it outwith London, and Elizabeth Whelan kept me busy with a liberal supply 
115 See WHO, Expert Committee (2007). See also Glossary, page 122.
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of manuscripts.116 These I farmed out to other members of the editorial team 
and it seemed to go reasonably well. Looking back on the journal in its early 
days, the methods section seemed to me to be a very successful thing among 
the profession. 
We clearly made substantial profits, not only for the publisher, but also for 
the British Pharmacological Society; not only from the journal itself, but also 
from the various reprints, which were popular among some pharmaceutical 
companies. And in particular, I think the journal supplement, which we started 
– and we had a very good mechanism in those days to make sure that it wasn’t 
just the organ of the pharmaceutical company, but there was a member of 
the editorial board who was responsible for editing the proceedings of those 
meetings held by or sponsored by pharmaceutical companies – I think that 
was a model that was used by other societies in due course. It was very good in 
terms of producing revenue for the society and there’s no doubt that when the 
contract with Wiley–Blackwell comes to an end in due course, others will no 
doubt be courting you for the British Journal of Pharmacology. 
In addition to that, I have had the privilege of working on a number of other 
bodies. I worked on Prescribers’ Journal, which was a very cosy thing. I think we 
can be a little critical of Prescribers’ Journal, in that it was a bit late in producing 
guidance, but it was very readable, despite the fact that it was largely written in 
committee, by committee, which was rather a strange way of operating. But I 
enjoyed my time there and on the advisory board.117 
My other activity was to work on the British National Formulary (BNF) as 
chairman of the Joint Formulary Committee. Owen Wade, of course, has 
written the history of this in the British Medical Journal in 1993, but he and 
I were co-chairs of edition 12 of the new-style British National Formulary and 
I continued until the year 2000 edition, number 39.118 This was a fantastic 
time. Quite how I became chairman is an interesting story, but I think I was 
a nuisance, as is my wont. I particularly remember writing that I thought the 
advice on management of snakebite was inappropriate, and Owen Wade wrote 
back to me saying, ‘No, you have got it wrong’. So I wrote back and said, ‘No, 
116 Dr Jeffrey Aronson wrote: ‘The publisher Elizabeth Whelan has been associated with the BJCP since 1983, 
when the journal was transferred from Macmillan to Blackwell.’ Note on draft transcript, 14 July 2008.
117 See Glossary, page 125.
118 Wade (1993, 2003). 
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you have got it wrong’, and the advice was subsequently modified in the light 
of experience, particularly of the late H Alistair Reid, who worked in Liverpool 
and Malaysia.119 So during my time, I suppose the circulation increased to 
over 200 000 copies twice a year of the paper version. It did grow in girth, 
but it also grew in stature and we managed to get it so that medical students 
received it twice during their training, although there were some problems 
when there were new medical schools coming along and expansion of student 
numbers, but Liam Donaldson, the CMO, with some reluctance, agreed to 
put some pressure to ensure that they got the requisite number of copies. So, a 
great organ. 
The Monthly Index of Medical Specialities (MIMS) of course is in my brief, but 
I only touch it to mention the fact that it’s not an organ that I have found 
helpful. It encourages A–Z prescribing, by which you start with the prescribing 
of a product which begins with the letter A and you work through B, C and 
eventually you get through to Y, which stands for ‘why not try this’. But it’s not 
very logical therapy. And finally, of course, I should declare that in November 
last year BMJ Publishing bought the excellent publication Drug and Therapeutics 
Bulletin, because they thought it was very important to preserve, despite the fact 
that the Department of Health no longer wished to sponsor it in England.120
flower: Thanks, Charles. We are going to come back to the Drug and Therapeutics 
Bulletin in a minute, but Jeff has a question for you.
aronson: Thanks for that advert for the BMJ, Charles. Can you remember 
when it was that you persuaded the Department of Health to send copies of the 
BNF to the medical students, because as you know last year, or very recently, 
the Department of Health has said they will no longer do that?
george: I met Sir Liam Donaldson, on 24 May 1999.
Professor trevor Jones: There are three other publications that I think are 
worthy of record. The Merck Manual, which I know is very American, but 
terrifically good, is almost small enough to go in your white coat pocket. Unlike 
the other two: Martindale’s Extra Pharmacopoeia, which I think as a quick guide 
is a super place to start, and, if I may say from my days at the Association of 
the British Pharmaceutical Industry (ABPI), the Medicines Compendium. It is 
now available on the Web to everybody, lay as well as professional. I think these 
119 Reid (1976).
120 For further details, see discussion on pages 51–2. 
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publications are good places to start. They are not research-based publications 
but essentially canonical records of the drugs that we use.121
george: Yes, I think Martindale is an excellent publication. They use exactly the 
same evidence base, but the way they present the information is very different. 
I still think it’s slightly unfortunate that Martindale starts with adverse effects, 
which doesn’t seem to me quite the right way round.122 I am dissatisfied with 
the interactive section of the BNF, but there are a limited number of times you 
can bang your head against a brick wall. I agree with you that the Merck Manual 
is also extremely useful, and the ABPI Compendium is much better now that 
people have tightened up their sections on poisoning, which were pretty awful 
at one stage. 
flower: It didn’t include polonium in those days as far as I remember; a 
grave omission.123 I would like to come to you, Andrew, in a minute about 
the Drug and Therapeutics Bulletin, but I wonder, since we are talking about 
the British Journal of Clinical Pharmacology, whether Geoff Tucker would like 
to say something about the journal, which obviously contributed a lot to the 
cohesion of the clinical side of the society, if I can call it that. Do you have any 
recollections you would like to share, Geoff?
Professor geoffrey tucker: I would just like to add the fact that there is more 
than one non-clinical pharmacologist here today. Although I am not a clinician, 
I had stewardship of the BJCP from the late 1980s through the 1990s, which I 
think was a particularly difficult time for clinical pharmacology. It coincided with 
the inexorable rise of the DNA stamp collectors, in almost inverse proportion 
to the demise of clinical pharmacology, I think, so it was a particularly difficult 
time to get things funded in our area and to get them published. But one of the 
saving graces, I think – and I want to bang the drum here for the non-clinical 
contributors to the clinical section – is the tremendous input we had from 
people interested in drug metabolism and pharmacokinetic–pharmacodynamic 
modelling through that period, because that was when we really began to 
understand the enzymology of drug metabolism, with implications for 
121 See, for example, Berkow (ed.) (1982). For a brief history of the British Pharmacopoeia, see Dunlop and 
Denston (1958); Wills (1986). See also http://emc.medicines.org.uk/ (visited 19 October 2007).
122 Professor Desmond Laurence wrote: ‘Yes, indeed. I tried to change this, but they would not listen.’ Note 
on draft transcript, 21 June 2007.
123 This is a reference to the poisoning of Aleksander Litvinenko, the former KGB agent, in London with 
polonium in November 2006. See Anon. (2007); Singh (2007).
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understanding drug interactions and the beginnings of understanding genetic 
variability in things.124 
And, to emphasize what Don [Davies] was saying earlier, I would like to make 
a plug for the non-clinicians out in the provinces who have made significant 
contributions to British clinical pharmacology. For example, Kevin Park and 
Dave Back in Liverpool, Andy Renwick in Southampton, a few of us in Sheffield 
and others in Glasgow. If it wasn’t for these individuals and their scientific input, 
the Journal would have been pretty thin in the 1980s and 1990s.125
reid: On the subject of the BJCP, I don’t want to spoil what is such a congenial 
afternoon, but I have distinct memories at the Hammersmith in the early 1970s 
of people being less than enthusiastic about the setting up of a new British 
Journal of Clinical Pharmacology. I wonder if anyone else has any recollections. 
I do not think it was quite as cosy as we are saying today. There were a number 
of influential people who wished to keep clinical pharmacology in the BJP and 
to avoid setting up another journal.126
Prichard: It was during my time as secretary of the Clinical Section of the BPS 
that I was responsible for the negotiations setting up the journal, as I remarked 
earlier.127 The opposition came from the main body of the Society. I was unaware 
of any of it from the clinicians or from Colin Dollery at the Hammersmith 
Hospital.128 He seemed to me to be supportive at the time. There was some 
opposition from the committee of the BPS and the Society as a whole. They 
were worried it would be a financial drain on the Society; we managed in the 
end to reassure the sceptics. The other source of opposition was from Professor 
Franz Gross, who was the editor of the European Journal of Clinical Pharmacology 
and felt we didn’t additionally need a British Journal.129 I dealt with that by a bit 
124 See, for example, Lennard et al. (1984).
125 Back et al. (1984); Renwick et al. (1988); Lewis et al. (1991); Donnelly et al. (1989).
126 Professor John Reid wrote: ‘There were a number of opponents to the founding of the BJCP, who 
expressed their views at the annual general meeting of the British Pharmacological Society. As far as I know, 
the minutes of the annual general meeting were not formally published!’. E-mail to Mrs Lois Reynolds, 7 
July 2008.
127 See page 27.
128 See note 126.
129 Professor Franz Gross (1913–84) was a founder editor of the European Journal of Clinical Pharmacology. 
See Gross (1978); see also Glossary, page 122.
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of masterly inactivity, not being over-diligent in replying to the correspondence 
from Germany, because I didn’t want any ammunition to get into the hands 
of the Society at large. I was quite convinced it was very important for the 
development of British clinical pharmacology to have our own journal. As I 
said earlier, I was delighted that Paul Turner agreed to become the first editor, 
the first secretary of the board. In response to a question from Paul at that time, 
I remarked that I had no ambitions in that direction, and I was convinced he 
would do the task well, as he did.
aronson: Two things I wanted to say. The first was to say that Mark Caulfield 
talked about Paul Turner, and everybody knows Paul Turner was the first 
secretary, as the post of editor-in-chief was then called. If you look at the first 
issue or two, maybe even more, a lot of the papers came from Bart’s, and it was 
quite clear that Paul worked very hard to try to get high-quality material into 
the journal to kick it off, and I think he did a brilliant job, and of course it did 
eventually attract work from other institutions. But a lot of the early stuff came 
from Bart’s. 
The other thing is to say that I think Geoff Tucker has understated his role here. 
He put into my hands in 2003 a really thriving journal, despite all the problems 
that he describes, making a large amount of income for the Society, which we 
use to fund all our worthwhile activities. We now have two European editors 
and an Australasian editor, who were all in place, and, of course, a reviews 
editor, when Geoff was in post, and now we have a North American editor. 
It really is thriving, and I think he has understated his contribution to that; it 
really is a credit to the Society and a credit to the previous editors, chairmen of 
the editorial board, that it is now thriving the way that it is.
flower: If I could make a general remark about your behaviour, you are all 
being far too modest – that is coming through very strongly to me as chairman. 
Andrew, I think it is time for you to talk about the Drug and Therapeutics 
Bulletin, without being modest.
herxheimer: When I was at the London Hospital I was still doing research, 
looking at the effects of this drug or that drug on whatever function. And then 
I came to the conclusion that it was really a bit of a waste of time to spend six 
months or longer doing that, while there was so much that was known that 
nobody was using, that was just going to be published, sit there and gather 
dust. And what was really needed was for the information to be got to every 
prescriber. I had been in the US and seen the Medical Letter, which was new in 
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1959, and Owen Wade had imported the Medical Letter to Northern Ireland 
with British names at right-angles in the margin, and distributed it in Northern 
Ireland.130 I felt we ought to have this for the whole of the UK. How could that 
be done? So I persuaded the Consumers’ Association to try it. And I translated 
a couple of issues from American (i.e. drug names and spelling) into English 
and that seemed to be not very difficult and so we started the British edition of 
the Medical Letter by subscription, and gradually got a small circulation started. 
The Americans were very interested in checking that no commas or anything 
else were different and they wanted to see everything before it was published 
and that became rather difficult, before e-mail and so on. We also needed 
articles about things that didn’t exist in America, so we had articles of our own, 
and then eventually we became separate. The subtitle of the Medical Letter was 
‘Medical Letter on Drugs and Therapeutics’, and so we called it the Drug and 
Therapeutics Bulletin. In 1962 we had started from the US edition of Medical 
Letter and became independent in the UK in 1963. We had a small circulation, 
a few thousand people, and then at one point we persuaded the Department of 
Health that junior doctors should get it, and so that was the bulk subscription. 
The bulk subscription in Northern Ireland was there all the time, it was an 
extremely important and welcome support for the whole activity. And as this 
went on for many more years, there were more and more medical students 
and junior doctors, but the Department of Health decided that it didn’t want 
to take anybody off the list. So eventually, in the 1970s, when David Owen 
was Health Minister and Jennifer Jenkins (Roy Jenkins’ wife) was the chair of 
the Consumers’ Association, she asked him at a dinner at the Jenkins’: ‘How 
about sending it to all the doctors in the country?’ He thought that was a good 
idea and it happened. That arrangement continued until the middle of last 
year (2006). Throughout, the Bulletin’s assessment was impartial, with many 
referees; the drafts were sent to the drug companies and drafts sent to people 
in the Medicines Control Agency, and so on, for comment. We considered all 
the arguments, but we had the final word. There was no need to engage in long 
arguments and correspondence. And the motto of the Bulletin was that you had 
to be able to read the whole issue without having to sit down, so it was kept as 
short as practicable. I am afraid it’s no longer possible to read the whole thing 
standing up, but it’s still desirable. We had an advisory council who were very 
distinguished and did a lot of work, but what was unique, I think, was that the 
Consumers’ Association would publish something which was only for a small 
section of the public, not for consumers at large, and that was pretty odd. The 
130 See Glossary, page 124.
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argument was, of course, that if doctors prescribed well, then all consumers 
would benefit. But sadly this attitude did not survive the most recent changes 
in management in the Consumers’ Association. 
Wade: My only comment is that one of the people who helped a great deal 
with Prescribers’ Journal and certainly with the BNF was Dr Ed Harris. He was 
Deputy Chief Medical Officer (DCMO, Department of Health, 1977–89) at 
that time, and, you know, it’s nice to pay tribute to him for the help that he 
gave us.131
Jones: Just a reflection on the Drug and Therapeutics Bulletin. I think over the 
years it has been a tremendously valuable point of reference for prescribers, to 
the benefit of patients. But I have to say, during my tenure at ABPI in the latter 
years, a rather large number of folks in the industry thought it was a gift to the 
politicians to promote rather old ‘generic’ drugs, rather than an objective review 
of all available medicines. Of course, one has to recognize that the research-
based companies needed to defend their own products, but I think it is a pity 
that the reputation of the Bulletin, in my opinion, has not been maintained, 
and doesn’t look, in my opinion, as objective as it used to.
herxheimer: The relationship with pharmaceutical companies was always a bit 
tense: companies didn’t like their own products to be criticized. They were quite 
enthusiastic when other companies’ products were being criticized, and that’s 
just a fact of life. We were sued only once, which was very early on, when we 
concluded: ‘No preparation for softening ear wax [including Cerumol drops] 
had been shown to be better than a simple vegetable oil’.132 That action was very 
troublesome, but was settled on the steps of the court, with each side paying its 
own costs. So a softening occurred in that direction.
flower: I thought you were going to say that you were sued by the olive oil 
manufacturers.
herxheimer: But we did have rather legalistic letters threatening to sue us. I 
remember another occasion when the company insisted on having a meeting, 
which we hardly ever did; but they came and they talked about their side of 
the issue. We realized that their claims were even weaker than we had said they 
were, and so we made that point in the revised version of the article.133 
131 See Griffin (2006); Wade (2003).
132 Anon. (1968). For a recent review, see Burton and Dorée (2003).
133 Anon. (1983). See also Anon. (2002).
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Barnett: As one whose current occupation is well aware of the tensions between 
independent advisors and the drug industry, may I say that I found as a young 
man, which seems like a hell of a long time ago, growing up and understanding 
clinical pharmacology and therapeutics, the Drug and Therapeutics Bulletin to 
be an incredibly useful reference base, and it still remains that way. There have 
been some differences of opinion between the Drug and Therapeutics Bulletin 
and the way in which the National Institute for Health and Clinical Excellence 
(NICE) now carries out its business, but in principle it’s the same concept, an 
independent review of the real evidence and independent advice on what’s the 
best to do. I think that’s the way it remains and I think NICE has taken on that 
banner now. But it also means that it is actually where clinical pharmacologists 
can make their point to everybody else, in a well-respected publication in the 
medical community, and long may it continue in whatever guise it takes on.
ferner: I am going to take the opportunity, since the temperature is rising 
slightly, to attract the attention of both David Barnett and Iain Chalmers to 
the demise of Prescribers’ Journal. Although Owen Wade and then Linda Beeley 
and Jeff Aronson were very influential and expert chairs of the committee of 
management of Prescribers’ Journal, I was the last chair of that committee. In the 
way that the Department of Health have withdrawn funding from the Drug and 
Therapeutics Bulletin and also from the Adverse Drug Reactions Bulletin, which I 
think Phil Routledge may talk about, the Department of Health also withdrew 
funding from Prescribers’ Journal, but in rather a circuitous way.134 They gave the 
money that they had spent on Prescribers’ Journal to NICE, and NICE, enthused 
by or inflamed by ideas of evidence-based medicine and systematic reviews, that 
can only have come from Oxford, criticized Prescribers’ Journal. I think unfairly, 
because as you have heard from Charles George, although Prescribers’ Journal 
hid behind named individuals, it was really a carefully researched, evidence-
based, and readable guide to therapeutics, in his time at any rate. So for the 
excuse that there was no evidence behind it, and that the evidence that might 
have been behind it hadn’t been reviewed, it was demolished. This is a small 
requiem for Prescribers’ Journal.
sir iain Chalmers: One of the nice things about the transcripts of these Witness 
Seminars is that people have an opportunity to reconsider what they have said 
and to provide references to the evidence supporting them. I had absolutely 
nothing to do with decisions about Prescribers’ Journal. Furthermore, I have 
never spoken or written about evidence-based medicine, because I haven’t been 
134 See Boseley and Hall (2006).
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a prescriber since 1973 and I didn’t feel I had any authority to speak about the 
topic. By contrast, I have views about evidence-based patient choice, because I 
am a patient.
flower: I don’t know whether Owen would like to say a few words about BNF; 
would you like to add anything to the discussion we have already had, Owen, 
since we are just talking about these publications? 
Wade: The BNF had been in existence since it took over from the National War 
Formulary after the war, and it was produced every three years then.135 It was Dr 
Edmund (Ed) Harris, deputy CMO, who enabled us to completely change the 
BNF, so that instead of being ‘a selection of drugs’ as it then was, it included 
every medicine on the market that could be prescribed. I think the people I 
worked with and those who have succeeded me, like Charles George and Martin 
Kendall, have made it a tremendous success: it is widely used and well thought 
of. I never dreamt it was going to be as successful as it has been.136
mcdevitt: I think the thing that transformed the BNF was the decision to 
publish it twice a year. Until that time it was largely irrelevant, because the 
things that you were wanting information about, which were usually the new 
drugs that you could find in MIMS, just weren’t in it. Now every houseman and 
most other doctors, carry their copy of the BNF around with them. I think it 
has had an absolutely huge influence on prescribing. The only caveat I would 
make is that some medical students, because this was given to them free, felt 
that this was all they needed to learn clinical pharmacology and I would have to 
say that I totally disagree with that.
george: Could I just add that Ed Harris asked for the revised format of the 
BNF, because general practitioners, 80 per cent of them said that they used 
other sources of information and that the old small blue-style hardback thing 
was not meeting their needs. So whereas 80 per cent of general practitioners 
used to use other sources as their prime source of information, now 71 per cent 
say that the BNF is their main source of information about prescribing matters. 
And actually, it does profoundly influence the way in which they prescribe.137
aronson: I think those last two comments sum it up. The fact that it was six-
monthly rather than three-yearly. And the fact also that it gave so much more 
135 See Figure 6, page 54.
136 Wade (1993).
137 Watkins et al. (2003).
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information that was also important. This [holding up a copy] is the National 
War Formulary, second edition dated 1943, I got it in a special issue – 76 pages.
The titles are in Latin. The measures are apothecaries’. Then 1946 – a huge 
change when the new BNF came out. But the change in 1981 was even more 
striking; it really was a huge change in the kind of information that was being 
given to doctors. 
flower: Does the War Formulary contain any useful advice about ear wax?
Wade: I think we owe a lot to Ed Harris. He and I discussed the business of 
getting it out six-monthly. We were fed up with doctors using MIMS all the 
time, and it was partly to compete with MIMS that we initially produced it 
six-monthly.
flower: Does anybody else want to say anything about publications, formularies 
and pharmacopoeias, or journals, because if not I think we could move on.
herxheimer: I would just like to add a footnote or postscript that at the 
Clinical Pharmacology Congress, the first one in London, we had an informal 
figure 6: Cover of the second edition of the  
National War Formulary, 1943.
Clinical Pharmacology in the UK, c. 1950–2000: Influences and institutions
55
meeting among about half a dozen people who were publishing independent 
drug bulletins in other countries. And that led to the start of the International 
Society of Drug Bulletins, which was then founded in 1986.138 I think, in a way, 
that completes the story of the independent drug bulletins.
flower: That’s probably a good point at which to leave the topic of publications. 
I would like to move on and talk a little bit about the way in which clinical 
pharmacology, the academic departments, the enterprise, if you like, expanded 
its scope and about the different directions everyone took; cardiovascular, 
neuropharmacology, drug metabolism, psychopharmacology, and so on. 
Perhaps I will begin by asking if anyone has any views or ideas about the way in 
which developments in UK pharmacology impacted on the growth of clinical 
pharmacology overseas in the sense that lots of overseas fellows were trained in 
our medical schools, our hospitals, academic departments, and so on. 
Jones: During my time with the Wellcome Foundation, I served on the US 
Burroughs Wellcome Fund, which is like the Wellcome Trust here but much 
smaller. George Hitchings and Trudy Elion and others were members of 
that Board as well.139 It was a way of giving cash to bright young people to 
do their research in different areas, tropical diseases, etc. One of the areas was 
experimental pharmacology and nobody knew what that was, so very few people 
actually started to apply for grants. But, based upon what was going on here in 
the UK, we changed that to clinical-based pharmacology and I think that did 
stimulate a huge amount of further effort in the US in this discipline. I have to 
say that was at a time here when also, it seemed to me, that fewer people wanted 
to become clinical pharmacologists. When I got to the ABPI, several companies 
had put money into a pot to give to registrars in this discipline, and very few 
took up the cash. Now, that could have been due to something else. In the UK, 
postgraduates followed an MD route, then went back to their specialty, whereas 
in the US the MD PhD was allowing people to be experimental and do their 
138 Dr Andrew Herxheimer wrote: ‘The International Society of Drug Bulletins has grown to embrace 
72 independent bulletins in 36 countries throughout the world and has gained international 
influence.’ Note on draft transcript, 4 August 2007. See www.isdbweb.org (visited 11 October 2007); 
Anon. (2002): 25.
139 Dr George Hitchings was director of the Burroughs Wellcome Fund from 1971 to 1994 and president 
from 1971 to 1990; Professor Gertrude Elion worked for Burroughs Wellcome as a research scientist from 
1944 until her retirement in 1983 and  a research professor at  Duke University, Durham, North Carolina 
until her death in 1999. Sir James Black, Gertrude Elion and George Hitchings shared the Nobel Prize in 
Physiology or Medicine 1988 for their discoveries of important principles for drug treatment. See http://
nobelprize.org/nobel_prizes/medicine/laureates/1988/index.html (visited 9 November 2007). 
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clinical work at the same time. Here, unless you were on the clinical special path, 
two or three years out to do a PhD was probably going to disadvantage your 
career. But, I think that the US Burroughs Wellcome fund certainly increased 
clinical pharmacology activity in the US.
orme: The question you raised was really about the influence of the British 
clinical pharmacology body on people coming here. I think other people are 
probably better qualified than me to talk about that, but just an anecdote which 
may give the wrong flavour, but certainly in the early days in Liverpool we had 
a German research fellow who came from Heidelberg to work with us for a year 
and a half, and unfortunately we totally changed his life, because we were Dr 
Herr, Dr Professor for the first two weeks and after that it was Christian names. 
And then when he went back to Germany he could not cope with the German 
hierarchical system and left to go to the US, where he has been doing very well. 
I can’t mention names. 
I would just like to say a word the other way round – in fact, the influence that 
the UK generally, in clinical pharmacology, has had in Europe.140 As background, 
I helped to set up the European Association of Clinical Pharmacology and 
Therapeutics in the early 1990s and I am currently, at least for the next six 
months, chairman. And it’s been quite striking the influence that the UK and 
Sweden have had in the way that the French societies have come together to 
produce a single clinical section. The same is happening now in Germany; the 
way in which the Spanish society has used some of the UK things, particularly 
around teaching; we have seen improvements in Italy and in some of the eastern 
European countries; and they all cite what is going on or what had been going 
on in the UK. And at times we have had to say to them, ‘I am terribly sorry the 
UK isn’t actually doing all that well in clinical pharmacology’, for the reasons we 
have been discussing earlier on. But nevertheless they look to the UK in their 
professional work as to how to develop clinical pharmacology. We keep learning 
new things, not good things. Only a month ago, in discussion with a Spanish 
colleague, I discovered that the Spaniards had passed a law that says that all 
research ethics committees in Spain must be chaired by a clinical pharmacist, 
which doesn’t seem to me quite the right way of going about things.141 But, 
140 Orme and Sjöqvist (1991). 
141 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 set the target 
for the implementation of good clinical practice in the conduct of clinical trials on medicinal products 
for human use by 2004. Official Journal of the European Communities, 2001;1;L 121/34. For Spanish 
committees, see www.privireal.org/content/rec/spain.php (visited 5 June 2008). 
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you know, we are not winning all the battles. However, certainly Europe is still 
looking to the UK in terms of matters of clinical pharmacology.142
flower: I can support your point of view, because funnily enough when wind 
of this Witness Seminar got around, I was approached personally by two Italian 
clinical pharmacologists, asking me if they could come, and they both said exactly 
what you have said – that they had always looked to the UK as the fountainhead 
of clinical pharmacology. When I pointed out that this seminar was meant to be 
about UK clinical pharmacology, they were quite disappointed. 
mcdevitt: To bring the process earlier than that, I can’t exactly date it, but it 
was when I was secretary of the Clinical Section of the British Pharmacological 
Society – probably in the late 1970s – and it was really at the time when clinical 
pharmacology had got itself positioned within the clinical training programme 
in the UK as a clinical sub-specialty – we had a meeting in the Ciba Foundation 
in Portland Place, London, to which we invited representatives of clinical 
pharmacology from many European countries.143 At that stage we were really 
the envy of all that was going on in Europe and the reason was because clinical 
pharmacology was being muscled out, on the one hand by medicine and on the 
other by pharmacologists, in most of Europe, with the possible exception of 
Sweden. When it came to trying to get the thing harmonized within a European 
scene, which I think was the basis of the meeting, the groups that sponsored 
the specialists to go to the European meetings were groups like the BMA, etc. 
So the clinical pharmacologists weren’t getting a look in. And certainly at that 
stage what had happened within the UK was very much the envy of the other 
European clinical pharmacologists. In many ways, I think, a number of the other 
countries have moved on now, but at that stage they were largely in despair. 
herxheimer: One thing that happened in the 1960s – Brian [Prichard] 
thinks it is 1966 – was that there was a British Council meeting, a seminar 
on clinical pharmacology for people from other countries. And then there was 
another one, and that was very important, because there were people from 
Italy, Croatia, Tunisia with great enthusiasm, and that was very successful. 
142 Professor Desmond Laurence’s account of ‘The initiation of research ethics committees in the UK’ will 
be deposited along with other records of the meeting in GC/253 in archives and manuscripts, Wellcome 
Library, London. See also the Report of the Ad Hoc Advisory Group on the Operation of NHS Research Ethics 
Committees at www.dh.gov.uk/assetRoot/04/11/24/17/04112417.pdf (visited 14 April 2006). For an earlier 
assessment, see Wise and Drury (1996). 
143 See Lee and Spufford (1993). See also www.novartisfound.org.uk/hist.htm (visited 16 November 
2007).
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And a lot of those were very much influenced by that. I know especially 
about Croatia, because Professor Božidar Vrhovac from Zagreb really started 
from there.144 
The other thing I want to mention is that in 1956, at the XXth International 
Congress of Physiology in Brussels, clinical pharmacology didn’t exist.145 I had 
met Wim Lammers, a young pharmacologist who then became professor of 
pharmacology in Groningen, and while he was there, he persuaded the professor 
of medicine that Groningen needed a clinical pharmacologist. Because all 
the Dutch universities are state universities, and, to be employed by a state 
university, you had to have a nationally agreed description of who was qualified 
to apply for a chair. So, by definition, no qualified Dutchman existed, and they 
asked me if I would be part-time professor of clinical pharmacology and start to 
introduce it. I said yes, and they created a chair of clinical pharmacology on one 
day, and the next day they split it into two twin chairs of clinical pharmacology. 
The senior one was Professor Meyler of Meyler’s Side Effects of Drugs; he was 
running the place, he lived there, and I went there for a few weeks several times 
a year and that’s how it started.146 That was a very direct kind of descendant. 
Then later on, other Dutch universities started to have clinical pharmacologists 
and we trained a successor who then ran the department in Groningen. That’s 
another bit of the European dimension.
Chalmers: I am encouraged to ask a question, because of this extension of the 
discussion into Europe. I am puzzled why the name Paul Martini hasn’t been 
mentioned up until now.147 
orme: To respond to Iain as one of the erstwhile winners of the Paul Martini 
Prize, I did do a little bit of homework before I went to Germany and certainly 
his influence was very considerable. But I have to say I can’t give you chapter 
and verse at the moment, but I will just vouch for what Iain is saying, he did 
have a major impact in Germany at that time.
144 See, for example, Orme et al. (2002). Dr Jeffrey Aronson wrote: ‘Known to his friends as “Darko”.’ Note 
on draft transcript, 18 June 2008.
145 International Congress of Physiologists (1956).
146 Professor Leopold Meyler published his first edition of Side Effects of Drugs in 1952. Dr Andrew 
Herxheimer has been co-editor since the 6th edn (Meyler and Herxheimer (eds) (1968)). For a 
publishing history, see www.elsevier.com/framework_products/promis_misc/meylerhistorynew2005.doc 
(visited 3 June 2008).
147 Shelley and Baur (1999); Grosse-Brockhoff (1964); Wiedemann (1994).
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Vere: Like many other departments, we had a continual trickle of people from 
overseas coming through London, doing various different kinds of attachment 
studies. They came from China, from India, from Nigeria, Kenya, and so 
on. And I know some who went back had a considerable influence in their 
own countries. The Essential Drugs List in Sri Lanka, for example, was carried 
through by one of them.148 
The other thing which I think is worth mentioning is the BSc in London, 
where there were course units; one of the course units in many places was a 
unit in clinical pharmacology. Having the BSc students go through human 
experimentation in clinical pharmacology has, I know, had a considerable 
influence on the subsequent interests and training of those people. I certainly 
know of some surgeons who went through that and who clearly benefited from 
the exposure. 
Wade: There was a WHO meeting in 1969, in Copenhagen, after which there 
was a lot of cooperation between me in Northern Ireland, Barbro Westerholm, 
who later became chief medical officer in Sweden, and Per Knut Lunde in Oslo, 
comparing the use of drugs in our three countries. This spread to some other 
countries in Europe. The Drug Utilization Research Group (DURG) started 
148 The Essential Drugs List was first published in 1977 and the 15th edn became available in 2007. See 
www.who.int/medicines/events/fs/en/index.html (visited 16 November 2007).
figure 7: l to r: Per lunde, Barbro Westerholm and owen Wade, 1971. 
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then, and it is has grown a lot since those days in Europe, Israel, Australia and 
even Russia.149
aronson: I have an anecdote to match Mike Orme’s and then a serious aspect to 
the same story. We have had many foreign students over the years in Oxford, from 
Russia, China, Australia, Brazil, I could go on and on, like Duncan [Vere] said. 
I am sure we have all done that. We had one student from Sri Lanka who went 
back after getting his DPhil and when I next saw him he said, ‘You have made 
my life a misery’. I said, ‘Why’s that?’ He said, ‘You taught me to say no.’ And, 
of course, over there you don’t say ‘no’. Somebody asks you to do something and 
you say ‘yes’, and then you don’t do it. But, I expected him to say ‘no’ if ‘no’ was 
what he meant, and I would do the same with him, and that was very difficult 
for him to adapt back at home. The serious side of that story is when I went 
to visit him and discovered that there was an epidemic of self-poisoning with 
oleander seeds, mostly by young farmers, young men not doing well. Oleander 
seeds grow on a big yellow ornamental shrub. I said, ‘The pharmacology of what 
these seeds contain suggests to me that repeated doses of activated charcoal may 
be beneficial.’ So they did what may be, if not the largest, certainly one of the 
largest prospective randomized controlled trials of self-poisoning in any form. 
Within eight months they randomized 400 patients and reduced mortality from 
8 per cent to 2.5 per cent and that has changed practice in Sri Lanka.150 We are 
now doing another study in snakebite. I think this collaboration abroad has been 
very fruitful and very influential. I could tell other stories, but that’s just one. 
Prichard: I thank Andrew for mentioning the British Council courses. Professor 
Desmond Laurence was the director of studies and I had the privilege of assisting 
him. In fact, they were not just seminars but two-week courses in 1966 and 
1981, where we took actual and potential clinical pharmacologists from overseas 
around various centres in the UK, both in London and, indeed, out of London, 
and we certainly penetrated Scotland on at least one, if not both, occasions. 
Speaking of overseas fellows who have come here, I think one individual we 
should mention is Walter Aellig of Sandoz, Basel.151 He was a research fellow 
149 Shortly after the photograph in Figure 7 was taken, Per Lunde became responsible for the WHO Essential 
Drugs Policy for Developing Countries and Barbro Westerholm became the Chief Medical Officer of Sweden. 
See Bergman (2006). See also Wade (2006); www.rcgp.org.uk/pdf/TNG_06Winter_DURG.pdf (visited 
23 May 2008).
150 de Silva et al. (2003).
151 See, for example, Aellig (1981, 1994).
Clinical Pharmacology in the UK, c. 1950–2000: Influences and institutions
61
at UCH in 1968/9 and has been a tower of strength in supporting the BPS. 
The Sandoz Prize (renamed the Novartis Prize in 1997) was first presented 
by Professor Botand Berde; Dr Aellig took over in the late 1970s. He is also 
distinguished in that he gave the first communication of the inaugural session 
of the Clinical Section of the British Pharmacological Society in January 1970 
at UCL. He was recently honoured by being elected to Honorary Fellowship of 
the British Pharmacological Society in 1998. 
aronson: I could add to that that Walter Aellig, a huge supporter of the Society, 
was also for many years a member of the editorial board of the British Journal 
of Clinical Pharmacology, and was very sad when he had to give it up at the end 
of 2003.
davies: The chairman said we have been too modest. I should mention a two-
week workshop in clinical pharmacology that we ran at the Hammersmith for 
about 12 years from 1969, I think, which not only trained leaders in academia 
but also many people who took senior posts in the pharmaceutical industry. 
The other event that immensely increased the UK’s international reputation in 
clinical pharmacology was the first clinical pharmacology congress at Wembley 
[International Union of Pharmacology (IUPHAR) in 1980], which Colin 
Dollery took on, I think, when plans to hold it in the US fell through, and, we 
can say – modestly – that it was a very great success and a great shop window 
for British pharmacology.152
herxheimer: I want to add to what Duncan [Vere] said, which reminded me that 
at the London Hospital we had student projects in the normal course for all 
students. They each had to do a little project, and lots of those were clinical 
pharmacology projects. And they were really very exciting and enjoyable. They were 
long before ethics committees were thought of. Some of them were actually published 
as little papers. I remember two being published in the Lancet and I thought that 
was extraordinary for student projects.153 And that sensitized the students to clinical 
pharmacology thinking. Anybody else have that kind of experience?
flower: I think that is a very important point. When I was a student of 
physiology, we did all the experiments on ourselves, in the way that students 
just can’t do these days in most undergraduate centres, for various reasons. I 
think it’s an enormous detriment to our educational system actually.
152 The World Conference on Clinical Pharmacology and Therapeutics, London, Wembley Conference 
Centre, 9 August 1980, see Turner (ed.) (1980); See also Breckenridge (1991, 1993). See also note 110.
153 Benson et al. (1966); Herxheimer et al. (1967).
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aronson: The 1967 Lancet medical education paper by Quilliam and Turner 
describes a large number of experiments that they expected their students to 
do on themselves.154 For example, mydriasis and miosis in the eye, and using 
agonists and antagonists; you are right, we can’t do that any more.
george: You can, but you have to structure your curriculum to it, and one 
of the special study modules in Southampton is a fourth-year study in depth, 
and quite a number of students each year opt to go for clinical pharmacology. 
Provided you get your organization right, you can actually make sure that it’s 
properly ethically approved, etc.
reid: The BPS clinical pharmacology section is currently awarding prizes 
each year to medical schools for students doing research projects in clinical 
pharmacology. These become poster presentations at the December meeting of 
the BPS. There is some very high-quality work presented. At least two of our 
Glasgow students have won prizes in the last few years.155 
aronson: You are right, John, but these students are not doing the kind of 
research project that Quilliam and Turner described – demonstrating the actions 
of drugs on themselves – they are actually doing research projects in patients 
and so on. But you are absolutely right, they are of high quality.
Prescott: Alas, times have changed. I remember the days when we gave our 
students single doses of amphetamine and barbiturates in their practical classes 
so that they could experience the drug effects and identify which agent they had 
been given. To conduct such experiments now would be unthinkable. I have vivid 
memories of another practical class, which was supposed to show the effect of prior 
induction by phenobarbitone on the hexobarbitone sleeping time in mice. The 
whole class ended up chasing mice all over the laboratory and it was hilarious.156 
flower: Before we leave this debate, does anybody else want to chip in a 
last comment? One thing I mentioned earlier concerned the relationship 
154 Quilliam and Turner (1967).
155 Dr Jeffrey Aronson wrote: ‘A prize is awarded each year to the best student research project at each 
university that enters.’ Note on draft transcript, 18 June 2008.
156 Professor Laurie Prescott wrote: ‘The students had another very valuable learning experience when they 
inhaled amyl nitrite after breaking the little glass “pearls” in which it was formulated at the time. Pearl drops 
apart, this produced an immediate and very dramatic cardiovascular response, which they measured on each 
other and that they would never forget. Sadly, these days are gone forever thanks to the health and safety 
regulations.’ Letter to Dr Daphne Christie, 12 July 2007.
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between clinical pharmacology, as it became known, and ‘clinical 
pharmacy’. I was talking with Stuart in the tea break and he had a couple 
of comments about this, so I thought it would be a good point to bring 
him in.
dr stuart anderson: I think I could describe myself as a very early clinical 
pharmacist. I was a student of pharmacy at Manchester in the 1960s, when it was a 
four-year degree course, and I spent my vacations working in a hospital pharmacy. 
That experience convinced me that the proper place for the hospital pharmacist was 
much more on the ward than it was in the pharmacy counting tablets: that clearly 
all this new knowledge I was acquiring was of far greater benefit perhaps to these 
new medical students and junior doctors, who were struggling with prescribing 
on the ward. And I was supported in that view, if you like, by a number of things 
that were being published. They included various reports on prescribing errors 
and the design of prescription charts, and these were very often collaborations 
between clinical pharmacologists and senior pharmacists. And they came from 
hospitals like the London with Chris Barrett, the Westminster with John Baker 
and Aberdeen with Graham Calder, working with clinical pharmacologists. At the 
same time, I was conscious of other reports, the editorials in the Lancet and so on, 
which appeared to be claiming a broader advisory role for clinical pharmacology, 
staking out the ground, if you like.157 What I saw as the area that clinical pharmacy 
might evolve into was very much this same kind of territory. Anyway, when I 
graduated, obviously as a very junior hospital pharmacist, it was one of my first jobs 
to see if we could do something along these lines. And there were many obstacles. 
I have to say the biggest obstacle was usually chief pharmacists themselves, who 
were often resistant, but also there was in those places considerable hostility, I 
would say, from some clinical pharmacologists. For me the atmosphere changed 
completely when I moved to Alder Hey Children’s Hospital, Liverpool, when I 
was appointed principal pharmacist there in 1974 and clearly there were a lot 
of problems around paediatric therapeutics, not least children’s doses and so on. 
The group of people I worked with there was the senior registrars, who had the 
clinical pharmacology role, if you like, which resulted, of course, in the Alder Hey 
Book of Children’s Doses (ABCD), which carried on for quite a number of years.158 
I don’t recall any involvement from the clinical pharmacology unit; Mike [Orme] 
might know otherwise. I would be interested to know whether paediatric clinical 
pharmacology had emerged at that stage. 
157 See Appendix 1, page 77.
158 See Anderson et al. (1976). First edition published 1973.
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I moved to the Westminster Hospital in 1978, where I was chief pharmacist for a 
while, and things there were different again. The professor of clinical pharmacology 
and therapeutics then was Ariel Lant, who had been working very closely with the 
very dynamic district pharmaceutical officer, John Baker, and they were already 
developing the district drugs guide, which became quite a substantial book. And 
my understanding is that the Westminster District Drugs Guide became very 
influential in the design of the re-launched BNF in 1981.159 By the time I had 
moved to St George’s in 1983, the relationship between clinical pharmacology 
and clinical pharmacy had become one of complete collaboration. In fact, Joe 
Collier was on my appointment panel at that stage, and the two professionals – 
the hospital pharmacist on the one hand and the clinical pharmacologist on the 
other – were essentially a team, working together on the drug and therapeutics 
committee, on the design content of the St George’s Pharmacopoeia.160 So, there 
was a gradual transition really.161 I am interested to hear that in certain areas clinical 
pharmacists appear almost to have the upper hand.
Barnett: I think the interface between clinical pharmacy and clinical 
pharmacology is a very important one. When I was appointed as a senior lecturer 
I went into the doctor’s dining room and met a rather senior obstetrician/
gynaecologist who asked me what I did, and as I was new, I said I was a clinical 
pharmacologist and he said, ‘My God, they are letting the pharmacists in here 
now’. I didn’t know whether that was a compliment or not. The point is I 
do remember the important interface between clinical pharmacist, clinical 
pharmacy, and research pharmacy in San Francisco and clinical pharmacology. 
People like Malcolm Rowland, who came to San Francisco, subsequently went 
to Manchester, championed the pharmacokinetic approach within pharmacy 
departments then, as opposed to the UK, where this development was confined 
to departments of clinical pharmacology. I think this interface is very important, 
and is extended now to ward pharmacy. Certainly in my university, my clinical 
work, the interface between clinical pharmacy and clinical pharmacology is 
absolutely essential at all levels.
159 Westminster and Associated Teaching Hospitals Kensington, District Drugs Committee (1981). For 
details of the Guide, see Sutters et al. (1993).
160 Dr Stuart Anderson wrote: ‘The 13th edition was in 1995, by which time it had been re-named as 
a formulary.’ Note on draft transcript, 11 July 2008. See Wandsworth Health Authority, Drugs and 
Therapeutics Subcommittee (1985).
161 Dr Stuart Anderson wrote: ‘The relationship progressed from initial suspicion and hostility, through 
cooperation and collaboration, to one of equal partnership.’ Note on draft transcript, 20 June 2007.
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Wade: I want to comment on the cooperation with pharmacists, which has 
been so important as far as the BNF is concerned. It is produced by the staff 
of the Royal Pharmaceutical Society and that’s one of the reasons it is such a 
good production.162
tucker: With regard to British pharmaceutical scientists, Malcolm Rowland, 
Grant Wilkinson and (not to be modest) I have helped to underpin quantitative 
clinical pharmacology coming from the direction of pharmacokinetics.
orme: First, to respond to Stuart. He’s right that at this time the department 
at Liverpool did not have very much input into Alder Hey; I guess we were 
finding our feet. His successor at Alderley, Tony Nunn, worked with us in our 
department very closely and indeed we have actually trained a paediatric clinical 
pharmacologist, Imti Choonara, who is currently professor at the University of 
Nottingham in Derby.163 So we do have some input, but it was a bit late, Stuart. 
To respond to the general theme of the clinical pharmacist, I certainly totally 
agree with those people who said it must be a collaboration. Unfortunately, 
there are one or two of my colleagues in Europe who have got a real bee in their 
bonnet about the role of clinical pharmacists, and you only have to mention 
the word and they go ballistic, which is totally unhelpful, because collaboration 
works. But to revert to the Dutch problem. The title clinical pharmacologist is 
not protected there, so in fact most clinical pharmacists have the title clinical 
pharmacologist – it is not a medical title in the Netherlands, it’s a general title, 
so you have to define what you are talking about. In practice, if you talk to 
the Dutch – in fact, they do collaborate pretty well – but it’s when looked at 
from outside, you might say, ‘Well, clinical pharmacists have taken over clinical 
pharmacology’ – they haven’t as we understand it, but it’s easy to see why people 
think that is happening. 
grahame-smith: In Oxford, over the years that I was there, the tension between 
pharmacists, clinical pharmacists and clinical pharmacologists was diffused 
very, very effectively, by the Drug and Therapeutics Committee. Pharmacists 
sat on the Drug and Therapeutics Committee, clinical pharmacologists sat 
on the Drug and Therapeutics Committee, and physicians and surgeons, 
and people who had got the time to do it, sat on the Drug and Therapeutics 
Committee [laughter]. There was a wide representation of medicine, pharmacy 
and clinical pharmacology. And frankly, once it was established and running, all 
162 See Glossary, page 125.
163 Choonara et al. (2004).
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the tensions disappeared, and the pharmacists and the clinical pharmacologists 
got on well together and they mapped out their own areas of influence and so 
on, without it being written down or discussed. It just happened naturally, that 
they saw that there was different expertise in each group. I don’t know whether 
the Oxford Drugs and Therapeutics Committee still goes on, whether the 
pharmacists play their part in it, and whether interprofessional relationships 
are still good.164
aronson: Yes, it’s still the same in Oxford, David.165
mcdevitt: I start with an anecdote. I once went to Saudi Arabia and came 
face to face with a clinical pharmacist who had trained in America and 
he represented the extreme end of US clinical pharmacy, whose view was 
doctors should diagnose and pharmacists should prescribe – doctors don’t 
know anything about drugs. But I think there is another dimension to clinical 
pharmacy, beyond the ones that have already been mentioned. In most hospital 
setups there are a lot of pharmacists and very few clinical pharmacologists, so 
they can’t afford to be in competition. Certainly in Dundee we had ward 
pharmacists who didn’t just go to the ward and count up the pills, but as 
a generality they went on the ward rounds with the doctors and they were 
there to provide information about drugs, which a lot of doctors, clinical 
pharmacologists excepted perhaps, wouldn’t have known. And it greatly 
enhanced the quality of prescribing.
flower: As an ex-head of a school of pharmacy, I am glad to hear that.
george: Really to emphasize again the importance of information pharmacists, 
not only because they actually have access to the information and have the time 
to do it, but I have to say from my standpoint, when I got to Southampton 
one of the most arduous things was people asking me questions about things 
which were much more to do with pharmacy than clinical pharmacology, and 
the arrival of information pharmacists took a huge burden off my back so that 
I could get on with some research.
164 Professor David Grahame-Smith wrote: ‘Drug and Therapeutics Committees go back a long way. In 
Oxford, a Standing Committee on Medicines was first established on 10 July 1975, became the Drug and 
Therapeutics Committee in 1994 and finally the Medicines Advisory Committee in 1997. I suspect this 
mirrors generally the history of these local groups throughout the country.’ Note on draft transcript, 7 July 
2008. See, for example, Jenkings and Barber (2004).
165 Dr Jeff Aronson wrote: ‘It is now called the Medicines Advisory Committee and has executive powers.’ 
Note on draft transcript, 18 June 2008.
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Caulfield: We have had a very profitable interaction with both the School of 
Pharmacy and the pre-registration pharmacists in North-East Thames region 
for a number of years; Paul Turner started that and we continued it after he 
retired. At the School of Pharmacy, we taught a module, and in fact actually on 
that module on clinical pharmacology, which was very popular, there were about 
20–30 students from the School of Pharmacy who used to come over every year. 
And we used to do the type of human pharmacology experiments that Laurie 
was talking about, which we used to do with the second-year medical students as 
well. For some curious reason that I never really understood, in the mid-1990s 
the School of Pharmacy went in a different direction with a new curriculum and 
decided that that module, which coincided with reduced clinical pharmacology 
staff numbers, so it was stopped.166 Recently we have been asked whether we 
could reinstate it, or a variation on the theme. 
The pharmacy ward rounds were very good. All the pre-registration pharmacists 
came in from all over the North-East Thames and we used to do drug ward 
rounds, and we used to do the same for medical students. And the other 
interface that we have, which we preserve with the pharmacy, is a very strong 
relationship on an initiative about safe prescribing. This is in addition to the 
drugs and therapeutics committees, where not only do our senior people sit, 
but also our trainees. In the safe prescribing initiative, there’s a multidisciplinary 
team of pharmacists, senior nurses and specialist registrars (SpR), who look at 
‘near misses’ and critical incidents in prescribing to see whether any educational 
needs should be met there, as this is quite a serious issue for us now. We have a 
very strong interaction still with pharmacy, and it has been a long tradition both 
at Bart’s and the London for that to occur.
dr linda Beeley: I was an NHS clinical pharmacologist in Birmingham and ran 
the West Midlands Centre for Monitoring Adverse Reactions to Drugs, where 
I employed three pharmacists, to do all the work basically.167 But, I think it was 
very useful training. I used to have quite junior pharmacists who would come 
through for about six months and work with me doing various things connected 
with drug monitoring, producing information and bulletins, which we sent 
round the West Midlands. And then they would move on to other jobs, but I 
think it provided a useful training experience for quite a few pharmacists.
166 See, for example, Florence (2002).
167 Dr Jeff Aronson wrote: ‘Now run by Robin Ferner.’ Note on draft transcript, 14 July 2008.
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flower: I would like to stop the discussion on that subject now, because I am 
aware of the fact that we are heading towards the finishing line, and during 
the coffee break David Gordon told me he wanted to make a comment about 
clinical pharmacologists.
Professor david gordon: This relates to one or two of the things we have 
talked about in the last hour or so. I wonder whether the specialty – I cannot 
claim to be a clinical pharmacologist – is in a state of concern about what it is 
doing? It goes back about five years ago when I was invited to a debate at the 
Royal College of Physicians, about the nature of the undergraduate medical 
curriculum. Defending the GMC Education Committee were, of course, Sir 
Graeme Catto, the president of the GMC since 2002, and Roger Green, a 
member at the time. When I arrived I discovered that the entire opposition was 
made up of clinical pharmacologists, a kind of horde of clinical pharmacologists, 
who had come to descend on the undergraduate medical course and to tell us – 
deans of medical faculties, deans of medical schools – that we had got it wrong, 
because we weren’t teaching enough clinical pharmacology.168 Now that was a 
very good debate, and a good discussion, but deans of medical schools do get a 
kind of sense of déjà vu when they hear that, because it goes back to anatomists 
saying we don’t teach enough anatomy, and surgeons saying we don’t teach 
enough surgery or anatomy, and so on. Every subject can say that we don’t teach 
enough of it, and yet this keeps recurring. The latest instance I can think of was 
an article in the BMJ, I think, where the same point was made, rebutted pretty 
firmly, I have to say, in the correspondence column by the dean of the East 
Anglia Medical School, and I think we have to await real evidence of whether 
or not students are being taught enough clinical pharmacology.169 But are you 
all feeling a bit defensive? I am just wondering.
flower: I didn’t know what question you were going to ask, David, but you 
did say you were going to be provocative. As it happens, this was the topic that 
I wanted to wind up with and I wanted to ask a fairly generic question about 
where we are all going. I can see David Webb attracting my attention – unless 
it is an isometric stretch.
168 Dr Aronson wrote: ‘I wrote about this in an article (Aronson (1998)), I preferred the term “interaction”.’ 
E-mail to Mrs Lois Reynolds, 19 August 2008.
169 Aronson et al. (2006). For the rapid response e-letter from Professor Sam Leinster, dean of the University 
of East Anglia School of Medicine, Health Policy and Practice, and Dr Yoon Loke, senior lecturer in clinical 
pharmacology there, see www.bmj.com/cgi/eletters/333/7566/459 (visited 22 September 2008).
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Professor david Webb: I am not feeling defensive, but I was one of the authors 
of the piece that you refer to, and I have to say that some of us were in the process 
of putting together evidence at the time. Without this evidence it will be difficult 
to pursue the case for clinical pharmacology, but I think the argument we have 
actually been launching recently is not so much about clinical pharmacology, but 
more about the ability of junior doctors to prescribe. I think prescribing is the 
key. Interestingly, there has been a widespread recognition, unofficially, by every 
colleague that I talk to, that junior doctors have a problem with prescribing, and 
that’s fairly obviously in part because medicine has got so much more complex 
over the last ten or 20 years. I think we, as clinical pharmacologists, are probably 
concerned that the inability for us to teach a strand of training in pharmacology 
and therapeutics has also contributed to that problem. Now, I believe we do 
have some evidence, and I am not sure whether I am allowed to talk about it, but 
we had a meeting recently with the GMC and that was chaired by Peter Rubin 
and we have agreed to put together a working party to look at prescribing issues 
and how they might be addressed.170 I think there is a concern not just about 
doctors’ abilities to prescribe, but also that their attitude has moved to a position 
where they don’t actually think it matters if they get it right or not because there 
are pharmacists who can pick up on this, and I believe that we will have a very 
worrying loss of professional strength if we reach that position. So I think there 
is a concern that may well now have to be met.
Barnett: I want to echo that, because I think it’s really important. At one extreme, 
it would be impossible to believe that we would train surgeons without the skills to 
use a scalpel, and it seems unbelievable to me that we would train doctors who do 
not have the skills to use their pen properly and prescribe appropriately. However, 
I believe that there is a concern that this collaboration with clinical pharmacists, 
particularly with ward pharmacists, may potentially de-skill junior doctors. I think 
we may be reaching a point where doctors diagnose and pharmacists prescribe, 
and that is totally inappropriate for the twenty-first century.
reid: Can I come in again. I don’t disagree with anything that’s been said by 
David [Webb] and David [Barnett], nor David Gordon either, but I think 
this is not a matter for evidence. We have heard already about the pioneering 
work 30 or 40 years ago, about how diabolical prescriptions were. Pioneering 
170 In January 2007 the General Medical Council (GMC) convened the Safe Prescribing Working Group. 
See the recommendations and outcomes of the Safe Prescribing Working Group at www.chms.ac.uk/
publications.htm (visited 8 July 2008). See also Glossary, page 125–6.
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work could be done again now to show that it’s pretty awful, but what really is 
important is the perception here. Most of our final year medical students have a 
very low feeling of comfort in prescribing. Almost all the senior nursing staff on 
the wards have no confidence in the junior doctors’ prescribing; the pharmacists 
have no confidence in junior doctors’ prescribing. And the junior doctors don’t 
have any confidence either. So, whatever the evidence base, there’s a perception 
here which is undermining therapeutics and is a risk to patients, because – again 
echoing what David Barnett was saying – there’s no way someone straight after 
passing MB ChB should be allowed to go out and operate in any unsupervised 
way. They are prescribing potentially very dangerous drugs with drug interaction 
potential. I think we are not giving them enough formal grounding, as a result 
of some of the changes in the curriculum over the past 10 or 15 years.
Webb: I think it’s pretty clear that assessment drives learning. And I believe one 
of the problems we have at the moment is that if medical students realized that 
they had to be good prescribers, and they were put to a test in prescribing, they 
would become good prescribers, in the same way that they meet any test that 
they are put to. So I think that assessment clearly has to be a major part of the 
way forward.
Caulfield: I think learning is driven absolutely by assessment. We purged a lot 
of things in the revision of the curriculum and its integration into teaching. 
Some of those needed to go from the curriculum because the knowledge base 
we required of medical students was not entirely germane to the practice of 
medicine.171 There is one thing that you can do on day one as a doctor and that 
is kill someone with a pen if you are not a safe prescriber or you haven’t got 
a BNF. You probably won’t be able to kill them with your lack of knowledge 
of anatomy, although that’s possible if you are a surgeon. It’s much easier to 
kill people with drugs, and I think the whole prescribing arena has become so 
complex now that it is impossible to be safe without a very strong foundation 
in clinical pharmacology. If students are not exposed to an assessment that they 
can see is palpably in a specific area, geared to make them safe prescribers, they 
will often not learn the last component or a bit of a question, which, if they 
don’t quite answer it, nothing bad happens, because they will pass on knowing 
the physical signs and how to take a history from the patient. I shared the 
concern of Aronson et al. when they wrote that article, and I do believe that 
there is a way forward on that. In London we have put together a group, initially 
171 Mucklow (2001).
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under the chairmanship of Mike Farthing, to look at integrating the way in 
which medical schools that are still part of the University of London assess safe 
prescribing.172 Hopefully we can come to a common route to assess students 
using a mixture of a driving-test based Foundation Year 1 computer exam that 
has been developed by pharmacists at King’s, though it is not yet perfect. There 
are other computer-based learning and safe prescribing assessments which we 
have just been piloting at Bart’s and the London.173 Now all of our finalists have 
to do an assessment in safe prescribing using a computer-marked exam, which 
produces multiple scenarios for the same question, so you can have batches of 
30 or 40 students turn up for a session, do it, yet will never be able to tell the 
others anything other than the subject area of the exam. We are moving back 
to assessing the subject directly in a way that is meaningful and which will act 
as a hurdle prior to exit from the medical school, and we think that this is the 
only way forward. We have structured it so that it is not an impediment to 
exit, by actually holding the assessment away from the qualification date, and 
repeating it many times with support for learning along the way. I understand 
that the heads of medical schools’ reactions to these sorts of things (eg the 
BMJ) is an inward groan, but I think this is a serious problem and they should 
actively take it on board now. 
Prescott: Things have changed in other ways. In the olden days young doctors 
used to learn by the clinical apprenticeship system. Initially they had six- or 
12-month junior appointments where they were an integral part of the ward 
‘firm’. During this time they learnt how to prescribe from the senior medical staff, 
who by this time had usually worked out how to use drugs safely. Their example 
greatly influenced the way in which trainee doctors prescribed drugs. Now, the 
training of junior medical staff is horribly fragmented and there is no longer any 
recognizable apprentice system. Young doctors rotate dizzily from one specialty 
to another throughout their appointments and no one seems to have continuing 
172 Professor Michael Farthing chaired the Research Board of the General Medical Council’s Education 
Committee from 2004 to develop and supervise all their research initiatives. From August 2007, the Education 
Committee became responsibile for the content and standards for medical education from Foundation Year 1 
up to the point of full registration, an outcomes-based framework for programmes for provisionally registered 
doctors. Further details at www.gmc-uk.org/about/council/papers/2007_12/9%20-%20Work%20of%20
the%20Education%20Committee%202006-2007.pdf (visited 9 June 2008).
173 Professor Mark Caulfield wrote: ‘At Bart’s and the London, this has developed as a formative assessment 
where 120 students simultaneously sit the computer-based exam containing extended matching questions 
on safe prescribing. It is highly regarded by final year students and we hope it will shortly be adopted as a 
summative assessment.’ Note on draft transcript, 6 October 2008.  See Aronson et al. (2006).
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responsibility for them any more. In such circumstances it is impossible for them 
to learn good prescribing by example. This makes it all the more important for us 
as clinical pharmacologists to ensure that they receive proper training.
aronson: David Gordon made his point from the point of view of a dean of a 
medical school, and so it’s worth saying that when we met the GMC a couple 
of weeks ago at the meeting which David Webb referred to, the representative 
of the deans of all the London medical schools expressed her concern about the 
problem in prescribing, and agreed that something needed to be done. So this is 
the perception of deans as well. It was also the perception of John Tooke when 
we met the Council for the Heads of Medical Schools, to take Mark Caulfield’s 
point.174 They were initially critical, but they agreed that there is a problem, 
and that something needs to be done about it. Incidentally, as David [Webb] 
hinted, we regard this as being different from the manpower problem in clinical 
pharmacology, which is a separate problem. David Webb and Simon Maxwell 
highlighted it in their very good leader in the Lancet last year, but it is a separate 
problem from delivering the teaching; whether we can or whether others can, 
pharmacists, nurses, and others, we have got to find ways of doing it.175 It’s the 
prescribing that’s the problem. And I draw your attention to the last line of the key 
events which were initiated in 2006, as part of the 75th anniversary of the BPS: 
one of the initiatives that I hope the Society will do is a prescribing initiative,176 
and we have various ideas about changing the way we teach prescribing and the 
way we assess it, and we are going to be making some suggestions and doing 
something about that. 177 But we hope to be able to improve that.
ferner: I agree entirely with what David Webb said about examination being 
crucial. I am impressed by the fact that Mark Caulfield has a computer to 
examine his students. Maybe that will be appropriate when computerized 
prescribing comes. We still retain in Birmingham a therapeutics exam, which 
I guess Owen Wade might recognize, which owes a lot to Professor Martin 
Kendall, and which involves actual real people, not patients – fortunately – as 
174 Some time after this meeting Professor Sir John Tooke’s report on Modernising Medical Careers (MMC), 
Aspiring to Excellence, was published, which suggested a reworking of many aspects of postgraduate medical 
education (PGME). See Glossary, page 124.
175 Maxwell and Webb (2006). Breckenridge et al. (2006).
176 See Glossary, page 125.
177 See note 6. See also the 75th Anniversary Supplement of the BPS [British Journal of Pharmacology (2006) 
147: S1–307]; Cuthbert (2006); Aronson (2006). 
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many of the prescriptions would kill them. But there’s a glut of junior medical 
staff, as you know.178 The anger that David Gordon is worried about is not 
anger; I think it is sadness that somehow a discipline which is very different 
from, let us say, anatomy or physiology and is a crucial practical skill for people 
to learn, but which is not organ-based, should have been lost to a generation 
of doctors.
orme: As an erstwhile dean, perhaps I should respond to some of these particular 
issues; David Gordon and I have discussed this on a number of occasions, also 
with David’s predecessor (Professor Steve Tomlinson) in Manchester. In Liverpool 
we had a very didactic course where everything was measured in hours, and you 
had to have 300 hours of anatomy, and so many hours of this, and so many 
of that. The first two years was a total disaster. Students got browned off, they 
didn’t remember anything, and it took them probably six months to recover. 
In my view, the course which we introduced was a considerable improvement. 
Now, not everyone would agree with that. Indeed, my senior colleague Alasdair 
Breckenridge and I debated this, and I know he is not entirely wedded to the 
idea of problem-based learning; but nevertheless, in terms of objectivity there is 
one particular study, which Andrew Herxheimer will probably know, because it 
was done by one of his colleagues in Amsterdam, comparing about 20 different 
European medical schools, those that had problem-based learning and those that 
did not. There wasn’t much in the way of definite results. But the one definite 
result, in statistical terms, was that students from medical schools with problem-
based learning produced better prescribers than those from schools which did 
not, or had, if you like, the old didactic system.179 However, I will be the first to 
admit that not everything in the course was perfect. One of the things I regret is 
that, although I think students got a good exposure to pharmacology and clinical 
pharmacology in the various sessions in the course, they did not get adequate 
training in prescribing, much as it pains me to say so. I fully accept that assessment 
drives learning, and unless you have got a proper assessment system, then the 
students are not going to learn how to prescribe. So I think that is fundamental, 
but it can be built into problem-based systems. You don’t necessarily have to have 
a factual multiple-choice question (MCQ) to test whether students can prescribe 
or not. So, I would hold my hand up and say, ‘Yes, things are not perfect. We do 
need to have medical students taught how to prescribe throughout the course, 
178 Hall (2008). See www.telegraph.co.uk/news/uknews/1544307/Doctors’-training-system-’a-shambles’.
html (visited 3 June 2008). 
179 Bruijnen et al. (2000). See, for example, de Vries (1993); Queneau et al. (1993).
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but particularly in their final year and there needs to be some form of assessment 
of their skills’.180
flower: OK, David, the last comment is going to be yours, because I don’t want 
to finish in the midst of an education debate.
grahame-smith: One of the things that I have pondered is the tension that 
I think now exists between prescribing led by evidence-based medicine and 
prescribing, as it were, de novo from a clinical pharmacologist’s mind. Let me 
just explain this. Take the ‘polypill’: aspirin, a statin, maybe a bit of β-blocker, 
put it all together and anybody over the age of 55 gets it.181 Now the young 
student, I think, will look at that and ask: ‘Why the hell do we need to know 
any clinical pharmacology, we can give this thing to everybody’, a little bit like 
the situation with statins.182 Now, I see the oral contraceptive, and several other 
potent drugs, possibly coming off medical prescription and being bought over 
the counter at the pharmacy. Now, the young mind-in-training in medicine 
must look at this and say, ‘What are these people called clinical pharmacologists 
going on about pharmacokinetics, pharmacodynamics, drug metabolism 
and benefit–risk ratios, when you can go and buy a lot of this stuff from the 
chemist’s shop and do what you like with it?’ Does anybody else perceive a 
tension there? Or has anybody experience of the youngsters saying, ‘Why do we 
need to know all this if you can give this combination?’ We are not there yet, 
but it’s being mooted pretty strongly that a ‘polypill’ will stop everybody from 
having a vascular event. 
Prescott: What David has just said is very true and very familiar. It seems that 
today you no longer need specialist knowledge to use drugs properly and anyone 
can do it. What we are seeing is surely the dumbing down of therapeutics. 
flower: Colleagues, it is six o’clock, and as I told you I had two jobs today, one 
was to get to tea at four o’clock and the other is to finish by six o’clock in time 
for a glass of wine. I think we have got there. I have really enjoyed this afternoon; 
you have been a wonderful, if somewhat over-modest, collection of witnesses, 
and I have enjoyed listening to what you had to say. Hopefully, everything will 
180 See, for example, the UCL document on Medical School Examination Boards, including assessment 
requirements, compiled and edited by Professor Jane Dacre and Ms Gaynor Jones, at www.ucl.ac.uk/
medicalschool/about-medicalschool/mgt-structure/MBBS_3_Examination_Boards_0708.pdf (visited 15 
July 2008).
181 Wald and Law (2003). See also Collier (1984).
182 See Reynolds and Tansey (eds) (2006): 7, 36, 47, 53–4, 74–86.
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be captured faithfully on tape. Tilli, are there housekeeping announcements 
that you would like to make?
tansey: I would like to thank you all very much for coming. It’s been a very 
interesting afternoon, with some fascinating and amusing anecdotes, but also 
clearly some thoughtful reflections on serious issues. What happens now is that 
the tape recording of the entire meeting is transcribed, which will take between 
four and six months before the transcript comes through your letterbox. At that 
point we would ask for your help in translating the verbatim record into written 
text. We will add footnotes, bibliographies, biographies, appendices, glossaries, 
and hopefully that transcript will also help form the agenda for the second 
meeting, which we are going to hold on 25 September 2007. We will keep 
you informed. May I say once again, thank you all for coming to this meeting. 
And thank you to Jeff for suggesting it, and particularly to Rod for chairing 
it so ably.
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Appendix 1
Clinical pharmacology: dates of key publications and events 
Jeffrey Aronson  
1946 British National Formulary 
1954 Gaddum J H. (1954) Clinical pharmacology. Proceedings of the Royal 
Society of Medicine 47: 195–204.
1960 Dilling W J. (1960) Clinical Pharmacology, 20th edn, revised by 
Alstead S with Macarthur J G, Thomson T J, Anderson W F. 
London: Baillière, Tindall & Cassell, 1960.
Laurence D R. (1960) Clinical Pharmacology. London: Churchill.
1961 Prescribers’ Journal
1962 Drug and Therapeutics Bulletin
1963 Committee on Safety of Drugs (Dunlop Committee) established
1966 Dollery C T. (1966) Clinical pharmacology. Lancet i: 359–60.
1967 Quilliam J P, Turner P. (1967) Clinical pharmacology. Its role and 
its integration into the education of the medical student. Lancet 
ii: 1081–3.
Anon. (1967) Future of clinical pharmacology. British Medical 
Journal i: 125.
1968 Medicines Act, which created the Medicines Commission and led 
to the Committee on Safety of Medicines (1971); the DHSS 
Medicines Division (later Medicines Control Agency) administers 
the Act.
1969 Anon. (1969) Clinical pharmacology as a specialty. British Medical 
Journal ii: 331–2.
Royal College of Physicians of London, Committee on Clinical 
Pharmacology. (1969) Report of the Committee on Clinical 
Pharmacology. London: Royal College of Physicians.
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1970 Establishment of the Clinical Section of the British Pharmacological 
Society
Anon. (1970) Editorial: the image of clinical pharmacology. Lancet 
i: 129.
WHO. (1970) Clinical Pharmacology. Scope, organization, training: 
Report of a WHO Study Group, World Health Organization 
Technical Report series no. 446. Geneva: WHO.
1972 Establishment of the Unit of Clinical Pharmacology, Oxford 
University, by the Medical Research Council
1974 First issue of the British Journal of Clinical Pharmacology
1981 New version of the British National Formulary
1986 Anglo–American Workshop on Clinical Pharmacology held at Airlie, 
Virginia, 15–18 May
1989 Establishment of the Medicines Control Agency 
1999 Royal College of Physicians, Working Party. (1999) Clinical 
Pharmacology and Therapeutics in a Changing World: Report of a 
working party. London: Royal College of Physicians. 
Establishment of the National Institute of Clinical Excellence
2003 Medicines and Healthcare products Regulatory Agency created from 
the merger of the Medicines Control Agency and the Medical 
Devices Agency
2005 Medicines Commission and Committee on Safety of Medicines 
disbanded; Commission on Human Medicines established
2006 75th anniversary of the British Pharmacological Society
BPS Prescribing Initiative 183
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183 Professor Owen Wade suggested that two further publications be added to the list: 
*Goodman L, Gilman A. (1941) The Pharmacological Basis of Therapeutics: A textbook of pharmacology, 
toxicology and therapeutics for physicians and medical students. New York, NY: Macmillan Company. 
‘I first read the book in 1947 when I was a house surgeon at Addenbrooke’s Hospital, Cambridge. It was 
a copy owned by Mr Hopkins, the chief pharmacist of the hospital and I used to read it at night in the 
pharmacy when I lived in the hospital as a resident house officer for six months. This book was an enormous 
influence in my life. Like so many books, the first edition, all of which was written by the two authors, was a 
much better read than its many further editions, which had a number of contributors. By an extraordinary 
coincidence, when Mr Hopkins retired and moved to live near his son, my eldest brother, David Wade, who 
had just retired as a cardiac surgeon in Edinburgh, bought his home in Kingston, just outside Cambridge, 
and David and his wife Agnes, lived there for many years.’
* Crooks J, Calder G, Weir R D. (1967) Drugs in hospitals. Journal of the Royal College of Physicians 1: 233–44.
‘Jim Crooks was a great friend and colleague of mine and after discussions with him, he and Dr William 
Wallace in my department (Belfast) made a detailed study of the prescribing of drugs; he in the Aberdeen 
General Hospitals, Wallace in the Belfast City Hospital. They both found ‘casual and inefficient handling 
of drugs’ which resulted in many errors of drug administration to patients. This was the basis of the 
development of the Aberdeen Prescription Sheet, which in one form or another is now used in all NHS 
hospitals in the UK. It was a very important development.
When this paper was published, some astute journalist working for the Belfast Telegraph commented on 
“all the erroneous drug prescribing in the Royal Victoria Hospital (RVH)”, which was where my university 
department was based. I had not seen the Journal and was taken by surprise to have a visitation from the 
senior physician of the RVH and two infuriated colleagues demanding that I must immediately deny than 
any such errors occurred in the RVH. Unwillingly, I agreed to the publication of a statement that the 
newspaper’s report was mistaken and there was no evidence of errors of drug administration at the RVH. 
Unwilling – and with my tongue in my cheek – because I knew that if Dr Wallace had done the study in the 
RVH, I was sure he would have found identical errors to those he had found in the Belfast City Hospital.’ 
Note on questionnaire ‘Toward a map of the history of academic departments of clinical pharmacology in 
the UK’, n.d.
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dr stuart anderson
FRPharmS FHEA (b. 1946) 
graduated in pharmacy from 
the University of Manchester in 
1969. After experience in north 
Wales, he was appointed principal 
pharmacist in 1974 at Alder Hey 
Children’s Hospital, Liverpool; 
chief pharmacist in 1978 at 
Westminster Hospital, London, 
and director of pharmacy in 1983 
at St George’s Hospital, London; 
moved to the School of Pharmacy, 
University of London, in 1993, 
and is now associate dean of studies 
at the London School of Hygiene 
and Tropical Medicine, London. 
He is a former president of the 
British Society for the History of 
Pharmacy and a former chair of the 
Society for the Social History of 
Medicine; currently vice-president 
of the International Academy for 
the History of Pharmacy.
dr Jeffrey aronson
FRCP FBPharmacolS FFPM  
(b. 1947) trained in the University 
of Glasgow (1964–73) and 
the MRC Unit of Clinical 
Pharmacology, Oxford, under 
Professor David Grahame-Smith. 
He is currently reader in clinical 
pharmacology at the University of 
Oxford and honorary consultant 
physician in the Oxford Radcliffe 
Hospitals Trust. He was president of 
the British Pharmacological Society 
(2008/9); vice-chairman of the 
Medicines Commission (2002–05); 
and editor-in-chief of the British 
Journal of Clinical Pharmacology 
(2003–07). He has been chairman 
of the British Pharmacopoeia 
Commission’s Expert Advisory 
Group on Nomenclature since 
2006; a member of the Formulary 
Committees of the British National 
Formulary since 2006 and the 
British National Formulary for 
Children since 2003.  
For full curriculum vitae and  
list of publications, see  
www.clinpharm.ox.ac.uk/JKA 
(visited 22 July 2008).
Professor david Barnett
CBE FRCP (b. 1944) trained 
at Sheffield University. He was 
a Merck international fellow in 
clinical pharmacology in San 
Francisco, California, (1975–77); 
chair of the Specialist Advisory 
Committee for the Royal College 
of Physicians (1966–2000) and 
vice-chair of the Leicester Royal 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources. 
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Infirmary NHS Trust (1994–99). 
He is currently chairman of the 
Appraisal Committee for the 
National Institute for Health and 
Clinical Excellence and has been 
professor of clinical pharmacology 
at the University of Leicester 
Medical School and honorary 
consultant physician with a special 
interest in cardiovascular medicine 
at the University Hospitals of 
Leicester NHS Trust since 1984.
dr linda Beeley
FRCP (b. 1939) trained at the 
University of Oxford and then at 
the Radcliffe Hospital, Oxford. She 
held registrar posts at the Queen 
Elizabeth Hospital, Birmingham, 
and a lectureship in the department 
of clinical pharmacology, University 
of Birmingham. She was appointed 
consultant clinical pharmacologist 
at the Queen Elizabeth Hospital in 
1980 and set up and directed the 
West Midlands Monitoring Centre 
for the Committee on Safety of 
Medicines (1980–93); a member 
of the Subcommittee on Safety, 
Efficacy and Adverse Reactions 
of the Committee on Safety of 
Medicines (1986–92); chairman of 
Prescribers’ Journal (1984–89); and 
consultant to the British National 
Formulary (1980–97). She retired 
from the NHS in 1993. See Wade 
and Beeley (1976); Beeley (1992). 
Professor sir James Black 
Kt OM FRCP FRS (b. 1924) 
was professor and head of the 
department of pharmacology, 
University College London, (1973–
77), director of therapeutic research 
at Wellcome Research Laboratories 
(1978–84); and professor of 
analytical pharmacology at King’s 
College Hospital Medical School, 
London (1984–93). He was 
chancellor of Dundee University 
(1992–96). He shared the 1988 
Nobel Prize for Physiology or 
Medicine for ‘discoveries of 
important principles for drug 
treatment’ with George Hitchings 
(1905–98) and Gertrude Elion 
(1918–99).
dr nicolas Boon
FRCP FESC (b. 1950) was clinical 
lecturer and senior registrar at 
the John Radcliffe Hospital in 
Oxford (1983–86); consultant 
cardiologist at the Royal Infirmary 
of Edinburgh from 1986; honorary 
reader at the University of 
Edinburgh from 2005; honorary 
senior lecturer (1986–2005); 
and president-elect of the British 
Cardiac Society from 2005.
sir alasdair Breckenridge
Kt CBE RCP FRCPE FRSE 
FMedSci (b. 1937) following house 
jobs was lecturer and senior lecturer 
at the Hammersmith Hospital, 
London and the Royal Postgraduate 
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Medical School (1964–74); 
professor of clinical pharmacology, 
University of Liverpool (1974–
2002); and has been chairman of 
the MHRA since 2003. He was a 
member of the CSM (1982–2003), 
serving as vice–chairman (1996–
98) and chairman (1999–2003). 
He was also a member of the 
Medical Research Council  
(1992–96).
Professor Bernard Brodie 
PhD (1907–89) British born, 
educated at McGill University, 
Toronto, gained his PhD in 
organic chemistry from New 
York University (NYU) in 1935 
and joined the pharmacology 
department there. He moved to 
NYU’s Goldwater Research Service 
in 1941, working on antimalarial 
therapy for war use. He became 
head of the laboratory of Chemical 
Pharmacy in the National Heart 
Institute, Bethesda, MD (1950–
70). His work included the fields 
of anti-malarials, analgesics, anti-
arthritic and anti-arrhythmic agents 
and the control of CNS function. 
See Costa et al. (1989).
Professor morris Brown
FAHA FMedSci (b. 1951) trained 
at Trinity College Cambridge 
and University College Hospital, 
London. He was a MRC senior 
fellow, Royal Postgraduate Medical 
School (1982–85) and has been 
professor of clinical pharmacology, 
Cambridge and fellow of Gonville 
and Caius College, Cambridge, 
since 1985. He was president of 
the British Hypertension Society 
(2005–07) and winner of the Lilly 
Gold Medal 2002; the British 
Pharmacological Society; Walter 
Somerville Medal of the British 
Cardiovascular Society 2006. 
Professor george Brownlee
DSc (b. 1911), pharmacologist, 
joined the Biological 
Standardization Labs of 
Pharmaceutical Society, London, 
and then the Wellcome Research 
Labs, Beckenham, from  
c. 1940, and later was head of the 
chemotherapeutic division. He was 
appointed reader in pharmacology 
at King’s College, University of 
London in 1949; and professor 
of pharmacology (1958–78), 
later emeritus. He was editor 
of the Journal of Pharmacy and 
Pharmacology (1955–72). 
sir thomas lauder Brunton
FRCP FRS (1844–1916) qualified 
at Edinburgh University. His MD 
thesis demonstrated that amyl 
nitrite would relieve the pain of 
angina pectoris and temporarily 
lower blood pressure. He returned 
to the Middlesex Hospital, 
London, in 1870 as a lecturer on 
materia medica and pharmacology. 
The following year he moved to a 
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similar post at St Bartholomew’s 
Hospital, London, was elected 
assistant physician in 1875 and 
physician (1895–1904). 
Professor edith Bülbring
FRS (1903–90) German-born 
pharmacologist and physiologist, 
was educated at the universities 
of Bonn, Munich and Freiburg, 
and worked as a research assistant 
in pharmacology to Professor 
Paul Trendelenburg in Berlin 
(1929–32). She was dismissed 
in 1933 because of her Jewish 
background, and offered a post in 
J H Burn’s new Pharmacological 
Laboratory of the Pharmaceutical 
Society of Great Britain, University 
of London (1933–38), then in the 
University of Oxford from 1938 
as demonstrator, lecturer and later 
reader and professor (1967–71) 
in the pharmacology department. 
She became a naturalized citizen in 
1948. See Brading (1993).
Professor mark Caulfield
FRCP FMedSci (b. 1960) graduated 
in medicine in 1984 from the 
London Hospital Medical College 
and trained in clinical pharmacology 
at St Bartholomew’s Hospital 
where he developed a research 
programme in molecular genetics 
of hypertension. He is currently 
director of the William Harvey 
Research Institute and the London 
Genome Centre at Bart’s and the 
London (since 2002); national 
co-ordinator of the MRC British 
Genetics of Hypertension Study 
(since 1996); principal investigator 
of the Genetics of Pre-eclampsia 
Consortium; and deputy chair 
of the London Biobank Regional 
Collaborating Centre (since 2002). 
sir iain Chalmers
FRCPE FFPH FMedSci (b. 1943) 
has been editor of the award-
winning James Lind Library since 
2003. He was director of the UK 
Cochrane Centre in Oxford from 
1992 to 2002, and director of the 
National Perinatal Epidemiology 
Unit, Oxford (1978–92). See  
www.jameslindlibrary.org/ (visited 
4 June 2008).
Professor Joe Collier
FRCP (b. 1942) was professor of 
medicines policy and a clinical 
pharmacologist at St George’s 
Hospital and Medical School, 
London, where he has worked 
continuously since 1964 as student 
and teacher until his retirement in 
2007. He is the editor of Drug and 
Therapeutics Bulletin, president of 
the International Society of Drug 
Bulletins, a member of the UK 
Medicines Commission, and a 
writer and broadcaster.
Professor James Crooks
CBE FRCP MFCM (1920–83) 
was professor of pharmacology and 
therapeutics at the University of 
Clinical Pharmacology in the UK, c. 1950–2000: Influences and institutions – Biographical Notes 
105
Dundee and was made a member 
of the Faculty of Community 
Medicine in 1978.
Professor david (dai)  
margerison davies
(1923–2002) qualified at the 
London Hospital in 1949 and after 
house jobs, took a junior registrar 
post at a sector psychiatric hospital, 
flirted with medical journalism, 
and spent three years as medical 
registrar at the Bolingbroke 
Hospital, south London, before 
returning to the London Hospital 
as senior registrar to Lord (Horace) 
Evans and then receiving room 
physician and, at the same time, 
medical correspondent of the News 
Chronicle. He was a consultant 
physician at Shotley Bridge General 
Hospital, Co. Durham (1962–86). 
When Michael Rawlins was 
appointed to the Ruth and Lionel 
Jacobson Professor of Clinical 
Pharmacology at the University 
of Newcastle upon Tyne (1973–
2006), he joined him as honorary 
senior lecturer until appointed to 
the foundation chair of clinical 
pharmacology at the Chinese 
University of Hong Kong (1986–88).
He served on the Committee on 
Safety of Drugs and Committee on 
Safety of Medicines (1968–86), and 
on the Prescription-Only Medicines 
Subcommittee of the Medicines 
Commission (1970–72). He started 
the Adverse Drug Reaction Bulletin 
in 1966 and co-founded the 
Adverse Drug Reactions and Acute 
Poisoning Reviews (now Toxicological 
Reviews) in 1982. See de Glanville 
and Ferner (2003).
Professor donald s davies
FRSC FRCPath HonFRCP 
(b. 1940) completed his PhD at  
St Mary’s Hospital Medical School 
in 1965 and following a two year 
post-doctoral fellowship at the 
National Institutes of Health, 
US, joined the MRC Clinical 
Pharmacology Research Group at 
the Royal Postgraduate Medical 
School (RPMS), Hammersmith 
Hospital, London. In 1980 he was 
appointed professor of biochemical 
pharmacology at RPMS and in 
1987 became director of the clinical 
pharmacology department as well 
as director of the department of 
health toxicology unit at Imperial 
College London.
Professor sir Colin dollery 
Kt FRCP FMedSci (b. 1931) 
qualified at Birmingham and 
trained at the Hammersmith 
Hospital, London, where he 
has been a consultant physician 
since 1962. He was a lecturer in 
medicine (1962–65); professor of 
clinical pharmacology (1965–87); 
professor of medicine (1987–91); 
and dean (1991–96) at the Royal 
Postgraduate Medical School, 
Hammersmith Hospital until 
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his retirement. He was pro-vice-
chancellor for medicine (formerly 
medicine and dentistry), University 
of London (1992–6). He has been 
a senior consultant in research and 
development, at GlaxoSmithKline 
(formerly Smithkline Beecham) 
since 1996.
Professor anthony dornhorst
CBE FRCP (1915–2003) joined 
St Thomas’ Hospital Medical 
School, London, as a house officer 
in 1938 and served in the Royal 
Army Medical Corps in Palestine, 
North Africa, Italy and Berlin. 
He returned to St Thomas’ and 
was appointed reader in 1949 and 
consultant in 1951. He held the 
foundation chair of medicine at St 
George’s Hospital Medical School, 
London, (1959–80); was a member 
of the advisory council of the Drug 
and Therapeutics Bulletin (1962–
67) and a member of the Medical 
Research Council (1973–77). See 
Collier (2003).
Professor robin ferner
FRCP (b. 1949) trained in 
chemistry and then in medicine, 
qualifying at University College 
Hospital, London, in 1978. He 
was senior registrar in the National 
Institute of Health and Clinical 
Excellence in Newcastle upon 
Tyne (1984–90) and has been 
a consultant physician at City 
Hospital, Birmingham, formerly 
Dudley Road Hospital since 
1990. In 1993 he was appointed 
director of the West Midlands 
Centre for Adverse Drug Reactions, 
and honorary senior lecturer in 
Medicine at the University of 
Birmingham. In 2006 he was 
made honorary professor of clinical 
pharmacology at the University of 
Birmingham.
Professor roderick flower
FMedSci FRS (b. 1945) trained 
as a physiologist at Sheffield 
University, subsequently receiving a 
PhD in experimental pharmacology 
from the University of London 
and a DSc in 1985. After 12 
years working in industry at the 
Wellcome Foundation, he left to 
take the chair of pharmacology at 
the University of Bath in 1985. In 
1990 he returned to London to 
establish a new unit at the William 
Harvey Research Institute, Bart’s 
and the London. During this 
time he was head, on a part-time 
basis, of the clinical pharmacology 
department, and was president of 
the British Pharmacological Society 
(2000–03).
dr arthur fowle
FRCP (b. 1929) trained at King’s 
College Hospital, London, 
intending to practise cardiology. 
He joined Wellcome Research 
Laboratories, Beckenham, in 1965 
as a clinical physiologist. Security of 
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tenure was promised if he became 
a part-time consultant physician in 
the NHS. In the interval, clinical 
pharmacology was recognized as 
the discipline which he practised. 
He became head of the clinical 
pharmacology department in 1968 
and part-time consultant general 
physician in the same year. He 
retired from Wellcome in 1992. 
Professor sir Charles george
Kt FRCP FFPM FMedSci  
(b. 1941) studied medicine at the 
University of Birmingham and after 
junior posts in the West Midlands 
and Manchester trained in clinical 
pharmacology with Professor 
Colin Dollery and Dr Alasdair 
Breckenridge. He moved to the 
University of Southampton as a 
senior lecturer in 1974 and a year 
later became professor of clinical 
pharmacology there. He served two 
terms as dean of medicine (1986–
90; 1993–8) and was chairman 
of the General Medical Council’s 
Education Committee before he 
became medical director of the 
British Heart Foundation (1999–
2004); president of the British 
Medical Association (2004/5) and 
has been chair of their Board of 
Science and Education since 2005.
Professor sir abraham goldberg
Kt DSc FRCPGlas FRCPE FRCP 
FFPM FRSE (1923–2007) held 
posts at the University of Glasgow 
(1956–99); was chairman of the 
Committee on Safety of Medicines 
(1980–86); foundation president 
of the Royal College of Medicine’s 
Faculty of Pharmaceutical Medicine 
(1989–91); and editor of the 
Scottish Medical Journal (1962/3).
Professor david gordon
FRCP FMedSci (b. 1947) is a 
general physician. He began his 
academic career in the medical 
unit at St Mary’s Hospital Medical 
School. In a prolonged break from 
his conventional academic medical 
career he was a member of the staff 
of the Wellcome Trust, London, 
responsible for support of  
biological and medical research 
across a wide range of subjects, 
and for the career development 
of clinical and basic biomedical 
scientists. He worked at the 
University of Manchester (1999–
2007), most of that time as dean of 
the medical faculty. He was chair 
of the Council of Heads of Medical 
Schools and also the president of 
the Association of Medical Schools 
in Europe. He has been visiting 
professor at the University of 
Copenhagen since 2007.
Professor david grahame-smith
CBE FRCP (b. 1933) was Rhodes 
professor of clinical pharmacology, 
University of Oxford (1972–
2000), honorary director of the 
Medical Research Council Unit 
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of Clinical Pharmacology, Oxford 
(1972–92), honorary director of 
the Oxford University SmithKline 
Beecham Centre for Applied 
Neuropsychobiology (1989–99) 
and honorary consultant in clinical 
pharmacology and general internal 
medicine to the Oxford Radcliffe 
Hospitals (1972–2000).
dr andrew herxheimer
FRCP (b. 1925) worked 
in preclinical and clinical 
pharmacology at St Thomas’ 
Hospital Medical School, the 
London Hospital Medical 
College and at Charing Cross and 
Westminster Medical School until 
1991. He was founding editor 
of the Drug and Therapeutics 
Bulletin (1962–92), while 
simultaneously working with 
Consumers International. In 1986 
he became the first chairman 
of the International Society of 
Drug Bulletins. He was also 
extraordinary professor of clinical 
pharmacology at the University of 
Groningen (1968–77). He is part-
time consultant at the Cochrane 
Centre in Oxford (since 1992), 
and has been its emeritus fellow 
since 1995. In 1996 he and Dr 
Ann McPherson started the DIPEx 
project. See www.dipex.org, www.
adverseeffectsmethods, and 
cochrane.org; (sites visited 11 
October 2007).
sir harold himsworth
KCB FRCP FRS (1905–93) was 
appointed professor of medicine 
and director of the medical unit 
at University College Hospital, 
London, in 1939 and was secretary 
of the Medical Research Council 
(1949–68). See Gray and Booth 
(1994).
Professor John hope 
(1725–86) held the chairs of 
materia medica and of botany at 
the University of Edinburgh from 
1761 to 1768, giving lectures on 
materia medica in the winter and 
on botany starting in May. He 
resigned as professor of materia 
medica in 1768 on appointment 
to the Regius chair of botany at 
Edinburgh. See Hope (1770).
dr Kenneth hunter
FRCP (b. 1939) graduated in 1963, 
having trained at Cambridge and 
University College Hospital (UCH) 
Medical School. His postgraduate 
training included experience in 
clinical pharmacology at UCH 
and the Hammersmith Hospital, 
London. He became a consultant 
physician with a special interest in 
diabetes in Plymouth in 1977, was 
a councillor at the Royal College of 
Physicians (1994–97) and gave the 
Fitzpatrick Lecture in the history of 
medicine there in 2001. 
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Professor sir robert Brockie 
hunter (Baron hunter of 
newington) 
Kt MBE DL FRCP FRCPE FACP 
FIBiol FFCM (1915–94) qualified 
at Edinburgh University; was a 
founder member of the Committee 
on Safety of Drugs in 1963. He 
became professor of therapeutics, 
university administrator, principal 
and vice-chancellor of Birmingham 
University (1968–81). 
Professor trevor Jones 
CBE (b. 1942) was research 
and development director of the 
Wellcome Foundation (1987–94). 
He is a founder member of 
the public–private partnership, 
Medicines for Malaria Venture 
(MMV) and a member of the World 
Health Organization Commission 
on Intellectual Property Rights, 
Innovation and Public Health. He 
was a member of the Medicines 
Commission (1982–94); director 
general of the Association of the 
British Pharmaceutical Industry 
(1994–2004); a member of council 
of the International Federation of 
Pharmaceutical Manufacturers & 
Associations (1994–2004) and the 
board of the European Federation 
of Pharmaceutical Industries and 
Associations (1994–2004). He is 
also deputy chairman of council 
and a visiting professor at King’s 
College London; a director of 
Allergan Inc. US, ReNeuron Ltd, 
BAC, BC, People in Health Ltd, 
VeronaPharma plc and NextPharma 
Technologies Ltd.
Professor martin Kendall 
OBE FRCP FFPM was professor 
of clinical pharmacology at 
the University of Birmingham 
Medical School, a member of the 
Commission on Human Medicines; 
chairman of the Formulary 
Development Committee; 
and clinical examiner for the 
Membership Exam of the Royal 
College of Physicians. 
Professor louis lasagna 
MD (1923–2003) qualified at 
Columbia University and joined 
the Johns Hopkins University 
in 1954 and later established 
a department of clinical 
pharmacology there. In 1970 
he moved to the University of 
Rochester School of Medicine 
and Dentistry as chairman of the 
department of pharmacology and 
toxicology and in 1976 founded 
the Center for the Study of Drug 
Development, until he and the 
Center moved to Tufts University, 
Boston, MA, in 1984, where he 
was dean of the Sackler School of 
Graduate Biomedical Sciences until 
his retirement in 2002. 
Professor desmond laurence
FRCP (b. 1922) qualified in 
medicine from St Thomas’ Hospital 
Medical School, London, in 1944 
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and was appointed lecturer in 
therapeutics there in 1950. He was 
senior lecturer in pharmacology 
and therapeutics at University 
College Hospital Medical School 
jointly with University College 
London (1954–61) and professor 
there (1961–89). He served on the 
Committee on Safety of Drugs, 
Committee on Safety of Medicines 
and the Medicines Commission 
(1963–88). In 1967 he was a 
member of the Royal College 
of Physicians committee on the 
supervision of the ethics of clinical 
investigations and institutions, and 
subsequently served on the college’s 
Committee on Ethical Issues in 
Medicine. For 26 years he served 
on research ethics committees as 
chairman or member. 
Professor alastair macgregor
FRCP FRCPE FRCPGlas (1919–
72) qualified at the University 
of Glasgow; served as surgeon 
lieutenant in the Royal Navy 
Volunteer Reserve (1944–46); was 
clinical assistant at the Western 
Infirmary, Glasgow (1946–48); 
lecturer in therapeutics at the 
University of Sheffield (1948–52); 
senior lecturer in therapeutics 
at the University of Edinburgh 
(1952–59); and Regius professor of 
materia medica in the department 
of therapeutics and pharmacology 
at the University of Aberdeen 
(1959–72).
Professor Paul martini 
(1889–1964) was chief physician 
and director of St Hedwig 
Hospital, Berlin (1927–31) 
and was professor for internal 
medicine at the University of 
Bonn (1931–59). He published 
Methods of Therapeutic Examination 
in 1932. His textbook Principles 
and Practice of Physical Diagnosis 
appeared in English in 1935. 
He was president of the German 
Society for Internal Medicine 
in 1948. The Paul Martini 
Foundation was established by 
the Medizinisch-Pharmazeutische 
Studiengesellschaft in 1966 to 
promote pharmaceutical research 
in Germany through the support of 
students of clinical pharmacology. 
Professor denis mcdevitt 
DSc MD FRCP FRSEd  
(b. 1937) trained at Queen’s 
University, Belfast, and later at 
Vanderbilt University, Nashville, 
Tennessee. He was professor of 
clinical pharmacology at Queen’s 
University, Belfast (1978–83); 
professor of clinical pharmacology 
at the University of Dundee (1984–
2002); and dean of medicine, 
dentistry and nursing in Dundee 
(1994–97). He was secretary 
(1978–82) and subsequently 
chairman (1985–88) of the 
Clinical Section of the British 
Pharmacological Society, of which 
he is now an honorary fellow. He 
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was president of the Association 
of Physicians of Great Britain and 
Ireland (1987/8), a member of the 
Medicines Commission (1986–95; 
vice-chairman, 1992–95) and a 
member of the General Medical 
Council (1996–2003; treasurer, 
2001–03).
Professor Walter nimmo
(b. 1947) was educated at Bathgate 
Academy and qualified at the 
University of Edinburgh. His 
early medical career included the 
Sir Stanley Davidson lectureship 
in clinical pharmacology and a 
lectureship in anaesthesia at the 
University of Edinburgh. In 1979 
he was appointed senior lecturer 
in anaesthesia at the University 
of Sheffield. In 1988 he was the 
founding managing director of 
Inveresk Clinical Research and chief 
executive of the Inveresk Research 
group of companies in 1996. 
Professor michael orme
FRCP FMedSci (b. 1940) trained 
as a clinical pharmacologist in the 
UK and Sweden and worked for 
most of his career in Liverpool. He 
was dean of the faculty of medicine 
in Liverpool (1991–96) and has 
taken a particular interest in 
education. He helped to found the 
European Association for Clinical 
Pharmacology and Therapeutics 
in the early 1990s and was its 
chairman (2003–07).
Professor sir William Paton
Kt CBE FRCP FRS (1917–93) 
was on the scientific staff of the 
National Institute for Medical 
Research (1944–52); reader in 
applied pharmacology at University 
College Hospital, London (1952–
54); held the Vandervell chair of 
pharmacology at the Royal College 
of Surgeons, London, (1956–59); 
and was professor of pharmacology 
at the University of Oxford and 
fellow of Balliol College (1959–
83). He was a member of the 
MRC (1963–67), a trustee of the 
Wellcome Trust (1978–87) and 
honorary director of the Wellcome 
Institute for History of Medicine 
(1983–87). His papers are held 
in archives and manuscripts, 
Wellcome Library, London, as 
PP/WDP, with further papers in 
GC/68/ and GC/154/A/11. See 
Rang and Perry (1996).
Professor sir stanley Peart
Kt FRCP FMedSci FRS  
(b. 1922) was professor of medicine 
at St Mary’s Hospital Medical 
School, University of London, 
(1957–87), later emeritus. He was 
master of the Hunterian Institute, 
Royal College of Surgeons of 
England (1988–92); trustee of 
the Wellcome Trust (1975–94), 
deputy chairman (1991–94) and 
consultant (1994–98); and a Beit 
trustee (1986–2003). He delivered 
the Goulstonian lecture in 1959, 
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the Croonian lecture in 1979,  
and was a founder member of  
the Academy of Medical Sciences 
in 1998.
dr anthony Peck
FRCP FFPM (b. 1933) qualified at 
the Middlesex Hospital, London, 
and gained his PhD in 1967 from 
the University of London. In 
1968 he was appointed assistant 
professor at the San Francisco 
Medical Center; was a clinical 
pharmacologist at the Wellcome 
Foundation (1969–94); part-time 
senior lecturer at the Middlesex 
Hospital (1969–98), later 
University College Hospital. He 
was also part-time senior medical 
assessor to the Medicines Control 
Agency (1994–2000).
Professor Brian Pentecost
OBE FRCP (b. 1934) qualified at 
St Mary’s Medical School, London, 
in 1957, was consultant physician 
and cardiologist at the United 
Birmingham Hospitals (1965–93); 
dean of postgraduate medicine and 
dental education there (1987–91); 
and honorary professor of medicine 
(1991–98). He has been advisor 
in cardiology to the Department 
of Health’s chief medical officer 
(1986–93), a member of the 
Committee on Safety of Medicines 
(1984–89; 1996–98), the Royal 
College of Physician’s Linacre 
fellow (director of training, 
1991–94) and medical director 
of the British Heart Foundation 
(1993–99).
Professor laurie Prescott 
FRCPE FRCP FFPM DCPSA 
FRSE (b. 1934) trained at 
Cambridge and the Middlesex 
Hospital, London. After junior 
hospital appointments in London, 
he was medical resident at the 
Boston City Hospital, Boston, 
Massachusetts, and then research 
fellow with Professor Lou 
Lasagna in the division of clinical 
pharmacology at the Johns Hopkins 
Hospital, Baltimore, Maryland. 
He returned to the UK as lecturer 
in therapeutics at the Aberdeen 
Royal Infirmary, Foresterhill 
(1965–69), and was senior 
lecturer, reader, and then professor 
of clinical pharmacology in the 
department of therapeutics and 
clinical pharmacology, University 
of Edinburgh (1969–97). He was 
honorary consultant physician to 
the Edinburgh Royal Infirmary and 
the Edinburgh Regional Poisoning 
Treatment Centre. 
Professor Brian Prichard
CBE FRCP FFPM FESC FACC 
FBPharmacolS (b. 1932) started 
preclinical studies at King’s College 
London in 1950 and qualified 
at St George’s Hospital Medical 
School, London, in 1957. He was 
appointed research assistant in 
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clinical pharmacology to Professor 
D R Laurence at University College 
Hospital Medical School, London, 
in 1961, and became professor 
in clinical pharmacology at 
University College London (UCL) 
in 1980. He is past president 
of the International Society for 
Cardiovascular Pharmacotherapy, 
past vice-dean of the faculty of 
clinical sciences at UCL, and 
was foundation secretary of the 
Clinical Section of the British 
Pharmacological Society (1970–75) 
and has been chairman of the 
Institute on Alcohol Studies since 
1993, a councillor in the London 
Borough of Wandsworth for over 
40 years and a medical officer to 
Boys’ Brigade camps. 
Professor Peter Quilliam
OBE FRCP (1915–2003) was 
professor of pharmacology at St 
Bartholomew’s Hospital, London, 
from 1962 until his retirement, 
later emeritus, and was a co-
founder of the charity, Help the 
Hospices. See Quilliam and  
Brown (2004).
Professor humphrey rang 
FRS FMedSci (b. 1936) was 
director of the Sandoz (later 
Novartis) Institute for Medical 
Research (1983–97); and professor 
of pharmacology at University 
College London (1979–83; 1995–
2001), now emeritus. 
Professor sir michael rawlins
Kt DL FRCP FRCPE FFPM 
FBPharmacolS FMedSci  
(b. 1941) qualified at St Thomas’s 
Hospital, London, where he 
was later lecturer in medicine 
(1967–71); moving to the 
Hammersmith Hospital, London, 
as senior registrar (1971/2), a 
visiting research fellow at the 
Karolinska Institute, Stockholm, 
Sweden (1972/3) and was Ruth 
and Lionel Jacobson professor 
of clinical pharmacology at the 
University of Newcastle upon Tyne 
(1973–2006). He was a member 
of the National Committee 
on Pharmacology (1977–83); 
the CSM (1980–98; chairman 
1993–98); Committee on Toxicity, 
(1989–92), the Standing Group 
on Health Technology Assessment 
(1993–5). He has been chairman 
of the National Institute for Health 
and Clinical Excellence since 1999.
Professor John reid
OBE FRCP FRCP(Glas) FRS(E) 
FMedSci (b. 1943) graduated in 
medicine from Oxford and trained 
in clinical pharmacology at the 
Royal Postgraduate Medical School 
(RPMS), Hammersmith Hospital, 
London. After a Medical Research 
Council travelling fellowship to 
the National Institutes of Health, 
Bethesda, Maryland, he returned 
to the RPMS as senior lecturer 
and later reader. In 1978 he was 
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appointed Regius professor of 
materia medica and therapeutics 
at the University of Glasgow and 
in 1989 translated to the Regius 
chair of medicine and head of 
the department of medicine and 
therapeutics. He is past president 
of the Association of Physicians 
of Great Britain and Ireland and 
of both the British and European 
Societies of Hypertension.
Professor alan richens 
PhD FRCP FFPM FBPharmacol, a 
clinical pharmacologist in the area 
of antiepileptic drugs.
Professor James ritter
DPhil (b. 1944) gained his first 
degree in animal physiology and 
a DPhil in pharmacology before 
completing clinical medicine at 
the Radcliffe Infirmary (Oxford) 
and training in Oxford, London 
and the Johns Hopkins Hospital 
Baltimore, Maryland, with 
specialist training in clinical 
pharmacology at Hammersmith 
Hospital, London. He has been 
head of the department of clinical 
pharmacology at Guy’s, King’s and 
St Thomas’ School of Medicine 
(King’s College, London); an 
honorary consultant physician 
at Guy’s Hospital, then at Guy’s 
and St Thomas’ NHS Trust since 
1988. He sat on the Subcommittee 
on Safety and Efficacy of the 
Committee on Safety of Medicines, 
has chaired local and multicentre 
research ethics committees and 
chaired the Thames Specialty 
Training Committee in Clinical 
Pharmacology. He is editor-in-chief 
of the British Journal of Clinical 
Pharmacology (2008– ) and has co-
authored the third and subsequent 
editions of Rang and Dale (1987).
Professor sir max rosenheim 
(Baron rosenheim of Camden) 
Kt FRCP FRS (1908–72) qualified 
at Cambridge and did house jobs 
at University College Hospital 
(UCH) and Westminster Hospital, 
London. He became first assistant 
to the medical unit at UCH under 
Sir Harold Himsworth in 1940 and 
served in the Royal Army Medical 
Corps (RAMC) from 1941, 
reaching the rank of brigadier in 
the Allied Land Forces South East 
Asia. He returned to the UCH 
medical unit as deputy director 
and was appointed professor there 
in 1954. He was a member of the 
Medical Research Council and 
the Tropical Medicine Research 
Board (1961–64) and president of 
the Royal College of Physicians, 
London, (1966–72). See Robson 
(1982).
Professor Phil routledge
MBE has been professor of clinical 
pharmacology at the School of 
Medicine, Cardiff University and 
consultant general physician at 
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the Llandough Hospital, Cardiff. 
He has been chair of the All Wales 
Medicines Strategy Group, head 
of Yellow Card Centre Wales; and 
chair of the All Wales Medicines 
Strategy Group. 
Professor heinz schild
FRS (1906–84), pharmacologist, 
qualified at the Munich Medical 
School. He worked in Sir Henry 
Dale’s lab (1932/3) and stayed in 
Britain working with Professor 
I de Burgh Daly at Edinburgh, 
and with S H Gaddum in Egypt; 
returning in 1937. He was interned 
in 1939 and on his release returned 
to the evacuated University 
College London department of 
pharmacology in Leatherhead, 
Surrey, from 1941. He became a 
British citizen in 1948. His method 
for obtaining the real equilibrium 
constant for antagonist binding 
contributed to the understanding 
of ligand receptor binding. 
Professor sir eric scowen
Kt FRCP FRCS FRCPE FRCPath 
FRPharmS FRCGP (1910–2002) 
qualified at St Bartholomew’s 
Hospital Medical School, London, 
and was house physician to Professor 
Francis Fraser, the first professor of 
medicine at Bart’s, leaving in 1937 
for Columbia University, New York, 
as a Rockefeller fellow. He returned 
in 1938 as a reader in medicine at 
Bart’s, where he remained throughout 
the war, serving as one of the 
Prime Minister’s physicians. He 
was physician there from 1946 and 
helped plan the rebuilding of the 
Medical College in Charterhouse 
Square, appointed as its warden in 
1951. In 1955 he became director 
of the medical professorial unit at 
Bart’s, and professor of medicine, 
University of London (1961–75). 
He was chairman of the British 
Pharmacopoeia Commission 
(1963–69); member of the 
Committee on Safety of Drugs 
(CSD) (1963–71); chairman of the 
CSD’s Subcommittee on Toxicity; 
twice chairman of the Committee on 
Safety of Medicines (1971–76; 1977–
80); member of the Committee on 
the Review of Medicines (1975–78) 
and chairman of the Council of the 
School of Pharmacy (1970–80).
Professor robin shanks
CBE FRCP FACP (b. 1934) 
was senior pro-vice chancellor, 
Queen’s University, Belfast, 
(1995–98). He was professor of 
clinical pharmacology at Queen’s 
University, Belfast, (1972–77), 
Whitla professor of therapeutics and 
pharmacology, Queen’s University, 
Belfast, (1977–98), and dean of the 
faculty of medicine (1986–91).
Professor reginald stephen  
(sam) stacey
(d. 1974) qualified at St Thomas’ 
Hospital Medical School, then 
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joined the medical unit there 
until appointed as professor of 
pharmacology and therapeutics at 
the College of Medicine, Baghdad, 
Iraq. He returned to St Thomas’ 
as reader in 1948 and professor 
(1958–70) where he was known for 
his work on blood-platelet function 
and 5-hydroxytryptamine (5HT). 
After retirement he joined the 
Wellcome Research Laboratories, 
Beckenham. See Anon. [S.E.S.] 
(1974). His papers, including 
descriptions of the development of 
courses of study in pharmacology 
and therapeutics, cover the period 
1931–74 and are held as MS826 at 
Senate House Library, University  
of London.
Professor e m (tilli) tansey
HonFRCP FMedSci (b. 1953) 
is convenor of the History of 
Twentieth Century Medicine 
Group and professor of the history 
of modern medical sciences at the 
Wellcome Trust Centre for the 
History of Medicine at UCL.
Professor sir John tooke 
Kt FRCP FMedSci (b. 1949) has 
been professor of vascular medicine, 
University of Exeter, since 1992; 
dean of the Peninsula Medical 
School since 2000; honorary 
consultant physician in diabetes 
and vascular medicine, Royal 
Devon and Exeter Healthcare NHS 
Trust since 2000; executive dean of 
the Peninsula College of Medicine 
and Dentistry, and chairman of 
the Council of Heads of Medical 
Schools, since 2006.
Professor geoffrey tucker
FRCP(E) FRCA FFPM 
FBPharmacolS FBTS FCCP  
(b. 1943) trained as a pharmacist 
and received his PhD from the 
University of London in 1967. He 
was research assistant professor 
at the Anesthesia Research 
Center of the University of 
Washington, Seattle (1967–73); 
and after various appointments 
at the University of Sheffield, 
he was professor and head of 
the academic unit of clinical 
pharmacology, later emeritus. 
He has been editor (1988–94) 
and chairman of the editorial 
board (1995–2002) of the British 
Journal of Clinical Pharmacology; 
received the Lilly Prize from the 
British Pharmacological Society in 
2000 for contributions to clinical 
pharmacology; and is chairman 
and co-founder of Simcyp Ltd, a 
University of Sheffield company 
specializing in the prediction of 
pharmacokinetics in populations 
since 2001.
Professor Paul turner
CBE FRCP FFPM (1933–94) 
qualified at the University of 
London and trained at Middlesex 
Hospital, the Royal Free Hospital, 
Clinical Pharmacology in the UK, c. 1950–2000: Influences and institutions – Biographical Notes 
117
London, and Edgeware General 
Hospital. He joined the staff 
of St Bartholomew’s Hospital, 
London in 1963 as a lecturer 
in clinical pharmacology, later 
reader; was professor of clinical 
pharmacology at the University of 
London; and consultant physician 
at St Bartholomew’s Hospital 
(1972–93). He was chairman of the 
Department of Health’s Committee 
on Toxicity (1976–91) and 
president of the Medical Society 
of London (1991/2). See Gillam 
(2000).
Professor Patrick Vallance
FRCP FMedSci (b. 1960) trained 
at St George’s Hospital Medical 
School, London, and qualified 
in 1984, where he was appointed 
as consultant and senior lecturer 
(1990–95). He left to take up the 
chair of clinical pharmacology 
at Univeristy College London. 
In 2002 he became head of the 
division of medicine and in 2006 
left to join GlaxoSmithKline as 
head of drug discovery. He chaired 
the Wellcome Trust pharmacology 
and physiology grants panel and 
was registrar of the Academy of 
Medical Sciences.
Professor duncan Vere
FRCP FFPM (b. 1929) trained in 
medicine at the London Hospital 
Medical College and completed a 
postgraduate research fellowship 
there. He was medical officer at 
the RAF Institute of Aviation 
Medicine; senior lecturer in 
medicine and consultant physician 
at the London Hospital; reader 
and then professor of therapeutics 
at the London Hospital Medical 
School and was appointed head of 
the department of pharmacology 
and therapeutics there in 1969. He 
was a member of the Committee 
on Safety of Medicines, the 
Committee on Dental and Surgical 
Materials and the Medicines 
Commission (1970–90), and a 
member of the Nuffield Enquiry 
into Pharmacy, St Christopher’s 
Hospice Research Committee.
Professor owen lyndon Wade
CBE FRCP HonFRCPI  
(b. 1921) trained at Cambridge and 
University College Hospital, and 
joined the MRC’s Pneumoconiosis 
Research Unit, (1948–51) under 
Charles Fletcher and Archie 
Cochrane. He worked with 
K W Donald in the early days of 
cardiac catheterization (1951–57) 
and spent a year as a Rockefeller 
fellow at Columbia University, 
New York, with Robert Loeb. 
He was appointed to the chair of 
pharmacology and therapeutics at 
Queen’s University, Belfast (1957–
71) and to the chair in clinical 
pharmacology at Birmingham 
University (1971–86), serving six 
years as the dean of the faculty 
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of medicine and dentistry and 
three years as pro-vice-chancellor. 
He was a member of the Joint 
Formulary Committee responsible 
for the British National Formulary 
(1963–86) and chairman of the 
Joint Formulary Committee 
(1978–86). He was chairman of 
the Subcommittee on Adverse 
Reactions of the Committee on 
Safety of Drugs. He was also a 
founder member of the World 
Health Organization Drug 
Utilization Research Group. See 
Wade (1996): 110; Figure 7.
dr mark Walport
FRCP FRCPath FMedSci  
(b. 1953) trained at Cambridge and 
the Middlesex Hospital Medical 
School; after junior appointments 
at the Hammersmith, Guy’s and 
the Brompton Hospitals, he 
became an MRC training fellow in 
the MRC Mechanisms in Tumour 
Immunity Unit, Cambridge, 
gaining his PhD in 1986. He was 
head of the rheumatology section 
in the Royal Postgraduate Medical 
School (1985–97); head of the 
division of medicine at Imperial 
College London (1997–2003); and 
has been director of the Wellcome 
Trust since 2003. He was awarded 
the Roche Rheumatology Prize in 
1991 and the Graham Bull Prize 
in Clinical Science (Royal College 
of Physicians) in 1996; and was a 
governor of the Wellcome Trust 
(2000–03). He is a co-author of 
Immunobiology: the Immune System 
in Health and Disease (Janeway  
et al. (1997)) and was chairman of 
the editorial board of the British 
Medical Bulletin (2002–04). A 
founder fellow of the Academy 
of Medical Sciences (1998), 
he was appointed a member of 
the Prime Minister’s Council 
for Science and Technology in 
2004 and the Office for Strategic 
Coordination of Health Research 
(2007– ). He chairs the Academic 
Careers Subcommittee of the UK 
Clinical Research Collaboration 
and Modernising Medical Careers 
(2004–) and co-chaired the 
independent review on the use and 
sharing of personal information in 
the public and private sectors for 
the Ministry of Justice (2007/8). 
Professor miles Weatherall
FIBiol (1920–2007) qualified 
at Oxford in 1943 followed by 
house jobs at the Hammersmith 
Hospital, London, and started 
pharmacological research in 
Edinburgh under Professor 
J H Gaddum, later becoming a 
lecturer there. He moved to the 
London Hospital Medical College, 
University of London in 1949 with 
the responsibility of introducing 
a new department and became 
professor of pharmacology there 
(1958–66). He moved to the 
Wellcome Research Laboratories 
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at Beckenham, Kent, in 1967 as 
head of the therapeutics research 
division and became director 
of establishment (1974/5–79), 
and served on the Medicines 
Commission (1979–81). See 
Hanley et al. (1970); Waters (2007).
Professor david Webb
FRCP FRSE (b. 1953) trained as a 
cardiovascular physician and clinical 
pharmacologist with Professor Joe 
Collier at St George’s Hospital and 
Medical School, London, before 
moving to Edinburgh, where he 
was appointed to the Christison 
chair of therapeutics and clinical 
pharmacology in 1995, and has 
subsequently led Edinburgh’s 
department of medical sciences 
(1998–2001), the Wellcome Trust 
Cardiovascular Research Initiative 
(1998–2001), and the Centre for 
Cardiovascular Science (2000–04). 
He was clinical vice-president to 
the British Pharmacological Society 
(BPS) (1996–98), chair of the Royal 
College of Physicians Committee 
on Clinical Pharmacology (1998/9) 
and chair of the BPS committee 
of heads and professors of clinical 
pharmacology (2004–07). In 2004 
he became UK counsellor to the 
clinical division of the International 
Union for Pharmacology and 
chairman of the Scottish Medicines 
Consortium. In 2006 he was 
appointed vice-president of the Royal 
College of Physicians of Edinburgh.
Professor richard tecwyn 
Williams
FRS (1909–79) was professor 
of biochemistry at St Mary’s 
Hospital Medical School, London 
(1949–76), and dean (1970–76). 
Following Sir Archibald Garrod’s 
work on the role of enzymes in 
drug metabolism, he developed 
detoxication chemistry as a science 
in its own right, and established 
the two-phase drug metabolism 
in animals. In 1931 he published 
the structure of gluconuronic acid, 
and spent the rest of his career 
examining the fate of foreign 
compounds in the body. See 
Neuberger and Smith (1982).
Professor andrew Wilson 
CBE FRCP FRCPGlas  
(1909–74) was Weir assistant in 
materia medica, University of 
Glasgow, (1933–37); lecturer in 
pharmacology and therapeutics, 
University of Sheffield and 
clinical assistant, Sheffield Royal 
Infirmary (1939–46); lecturer in 
applied pharmacology, University 
College London, and University 
College Hospital Medical School 
(1946–48), reader in the University 
of London (1948–51); professor 
of pharmacology, University of 
Liverpool (1951–74); and chairman 
of the British National Formulary 
Committee. 
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Professor frank Woods
CBE FRCP FRCPE FFPM  
(b. 1937) was professor of 
pharmacology and therapeutics 
at the University of Sheffield 
from 1976, becoming Sir George 
Franklin professor of medicine in 
1989 and director of the division of 
clinical sciences (south), University 
of Sheffield, and served as dean of 
the faculty of medicine (1988–98). 
He was awarded a CBE for his 
services to the Committee on 
Toxicity of Chemicals in Food, 
Consumer Products and the 
Environment and was chairman 
of the General Medical Council’s 
Health Committee.
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British Journal of Clinical 
Pharmacology
A ‘daughter’ journal to the British 
Journal of Pharmacology whose 
first issue was published bi-monthly 
in February 1974 with G M Wilson 
as chairman of the editorial board 
and Paul Turner as secretary and 
first editor. Originally published 
by Macmillan, it transferred to 
Blackwell in 1983. From 1975, 12 
issues were published a year. See 
Cuthbert (2006).
British Journal of Pharmacology
The BMJ Publishing Group agreed 
to sponsor the new BPS journal 
of four issues a year, originally 
entitled the British Journal of 
Pharmacology and Chemotherapy, 
the first published in spring 1946 
edited by H R Ing. Macmillan Ltd 
became the publisher in 1968 and 
the title shortened to the British 
Journal of Pharmacology, succeeded 
in 1983 by Blackwell, increasing in 
size to 24 issues a year in 1995. See 
Cuthbert (2006).
British National Formulary (BNF)
A listing of medicines that replaced 
the National War Formulary, in 
which names of the preparations 
were in Latin, the doses in minims 
and grains. It was founded in 
1948, closed in 1976 and started 
again in 1981. Wade (1993). For 
details of 50 editions of the British 
National Formulary, see www.
bnf.org/bnf/extra/current/popup/
BNFcommemoration.pdf (visited 9 
November 2007).
British Pharmacological society 
(BPs)
Established as a ‘daughter society’ 
of the Physiological Society in 
1931 by Walter E Dixon FRS 
(1871–1931), J A Gunn (1882–
1958) and Sir Henry Hallett Dale 
OM FRS (1875–1968). It met 
once a year until 1946 when the 
launch of the British Journal of 
Pharmacology increased its activities 
and from 1968 there were four 
meetings a year. There had been 
some discussion at the BPS AGM 
in 1968 about retaining British 
in the title. The 50th anniversary 
was celebrated by a short history 
[Bynum (1981)] and its 75th 
with a special supplement [British 
Journal of Pharmacology (2006) 
147: S1–307]. See Cuthbert 
(2006); Aronson (2006);  
Dollery (2006).
Glossary*
* terms in bold appear in the glossary as separate entries
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Clinical section, BPs
A section of the Society devoted 
to clinical pharmacology was 
formed at the end of the 1960s, 
proposed by C T Dollery, D R 
Laurence, B N C Prichard, R 
G Shanks, J R Trouce, P Turner 
and D W Vere. The section had 
two of the four BPS scientific 
meetings a year for papers on 
clinical pharmacology. For further 
details, see www.bps.ac.uk/
site/cms/contentChapterView.
asp?chapter=106 (visited  
7 May 2008).
Drug and Therapeutics Bulletin
A Which? publication that began as 
the UK edition of the US Medical 
Letter on Drugs and Therapeutics 
in 1962, changing its name a 
year later. It was independent 
of the pharmaceutical industry, 
Government and regulatory 
authorities with no advertising 
or commercial sponsorship and 
was distributed to all prescribing 
doctors in the UK from 1966 to 
2006, paid for with a grant from 
the Department of Health (DoH). 
It held its first conference in 1984 
and co-founded the International 
Society of Drug Bulletins (ISDB) 
in 1989. See Anon. (2002).
essential medicines
The first ‘model list’ of 208 
essential medicines was created in 
1977 for developing governments 
to select medicines for local public 
health needs to be incorporated 
into national lists, which preceded 
the famous 1978 Alma-Ata 
declaration on Health For All. The 
list is revised every two years by a 
group of experts; the March 2007 
list contains 340 medicines. See 
WHO, Expert Committee (2007). 
See also www.who.int/medicines/
services/essmedicines_def/en/index.
html (visited 26 October 2007). 
For a comparative list over the 30 
years, see www.who.int/medicines/
publications/essentialmedicines/
compar_table_who_edls.xls (visited 
3 June 2008).
European Journal of Clinical 
Pharmacology
Founded by Hans Dengler, Franz 
Gross and Hartmut Dost in 1968 
as Pharmacologia Clinica with 
Springer Verlag. Two years later it 
was renamed the European Journal 
of Clinical Pharmacology (EJCP) 
with Hans Dengler, Franz Gross 
and Luzius Dettli as co-editors. 
imperial Chemical industries  
ltd (iCi) 
Formed in 1926 from the merger of 
four chemical companies: Brunner, 
Mond; Nobel Industries; United 
Alkali; and British Dyestuffs, 
selling chemicals, explosives, 
fertilizers, insecticides, dyestuffs, 
non-ferrous metals and paints. 
The 1993 demerger of ICI 
Clinical Pharmacology in the UK, c. 1950–2000: Influences and institutions – Glossary 
123
Pharmaceuticals, created in 1957, 
and their agrochemicals businesses 
formed Zeneca (merged with Astra 
AB to create the pharmaceuticals 
company AstraZeneca in 1999; 
the agrochemicals business joined 
Novartis to form Syngenta in 
2000).  In 2008, ICI became 
part of AkzoNobel, a coatings 
manufacturer, selling decorative 
paints and performance coatings, 
and supplying specialty chemicals. 
Notable pharmaceuticals 
produced by its research group 
were sulfamethazine, the first 
sulfonamide antibiotic; Paludrine 
in the 1940s when supplies of 
the natural quinine treatment 
for malaria were threatened by 
hostilities; halothane (1951, an 
anaesthetic agent); Inderal (1965, 
a β-blocker), brodifacoum (1974, 
a rodenticide), Tenormin (1976, a 
β-blocker) and tamoxifen (1978, 
frequently used to treat breast 
cancer). See Reader (1970, 1975).
international Union of 
Pharmacology (iUPhar)
Founded in 1959 as a section 
of the International Union of 
Physiological Sciences, it has been 
an independent body since 1966, 
renamed the International Union 
of Basic and Clinical Pharmacology 
in 2006. International meetings 
are generally held every three 
years, the first in Stockholm, 
Sweden in 1961; the second 
in Prague, Czechoslovakia in 
1963. From 1990, the meetings 
alternate with the world congresses 
of the International Union of 
Biochemistry and Molecular 
Biology (IUBMB) and  
the International Union of 
Physiology (IUPS). 
Joint Planning advisory 
Committee (JPaC)
A committee established in 1985 to 
advise the Department of Health 
and Social Security on national 
targets for the total number of 
senior registrar posts by specialty 
group and on regional quotas, with 
17 members, and five observers 
from the Association of Medical 
Research Charities, the Welsh 
Joint Consultants Committee, 
the Department of Health, the 
Welsh Office and the Scottish 
Home and Health Department. 
The Committee continued until 
1990 when it was replaced by the 
Specialist Workforce Advisory 
Group (SWAG) and later by 
the Advisory Group on Medical 
Education Training and Staffing 
(AGMETS). See Anon. (1985). See, 
for example, Salter (1995).
Kempner’s rice diet
Dr Walter Kempner from Duke 
University, Durham, North 
Carolina, investigated the effect 
of diet on disease, including 
hypertension and diabetes, and 
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found that these conditions were 
rare when rice was a staple. Rice, 
fruit, juices, sugar, plus vitamin 
and iron supplements made up the 
regimen. For details, see Dunlop 
(1950). See also http://archives.
mc.duke.edu/mcakempnerw_pdf 
(visited 26 June 2008).
Medical Letter on Drugs and 
Therapeutics
Founded in the US as one of 
two newsletters (the other being 
Treatment Guidelines from The 
Medical Letter) in 1959 by Dr 
Harold Aaron and Arthur Kallet, 
also co-founder of the Consumers 
Union. See http://medlet-best.
securesites.com/html/who.htm 
(visited 9 November 2007).
merck fellowship in Clinical 
Pharmacology 
An award from the Merck 
Company Foundation to promote 
and strengthen the discipline 
of clinical pharmacology. Four 
fellowships have been awarded 
annually since 1965, later renamed 
the International Fellowship in 
Clinical Pharmacology, supported 
by the Merck Foundation. See also 
Sjöqvist et al. (2007).
Merck Manual of Diagnosis and 
Therapy (Merck Manual or 
Merck’s)
An alphabetical listing of agents 
of therapeutic value based on 
the US Pharmacopoeia, along 
with symptoms and diseases, 
first published in 1899 as Merck’s 
Manual of Materia Medica, in its 
18th edition (2006). Full text is 
freely available at www.merck.com/ 
mmpe/index.html (visited 9 
November 2007). See Morowitz 
(1976).
modernising medical Careers 
(mmC)
A policy statement from the UK 
Departments of Health in 2003 
outlining reforms to postgraduate 
medical education, including 
a shorter specialist foundation 
training period of two years, a 
computerized central selection 
process for training posts and 
revision of the non-consultant 
career grade. After the online 
Medical Training Application 
Service for junior doctors failed 
in 2006, Professor Sir John Tooke 
was appointed by the Secretary 
of State to investigate MMC 
procedures. His 2008 report, 
Aspiring to Excellence, suggested 
further reforms of postgraduate 
medical education. The report is at 
www.mmcinquiry.org.uk/Final_8_
Jan_08_MMC_all.pdf (visited 20 
June 2008). See also Delamothe 
(2008). 
Monthly Index of Medical 
Specialities (MIMS)
Established in 1959 by Medical 
Publications as a free service to 
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prescribing medical professionals by 
cooperating pharmaceutical manu-
facturers, whose editorial team was 
independent of pharmaceutical 
companies.
Prescribers’ Journal 
Designed to provide the physician 
with early and reliable information 
about new pharmaceutical products 
for use in general practice or in 
the hospital setting. It superseded 
Prescribers’ Notes, first introduced 
in February 1952, which aimed to 
promote economy in prescribing 
habits as well as information on 
prescribing matters.
Prescribing initiative
An initiative of the British 
Pharmacological Society that began 
after a series of events in which 
members of the Society highlighted 
problems with practical prescribing 
and its teaching. The first event 
was a press briefing at the Royal 
Institution’s Science Media Centre 
in July 2006, which was followed 
by the publication of an editorial 
in the British Medical Journal 
(Aronson et al. (2006)). This led to 
the formation of a working party, 
organized by the General Medical 
Council, at which the Society had 
representation; the problems were 
discussed and changes proposed 
to the 2008 version of Tomorrow’s 
Doctors. The Society agreed to fund 
a research registrar, for one year 
initially, to carry out a systematic 
review of the literature on methods 
of teaching practical prescribing, 
to formulate a curriculum, and 
to survey teaching methods 
current in the UK. This initiative 
began in February 2008. See, for 
example, www.newscientist.com/
article/dn9574-experts-warn-on-
dangerous-drugprescribing-errors.
html; www.dailymail.co.uk/news/
article-396399/Hundreds-dying-
doctors-lack-training-prescribing-
drugs.html (visited 16 July 2008).
royal Pharmaceutical society of 
great Britain
The professional and regulatory 
body for pharmacists in England, 
Scotland and Wales. See www.
rpsgb.org.uk/ (visited 16 November 
2007).
safe Prescribing Working group
The General Medical Council 
(GMC) convened a meeting 
of interested parties to discuss 
prescribing errors in junior doctors. 
The Safe Prescribing Working 
Group was asked to determine 
what a Foundation Year 1 doctor 
must know on his or her first 
day with regards to prescribing; 
to suggest ways to support the 
development of this knowledge 
through undergraduate education 
and foundation training, including 
assessment; and to consider ways 
to support junior doctors in their 
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prescribing. The recommendations 
and outcomes of the Safe Prescribing 
Working Group are available on the 
Medical Schools Council’s website at 
www.chms.ac.uk/publications.htm 
(visited 8 July 2008)
Wellcome foundation
The umbrella organization formed 
in 1924 by Henry Wellcome to 
absorb his libraries, museums, 
research laboratories and the 
pharmaceutical company of 
Burroughs Wellcome & Co. Sir 
Henry Wellcome’s will created 
the medical charity, the Wellcome 
Trust, which managed the 
Foundation until it was floated on 
the stock market and merged with 
Glaxo in 1995 (GlaxoSmithKline 
from 2001). For the history of 
the years to 1940, see Church and 
Tansey (2007).
Clinical Pharmacology in the UK, c. 1950–2000: Influences and institutions – Index
127
Aberdeen, 15, 35–6, 63
Aberdeen General Hospital, 79
Aberdeen prescription sheet, 31, 79
ABPI see Association of the British 
Pharmaceutical Industry
acetylcholine, 10
Addenbrooke’s Hospital, Cambridge, 
36
adverse drug reactions, 28–9
newspaper clippings, 29
Adverse Drug Reactions Bulletin, 52
Alder Hey Book of Children’s Doses 
(ABCD), 63
Alder Hey Children’s Hospital, 
Liverpool, 63, 65
amphetamine, 62
amyl nitrite, 62
anaesthesia, 29
angina pectoris, 13, 22–3
Anglo–American Workshop on 
Clinical Pharmacology, Virginia 
(1986), 15, 32, 78
animals, studies on, 9, 10, 62
antidepressants, 33
antivivisectionists, 10
Artemisia annua, 6
aspirin, 74
assessment see examination/assessment
Association of the British 
Pharmaceutical Industry (ABPI), 
51, 55–6
Medicines Compendium, 46–7
atropine, 16, 17
Australia, 44, 60
Ballard and Garrod, Elements of 
Materia Medica and American 
Therapeutics (1845), 7
barbiturates, 62
Bart’s see St Bartholomew’s Hospital, 
London
beds, hospital, 21, 27, 30, 32, 36, 
37–8
Belfast, 21, 42–3, 79
Belfast City Hospital, 79
β-blockers, 17, 22–3, 74
see also practolol; propranolol
biochemical pharmacology, 12, 18–19, 
33–4
Birmingham, University of,  13, 38, 
67, 72–3
BJCP see British Journal of Clinical 
Pharmacology
BJP see British Journal of Pharmacology
blood pressure
high see hypertension
measurement, 29
BMA see British Medical Association
BMJ see British Medical Journal
BMJ Publishing Group, 44, 46
BNF see British National Formulary
Bodleian Library, Oxford, 7, 8
BPS see British Pharmacological Society
brain, 33
Brazil, 60
British Council meeting, 57–8, 60
British Journal of Clinical Pharmacology 
(BJCP), 44–5, 47–9, 61, 121
75th anniversary of BPS, 6
establishment of, 27, 44, 48–9, 78
British Journal of Pharmacology (BJP), 
45, 48, 121
BPS 75th anniversary issue, 4
British Medical Association (BMA), 57
British Medical Journal (BMJ), 44,  
45, 46
article on better prescribing  
(2006), 68
Index: Subject 
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editorials on clinical pharmacology, 
8, 9, 26, 77
British National Formulary (BNF), 
45–6, 47, 53–4, 121
Ed Harris and, 51, 53
evaluation of, 53, 70
first issue, 4, 77
Joint Formulary Committee, 45
production, 65
recipients, 46, 53
revised format, 53, 64, 78
British Pharmacological Society (BPS), 
61, 121
75th anniversary, 4, 72, 78
Clinical Section see Clinical Section 
of the British Pharmacological 
Society
Prescribing Initiative, 72, 78, 125 
publication of BJCP, 44, 45, 48–9
visiting fellow to India, 27
Bruce, Materia Medica and 
Therapeutics,  (1884), 7
Bruce and Dilling’s Materia Medica and 
Therapeutics (Dilling, 1933), 7
Burroughs Wellcome Fund, Research 
Triangle Park, NC, US, 55–6
Cambridge, 36
carcinoid syndrome, 12
cardiac glycosides, 8
see also digitalis; digoxin
Cardiff, 28, 38–9, 44
cardiovascular pharmacology, 16, 17, 
19, 24
Cardiovascular Research Institute, San 
Francisco, California, US, 14
Cerumol, 51
Charterhouse Square see Bart’s
chemical pathology, 12, 20
Chief Medical Officer (CMO), 46
China, 59, 60
cinchona bark, 6
clinical medicine, 11–12, 32, 34
clinical pharmacologists
clinical practice see clinical practice
in history, 6
influences on career choices, 8–19
roles, 43–4
teaching see teaching
clinical pharmacology
academic departments, 19–22, 
23–30, 32–9
chronology of events, 4–5, 77–9
future, xx, 8, 72
industrial, 17–18
international influence on UK, 
56–61
need for rebranding, xxiii 
nomenclature, 4, 6–8
numbers of posts, 42–3
overseas, 56–61
paediatric, 63, 65
Clinical Pharmacology (Dilling,  
1960), 7
Clinical Pharmacology (Laurence, 
1960), 7, 77
Clinical Pharmacology and Therapeutics 
(journal), 15, 42
Clinical Pharmacology: Scope, 
organization, training (WHO, 
1970), 39 –41
Clinical Pharmacology Research 
Group, MRC, Hammersmith 
Hospital, London, 19
Clinical Pharmacology Unit, MRC, 
Oxford, 32–3, 78
clinical pharmacy, 63–6, 69
clinical practice, 21, 27, 30, 32, 37–8
clinical psychopharmacology, 33
clinical science, 11, 17–18
Clinical Section of the British 
Pharmacological Society  
(BPS), 122
Ciba Foundation meeting, 57
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establishment, 21–2, 61, 78
prizes for medical students, 62
setting up the BJCP, 27, 44, 48
clinical trials, 13, 22, 23, 60
European Directive, 56
CMO see Chief Medical Officer
Committee on Safety of Drugs, 77
Committee on Safety of Medicines, 
77, 78
Compendium of Physick (Salmon, 
1671), 7
computer-based assessment and 
learning see medical students
Consumers’ Association, 50–1
cortisone, 11
Council for the Heads of Medical 
Schools, 72
criminal psychology, 34–5
Croatia, 57–8
Crooks et al., ‘Drugs in hospitals’ 
(1967), 79
Cullen, Treatise of the Materia Medica 
(1789), 7
cyclizine hydrochloride (Marzine), 
17–18
DCMO see Deputy Chief Medical 
Officer
deans of medical schools, 11, 30, 68, 
72, 73
Department of Health, 42, 46, 50, 51, 
52
departments of clinical pharmacology, 
19–22, 23–30, 32–9
Deputy Chief Medical Officer 
(DCMO), 51, 53
developing countries, 26, 39
digitalis, 6
digoxin, 8, 15–16, 33, 43
Dilling’s Clinical Pharmacology (1960), 
7, 77
District Drugs Guide (Westminster, 
1981), 64
Dixon Memorial Lecture (1954), 8
dose–response relationships, 19, 22, 23
dropsy, 6
Drug and Therapeutics Bulletin, 46, 
49–52, 77, 122
drug and therapeutics committees, 
65–6, 67
drug interactions, 19, 48
drug metabolism, 19, 24, 47–8
drug regulation and safety, 35–6
Drug Utilization Research Group 
(DURG), 59–60
‘Drugs in hospitals’ (Crooks et al., 
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